

EXHIBIT 8

Sarepta-UWA Tenth Revised Trial Exhibit List

November 25, 2024

Confidential

DTX	Date	Beg Bates No.	End Bates No.	Description	Deposition Exhibit
DTX-0001	6/12/2018	SRPT-VYDS-0002641	SRPT-VYDS-0002756	Certified Copy of University of Western Australia Patent (U.S. Patent 9,994,851)	Strober 17 Hastings 25 Mandragouras 01 Wilton 05 Dowdy 05 Fletcher 09 Hastings 103 Wood 103 Wood 20
DTX-0002	3/12/2019	SRPT-VYDS-0002757	SRPT-VYDS-0002869	Certified Copy of University of Western Australia Patent (U.S. Patent 10,227,590)	Wilton 06
DTX-0003	4/22/2022	SRPT-VYDS-0002870	SRPT-VYDS-0002983	Certified Copy of University of Western Australia Patent (U.S. Patent 10,266,827)	Wilton 07
DTX-0004	9/14/2017	SRPT-VYDS-0002984	SRPT-VYDS-0005241	Certified Copy of File History for University of Western Australia Patent Application (App. No. 15-705,172 - U.S. Patent 9,994,851)	Mandragouras 02
DTX-0005	8/24/2018	SRPT-VYDS-0005242	SRPT-VYDS-0005992	Certified Copy of File History for University of Western Australia Patent Application (App. No. 16-112,371 - U.S. Patent 10,227,590)	
DTX-0006	8/24/2018	SRPT-VYDS-0005993	SRPT-VYDS-0006843	Certified Copy of File History for University of Western Australia Patent Application (App. No 16-112,453 - U.S. Patent 10,266,827)	
DTX-0007	9/26/2019	SRPT-VYDS-0006844	SRPT-VYDS-0006977	Sarepta Patent Application (U.S. Patent App. Pub. 2019/0292208)	
DTX-0008	12/10/2018	SRPT-VYDS-0211490	SRPT-VYDS-0211494	Certified Copy of University of Western Australia Patent Assignment (U.S. Patent Assignment 16/112,453)	Zenkus 03
DTX-0009	9/25/2017	SRPT-VYDS-0211495	SRPT-VYDS-0211500	Certified Copy of University of Western Australia Patent Assignment (U.S. Patent Assignment 15705172)	

November 25, 2024

Confidential

DTX-0010	12/7/2018	SRPT-VYDS-0211501	SRPT-VYDS-0211505	Certified Copy of University of Western Australia Patent Assignment (U.S. Patent Assignment 16112371)	
DTX-0011	7/18/2017	NS000000001	NS000000066	Nippon Shinyaku Patent (U.S. Patent 9,708,361)	Takagaki 05 Satou 02 Takeda 02 Watanabe 02 Feng 02
DTX-0012	8/20/2019	NS000000067	NS000000134	Nippon Shinyaku Patent (U.S. Patent 10,385,092)	Feng 12 Takagaki 07 Wood 18 Strober 16
DTX-0013	9/10/2019	NS000000135	NS000000201	Nippon Shinyaku Patent (U.S. Patent 10,407,461)	Takagaki 08
DTX-0014	11/26/2019	NS000000202	NS000000269	Nippon Shinyaku Patent (U.S. Patent 10,487,106)	Takagaki 09
DTX-0015	5/12/2020	NS000000270	NS000000339	Nippon Shinyaku Patent (U.S. Patent 10,647,741)	Takagaki 10
DTX-0016	5/26/2020	NS000000340	NS000000407	Nippon Shinyaku Patent (U.S. Patent 10,662,217)	Takagaki 11
DTX-0017	6/16/2020	NS000000408	NS000000476	Nippon Shinyaku Patent (U.S. Patent 10,683,322)	Takagaki 06 Satou 03 Takeda 03 Ueda 02 Watanabe 03 Luedtke 04 Jurayj 07 Pentelute 03
DTX-0018	2/6/2015	NS000000477	NS000000826	File History for Nippon Shinyaku Patent Application (App. No. 14/615,504 - U.S. Patent 9,708,361)	Feng 03 Dowdy 10
DTX-0019	3/20/2019	NS000000827	NS000000924	File History for Nippon Shinyaku Patent Application (App. No. 16/359,213 - U.S. Patent 10,685,092)	

Sarepta-UWA Tenth Revised Trial Exhibit List

November 25, 2024

Confidential

DTX-0020	3/26/2019	NS00009025	NS00017240	File History for Nippon Shinyaku Patent Application (App. No. 16/364,451 - U.S. Patent 10,407,461)	
DTX-0021	3/29/2019	NS00017241	NS00026054	File History for Nippon Shinyaku Patent Application (App. No. 16/369,427 - U.S. Patent 10,487,106)	
DTX-0022	6/24/2019	NS00026055	NS00034539	File History for Nippon Shinyaku Patent Application (App. No. 16/449,537 - U.S. Patent 10,647,741)	
DTX-0023	12/12/2019	NS00034594	NS00034977	File History for Nippon Shinyaku Patent Application (App. No. 16/712,686 - U.S. Patent 10,662,217)	
DTX-0024	12/17/2019	NS00034978	NS00035327	File History for Nippon Shinyaku Patent Application (App. No. 16/717,274 - U.S. Patent 10,683,322)	
DTX-0025 DTX-0584	2020-08-00	NS00035358	NS00035369	Highlights of Prescribing Information of Viltepso (Revised: 08/2020)	Magnus 03
DTX-0026 DTX-0405	8/12/2020	NS00035370	NS00035379	Letter from B. Dunn to Dr. Phillips re Accelerated Approval	Magnus 04
DTX-0027	9/28/2012	FRANK00000211	FRANK00000212	Email from L. Cowan to C. Garabedian; D. Frank; R. bestwick; P. Sazani; F. Muntoni; G. Dickson; and E. Kaye RE: [REDACTED] [REDACTED] - MEETING DELAYED 30 MINUTES- Meeting agenda	Bestwick 1
DTX-0028	2013-01-00	BESTWICK00000013	BESTWICK00000016	EXON 53 [REDACTED] [REDACTED]	Bestwick 02
DTX-0029	7/11/2012	SRPT-VYDS-0214705	SRPT-VYDS-0214707	Email from D. Frank to C. Garabedian RE: [REDACTED] [REDACTED] l	Bestwick 07 Frank 04
DTX-0030	7/2/2012	SRPT-VYDS-0214525	SRPT-VYDS-0214525	Email from D. Frank to R. Bestwick RE: Exon 53 Updates	Bestwick 08 Schnell 11 Frank 09
DTX-0031 DTX-0042	9/28/2012	SRPT-VYDS-0213938	SRPT-VYDS-0213940	Email from D. Frank to L. Cowan RE: [REDACTED] [REDACTED]	Bestwick 09 Frank 14

November 25, 2024

Confidential

DTX-0032	2/26/2013	SRPT-VYDS-0215407	SRPT-VYDS-0215425	Email from D. Frank to D. Mourich; F. Schnell; B. Leppert; R. Bestwick; and E. Naughton RE: [REDACTED] and attachment [REDACTED]	Bestwick 11 Frank 21
DTX-0033	6/12/2023			Notice to Take Deposition of Brian Forsa and Steve Wilton	Forsa 01
DTX-0034	4/12/2023			Nippon Shinyaku Co. Ltd. and NS Pharma, Inc.'s Notice of Deposition of Sarepta Therapeutics Pursuant to Fed. R. Civ. P. 30(b)(6)	Forsa 02 Jacoby 01 Jurayj 02 O'Malley 02 Schnell 01 Shanahan 01 Wong 01 Zenkus 02
DTX-0035 DTX-0631		SRPT-VYDS-0210679	SRPT-VYDS-0210695	Powerpoints presentation from Sarepta Therapeutics entitled [REDACTED]	Forsa 05
DTX-0036	2020-00-00	SRPT-VYDS-0210727	SRPT-VYDS-0210791	[REDACTED]	Forsa 07 Lu 06
DTX-0037 DTX-0630	6/8/2021	SRPT-VYDS-0209787	SRPT-VYDS-0209791	Powerpoint presentation from Sarepta Therapeutics entitled [REDACTED]	Forsa 09
DTX-0038 DTX-0622 DTX-1321		SRPT-VYDS-0201524	SRPT-VYDS-0201588	Research Report - [REDACTED]	Frank 01 Naughton 02 Schnell 18 Dowdy 07
DTX-0039	8/28/2012	SRPT-VYDS-0213849	SRPT-VYDS-0213850	Email from D. Frank to S. Fletcher RE: Travel to Perth!	Frank 05
DTX-0040	8/1/2012	SRPT-VYDS-0215457	SRPT-VYDS-0215457	Email from D. Frank to R. Bestwick RE: Ex53 [REDACTED]	Frank 10
DTX-0041	7/8/2019			European Patent Specification (3,018,211)	Feng 04

November 25, 2024

Confidential

DTX-0042 DTX-0031	9/28/2012	SRPT-VYDS-0213938	SRPT-VYDS-0213940	Email from D. Frank to L. Cowan and R. Bestwick RE: [REDACTED]	Frank 14 Bestwick 9
DTX-0043	12/18/2020			Prosecution History Excerpt of Patent application (17/126,366)	Feng 05
DTX-0044	10/4/2012	FRANK00000228	FRANK00000230	Email from R. Bestwick to L. Cowan et al. Fwd: [REDACTED]	Frank 16
DTX-0045	11/17/2012	SRPT-VYDS-0213827	SRPT-VYDS-0213828	Email from D. Frank to L. Cowan and E. Kaye RE: [REDACTED] [REDACTED] and attachment [REDACTED] [REDACTED]	Frank 19
DTX-0046 DTX-0364	9/29/2020			Experimental Report and declaration of Mr. Ueda for EP 3,018,211 dated 3/16/18 and 10/27/21	Feng 06 Watanabe 47
DTX-0047	5/18/2017	SRPT-VYDS-0213333	SRPT-VYDS-0213380	Commercial Supply Agreement	Jacoby 2
DTX-0048	6/22/2020	SRPT-VYDS-0213383	SRPT-VYDS-0213392	Third Amendment to Commercial Supply Agreement	Jacoby 3
DTX-0049 DTX-0635	4/14/2021	SRPT-VYDS-0213330	SRPT-VYDS-0213332	Fifth Amendment to Commercial Supply Agreement between [REDACTED] [REDACTED]	Jacoby 4
DTX-0050	8/18/2017			Japanese Patent Document (JP 6,193,343)	Feng 07
DTX-0051	6/9/2021	SRPT-VYDS-0220040	SRPT-VYDS-0220067	Technology Transfer, Validation and Commercial [REDACTED] Agreement	Jacoby 5
DTX-0052	6/24/2020	SRPT-VYDS-0219963	SRPT-VYDS-0219990	Packaging and Supply Agreement	Jacoby 6
DTX-0053	3/9/2017			Excerpts from Prosecution History for Japanese Patent 6,193,343 - Written Opinion (P12-0190-B)	Feng 08
DTX-0054				European Patent (EP 2,206,781)	Feng 09
DTX-0055	9/28/2021	SRPT-VYDS-0219884	SRPT-VYDS-0219891	Fourth Amendment to Commercial [REDACTED] [REDACTED] Agreement	Jacoby 7

Sarepta-UWA Tenth Revised Trial Exhibit List

November 25, 2024

Confidential

DTX-0056	8/25/2016			Excerpts from Prosecution History of European Patent No. 2,206,781 - Opposition fee to EUR 785	Feng 10
DTX-0057	7/1/2020	SRPT-VYDS-0213445	SRPT-VYDS-0213450	Second Amendment to [REDACTED] Agreement	Jacoby 8
DTX-0058	3/20/2019			Patent Application (10,385,092 for U.S. Patent 10,385,092)	Feng 11 (excerpt)
DTX-0059	6/8/2021			U.S. Patent 11,028,122	Feng 13
DTX-0060	4/3/2023			Sarepta's Response and Objections to NS's Second Set of Interrogatories (Nos. 14-21)	Jurayj 03
DTX-0061	2021-02-00	SRPT-VYDS-0006978	SRPT-VYDS-0006990	Highlights of Prescribing Information or Vyondys 53 (Revised 2/2021)	Jurayj 04 Sehinovych 02 Strober 11
DTX-0062	6/21/2021			Petition for Inter Partes Review for IP2021-01134 for Patent No. 9,708,361	Feng 14
DTX-0063		SRPT-VYDS-0007049	SRPT-VYDS0007050	3.2.S.1. General Information [Golodirsén, [REDACTED]]	Jurayj 05
DTX-0064		SRPT-VYDS-0007051	SRPT-VYDS-0007088	3.2.S.2 Manufacture [Golodirsén, [REDACTED]]	Jurayj 06
DTX-0065	6/20/2022			Decision Granting Institution of Inter Partes Review for IPR2021-01134 for Patent No. 9,708,361	Feng 15 Luedtke 07
DTX-0066	4/28/2021			Excerpts from Prosecution History of Application 17/333,677 - Certification and Request for Prioritized Examination Under 37 CFR 1.102(e)	Feng 16
DTX-0067	1/14/2013	SRPT-VYDS-0002988	SRPT-VYDS-0002999	Declaration (37 CFR 1.63) for Utility or Design Application Using an Application Data Sheet (37 CFR 1.76)	Mandragouras 03 Wilton 09
DTX-0068	7/14/2021			Excerpts from Prosecution History of Application 17/375,877 - Certification and Request for Prioritized Examination Under 37 CFR 1.102(e)	Feng 17

Sarepta-UWA Tenth Revised Trial Exhibit List

November 25, 2024

Confidential

DTX-0069	4/24/2023			Notice of Deposition of Plaintiffs Pursuant to FED. R. CIV. P. 30(b)(6)	Gendron 01 Magus 02
DTX-0070	9/14/2017	SRPT-VYDS-0004781	SRPT-VYDS-0004799	Amendment in Response to Non-Final Office Action Under 37 C.F.R. § 1.111	Wood 23 Mandragouras 05
DTX-0071				Gardner Gendron Curriculum Vitae	Gendron 03
DTX-0072	5/12/2016			Decision - Motions - 37 CFR § 41.125(a) (Substitute) - Patent 8,455,636 and Application 11/233,495)	Wood 25 Mandragouras 06
DTX-0073	7/25/2022	NS00036975	NS00036985	Nippon Shinyaku Organizational Chart	Gendron 04
DTX-0074	11/13/2020	NS00036995	NS00036998	Foreign document entitled "Viltepso performance (11/09-11/13) and activity status (11/02-11/06) report"	Gendron 05A
DTX-0075	11/13/2020	NS00036995	NS00036998	Viltepso performance (11/09-11/13) and activity status (11/02-11/06) report	Gendron 05
DTX-0076	12/25/2020	NS00037036	NS00037041	Viltepso Results (12/21-12/25) and Activity Status (12/14-12/18) Report	Gendron 06
DTX-0077	2005-00-00			S. Wilton & S. Fletcher, Antisense oligonucleotides in the treatment of Duchenne muscular dystrophy: Where are we now?, Neuromuscular Disorders 15:399-402 (2005)	Mandragouras 11
DTX-0078	2007-01-00			P.L. Harding et al., The influence of antisense oligonucleotide length on dystrophin exon skipping, The American Society of Gene Therapy 15(1):157-166 (2007)	Mandragouras 12 Wood 114 Kamholz 06 Meloni 03
DTX-0079		SRPT-VYDS-0163689	SRPT-VYDS-0163912	██████████ AVI BioPharma Notebook #2	
DTX-0080		SRPT-VYDS-0163463	SRPT-VYDS-0163688	██████████ AVI BioPharma Notebook	Naughton 07
DTX-0081	12/25/2020	NS00037036	NS00037041	Foreign document entitled "Viltepso Results (12/21-12/25) and Activity Status (12/14-12/18) Report"	Gendron 06A

Sarepta-UWA Tenth Revised Trial Exhibit List

November 25, 2024

Confidential

DTX-0082 DTX-1341		NS00074042	NS00074042	Forecast Model and Calendar Year Summary, Excel	Gendron 07
DTX-0083 DTX-1163		NS00036993	NS00036993	ASP Summary, ASP Report, Buckets, Period, NDCS	Gendron 08
DTX-0084	12/15/2017	SRPT-VYDS-0196643	SRPT-VYDS-0196711	Type C Meeting - Briefing Materials : Golodirsen (SRP-4053 Injection IND 119,982	O'Malley 03
DTX-0085		NS00036994	NS00036994	Income Statement	Gendron 09
DTX-0086 DTX-0281		NS00091316	NS00091316	Income Statement, 2020, 2021, 2022, 2023	Gendron 10
DTX-0087 DTX-0272	4/11/2023	NS00091312	NS00091312	Preliminary Royalty Rate of Viltepso for Fiscal Year 2023	Gendron 11 Toda 13
DTX-0088		NS00091313	NS00091313	Ship to R Farm, Ship to Clinigen	Gendron 12
DTX-0089 DTX-1412	8/22/2022	NS00090751	NS00090753	International Business Division; On the [REDACTED] and the [REDACTED] (updated version)	Gendron 13
DTX-0090	9/11/2018	SRPT-VYDS-0189075	SRPT-VYDS-0189178	Type B Pre-NDA Meeting Briefing Materials : Golodirsen (SRP-4053) Injection IND 119,982	O'Malley 06
DTX-0091	8/22/2022	NS00090751	NS00090753	Foreign document entitled "Presentation, On the [REDACTED] and the [REDACTED] (updated version)"	Gendron 13A Takagaki 28
DTX-0092	12/5/2022	NS00074025	NS00074033	NS Pharma 2022 Fiscal Year Sales Forecast Attainment	Gendron 14
DTX-0093	4/27/2020	NS00096857	NS00096857	Email from G. Gendron to S. Helfant re [REDACTED] Recommendation	Gendron 15
DTX-0094	4/16/2020	NS00096858	NS00096881	[REDACTED] Committee Presentation	Gendron 16
DTX-0095		NS00073479	NS00073508	[REDACTED] Agreement	Gendron 18
DTX-0096 DTX-1344		NS00074895	NS00074931	[REDACTED] Agreement	Gendron 19

Sarepta-UWA Tenth Revised Trial Exhibit List

November 25, 2024

Confidential

DTX-0097	9/28/2017			Declaration of F. Schnell in the matter of European patent no. 2206781 to The University of Western Australia and opposition thereto by Nippon Shinyaku Co., Ltd.	Schnell 03
DTX-0098	7/19/2023			Linkedin profile of F. Schnell	Schnell 04
DTX-0099		NS00075034	NS00075075	[REDACTED] Agreement.	Gendron 20
DTX-0100	4/2/2020	NS00074956	NS00074975	[REDACTED] Agreement between NS Pharma, Inc. and [REDACTED]	Gendron 21
DTX-0101	12/12/2019	SRPT-VYDS-0211422	SRPT-VYDS-0211435	Letter from W. Dunn to P. O'Malley RE: Accelerated Approval ; Approval Package for: Application Number: 211970Orig1s000	O'Malley 13
DTX-0102	2019-12-00	SRPT-VYDS-0211289	SRPT-VYDS-0211303	Highlights of Prescribing Information of Vyondys 53	O'Malley 15
DTX-0103		SRPT-VYDS-0227277	SRPT-VYDS-0227314	Powerpoint slides bearing bates range SRPT-VYDS-0227277 - SRPT-VYDS-0227314	Schnell 08
DTX-0104	11/16/2012	SRPT-VYDS-0206708	SRPT-VYDS-0206869	Letter from G. Zisimatos to C. Edlin RE: [REDACTED] [REDACTED] [REDACTED]	Schnell 12 Zenkus 11
DTX-0105		SRPT-VYDS-0164362	SRPT-VYDS-0164584	[REDACTED] AVI BioPharma Notebook	Schnell 16
DTX-0106		SRPT-VYDS-0163913	SRPT-VYDS-0164136	[REDACTED] AVI BioPharms Notebook BL #3	Schnell 17
DTX-0107		SRPT-VYDS-0227457	SRPT-VYDS-0227480	AVI BioPharma Notebook	Schnell 21
DTX-0108	4/25/2018			Declaration of F. Schnell In the matter of Appeal No. T518/18 European patent no. 2206781 to The University of Western Australia and opposition thereto by Nippon Shinyaku Co., Ltd.	Schnell 22
DTX-0109	11/13/2017	SRPT-VYDS-0227441	SRPT-VYDS-0227456	[REDACTED] Sarepta Therapeutics Notebook	Schnell 23

Sarepta-UWA Tenth Revised Trial Exhibit List

November 25, 2024

Confidential

DTX-0110 DTX-0658	2022-01-00	SRPT-VYDS-0232087	SRPT-VYDS-0232098	Highlights of Prescribing Information of Exondys 51 (Revised 01/2022)	Wood 15 Sehinovych 01
DTX-0111	2023-03-00			Highlights of Prescribing Information of Amondys 45 (Revised 03/2023)	Sehinovych 03
DTX-0112	2/21/2023			Study of SRP-4045 (Casimersen) and SRP-4053 (Golodirsen) in Participants With Duchenne Muscular Dystrophy (DMD) (ESSENCE)	Sehinovych 04
DTX-0113 DTX-0856	5/26/2020			D. Frank et al, Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy, Neurology 94(21):2270-2282 (2020)	Sehinovych 05
DTX-0114 DTX-0535	2022-00-00	SRPT-VYDS-0229866	SRPT-VYDS-0229878	L. Servais et al., Long-term safety and efficacy data of golodirsen in ambulatory patients with Duchenne muscular dystrophy amenable to Exon 53 skipping: a first-in-human, multicenter, two-part, open-label, phase 1/2 trial, Nucleic Acid Therapeutics 32(1):29-39 (2022)	Sehinovych 07 Strober 13
DTX-0115	9/7/2023			Memorandum Opinion and Special Master Order #5	Shanahan 03
DTX-0116	11/24/2008	UWA0000015	UWA0000046	Exclusive License Agreement between The University of Western Australia and AVI BioPharma, Inc.	Shanahan 04 Wilton 12 Zenkus 06 (with SRPT bates)
DTX-0117	4/10/2013	UWA0000051	UWA0000077	Amended and Restated Exclusive License Agreement between The University of Western Australia and Sarepta Therapeutics Sarepta International CV	Shanahan 09
DTX-0118	6/19/2016	SRPT-VYDS-0154890	SRPT-VYDS-0154894	First Amendment to License Agreement between The University of Western Australia and Sarepta Therapeutics, Inc. and Sarepta International CV	Shanahan 11 Zenkus 08

Sarepta-UWA Tenth Revised Trial Exhibit List

November 25, 2024

Confidential

DTX-0119	2/17/2009	UWA0000047	UWA0000050	Intellectual Property Assignment & Revenue Sharing Agreement between The University of Western Australia and S. Wilton, S. Fletcher, and G. McClorey	Shanahan 14 Wilton 13
DTX-0120	11/17/2020			Once a Wild Idea, Successful First-Generation Exon-Skipping Therapies Pave the Way for Personalized Treatment (November 17, 2020); mdaquest.org once-a-wild-1dea-successful-f1rst-generat1on-exon-sk1pping-therapies-pave-the-way-for-personalizedtreatments/	Wilton 01
DTX-0121	6/9/2023			Professor Steve Wilton, PhD, BSc (Hons) - Foundation Chair in Molecular Therapy (June 9, 2023); profiles.murdoch.edu.au/myprofile/steve-wilton/	Wilton 02
DTX-0122	6/28/2004			Certified Copy of University of Western Australia Patent (PCT/AU2005/000943)	Wilton 08
DTX-0123	1/5/2018	SRPT-VYDS-0155714	SRPT-VYDS-0155832	Laboratory Notebook of [REDACTED] [REDACTED]	Wilton 18 Adams 03 Dowdy 13
DTX-0124		SRPT-VYDS-0156085	SRPT-VYDS-0156292	Collins 3880 Account Book - [REDACTED] [REDACTED]	Wilton 18 Adams 03 Dowdy 13
DTX-0125	5/26/2005	WILTON0026261	WILTON0026262	Email from F. Muntoni to S. Wilton RE: [REDACTED] [REDACTED]	Wilton 20
DTX-0126		SRPT-VYDS-0158109	SRPT-VYDS-0158290	Collins 3880 Account Book - Abbie Fall [REDACTED] [REDACTED]	Wilton 21 Adams 06
DTX-0127	11/23/2005	WILTON0012314	WILTON0012314	Email to S. Wilton from A. Fall RE: [REDACTED]	Wilton 23 Adams 07
DTX-0128	3/2/2011	WILTON0018019	WILTON0018024	Email from M. Wood to S. Wilton	Wilton 33
DTX-0129	5/1/2019	SRPT-VYDS-0213508	SRPT-VYDS-0213541	Supply and Services Agreement between [REDACTED] [REDACTED] and [REDACTED]	Wong 05

Sarepta-UWA Tenth Revised Trial Exhibit List

November 25, 2024

Confidential

DTX-0130	2/4/2019	NS00074976	NS00074985	Title Model Addendum	Gendron 22A
DTX-0131	2/4/2020	NS00074933	NS00074955	██████████ Guidelines between NS Pharma and ██████████	Gendron 23
DTX-0132 DTX-0634		SRPT-VYDS-0213320	SRPT-VYDS-0213322	████████████████████ ████████████████████ ████████████████████	Wong 10
DTX-0133				Excel document related to ██████████ ██████████	Wong 11
DTX-0134 DTX-0629		SRPT-VYDS-0208199	SRPT-VYDS-0208200	Profitability analysis; ██████████	Wong 12
DTX-0135	8/1/2020	NS00075079	NS00075120	██████████ Agreement between NS Pharma and ██████████	Gendron 25
DTX-0136	11/17/2021	SRPT-VYDS-0207178	SRPT-VYDS-0207237	Amendment No. 2 to License Agreement between Sarepta Therapeutics, Inc. and BioMarin Leiden Holding BV	Zenkus 04
DTX-0137				Linkedin profile of J. Zenkus	Zenkus 05
DTX-0138	11/24/2008	SRPT-VYDS-0154831	SRPT-VYDS-0154862	Exclusive License Agreement between The University of Western Australia and AVI BioPharma, Inc.	Zenkus 06
DTX-0139	4/10/2013	SRPT-VYDS-0154863	SRPT-VYDS-0154889	Amended and Restated Exclusive License Agreement between The University of Western Australia and Sarepta Therapeutics	Zenkus 07
DTX-0140	6/22/2020	NS00075122	NS00075161	██████████ Agreement between NS Pharma and ██████████	Gendron 26
DTX-0141 DTX-0736	7/17/2017	SRPT-VYDS-0207092	SRPT-VYDS-0207177	License Agreement between Sarepta Therapeutics, Inc. and Sarepta International C.V. and BioMarin Nederlands BV and BioMarin Technologies BV	Zenkus 09 Hosfield 12

Sarepta-UWA Tenth Revised Trial Exhibit List

November 25, 2024

Confidential

DTX-0142 DTX-0628	4/14/2019	SRPT-VYDS-0207088	SRPT-VYDS-0207091	Amendment No. 1 to License Agreement between Sarepta Therapeutics, Inc. and ST International Holdings Two, Inc. and BioMarin Leiden Holding BV	Zenkus 10
DTX-0143	11/1/2012	SRPT-VYDS-0206870	SRPT-VYDS-0206933	██████████ Consortium Agreement, ██████████	Zenkus 12
DTX-0144 DTX-0627	12/5/2013	SRPT-VYDS-0206683	SRPT-VYDS-0206707	Non-Exclusive License Agreement between Royal Holloway and Bedford New College and Sarepta Therapeutics, Inc.	Zenkus 13
DTX-0145	2021-02-00			Highlights of Prescribing Information of Vyondys 53 (Revised 02/2021)	Zenkus 14
DTX-0146	12/21/2019	SRPT-VYDS-0204720	SRPT-VYDS-0204833	License, Collaboration, and Option Agreement By and Between Sarepta Therapeutics Three, LLC and F. Hoffmann-La Roche Ltd	Zenkus 15
DTX-0147	6/9/2021	SRPT-VYDS-0223093	SRPT-VYDS-0223095	Email from M. Today to J. Zenkus RE: ██████████	Zenkus 17
DTX-0148	6/10/2021	SRPT-VYDS-0223092	SRPT-VYDS-0223092	Email from J. Zenkus to M. Today RE: follow-up	Zenkus 18
DTX-0149	7/6/2021	SRPT-VYDS-0223211	SRPT-VYDS-0223214	Email from J. Zenkus to M. Today RE: ██████████	Zenkus 19 Toda 36
DTX-0150	8/1/2021	NS00074369	NS00074463	Duchenne's Muscular Dystrophy Presentation.	Gendron 27
DTX-0151	4/25/2021	NS00096000	NS00096000	Email from Y. Sugiyama to G. Gendron re ██████████ ██████████ 2021-4-23.docx	Gendron 30
DTX-0152	4/23/2021	NS00096001	NS00096004	██████████ Commercial Department	Gendron 31
DTX-0153	9/1/2022	NS00041924	NS00042003	██████████ presentation	Gendron 32
DTX-0154 DTX-0600	8/2/2022	NS00057814	NS00057855	Overview of ██████████ Strategy, NS Pharma Presentation	Gendron 33
DTX-0155	8/1/2022	NS00043395	NS00043422	Viltepso 2022 ██████████ Plan, NS Pharma Presentation	Gendron 37 Sudovar 08

Sarepta-UWA Tenth Revised Trial Exhibit List

November 25, 2024

Confidential

DTX-0156	8/4/2010	NS00036957	NS00036965	agreement between Nippon Shinyaku and [REDACTED] dated August 4, 2010	Takagaki 16 Takeda 05
DTX-0157		NS00035404	NS00035428	Product Quality Review, Application Number 212154Orig1s000, Center for Drug Evaluation and Research	Magnus 06
DTX-0158		NS00035429	NS00035450	Clinical Pharmacology Review(s), Application Number 212154Orig1s000, Center for Drug Evaluation and Research	Magnus 07
DTX-0159		NS00035451	NS00035579	Clinical Review(s), Application Number 212154Orig1s000, Center for Drug Evaluation and Research	Magnus 08 Melia 07
DTX-0160		NS00035580	NS00035605	Proprietary Name Review(s), Application Number 212154Orig1s000, Center for Drug Evaluation and Research	Magnus 09
DTX-0161		NS00035610	NS00035667	Other Review(s), Application Number 212154Orig1s000, Center for Drug Evaluation and Research	Magnus 10
DTX-0162		NS00035668	NS00035716	Non-Clinical Review(s), Application Number 212154Orig1s000, Center for Drug Evaluation and Research	Magnus 11
DTX-0163		NS00035717	NS00035726	Risk Assessment and Risk Mitigation Review(s), Application Number 212154Orig1s000, Center for Drug Evaluation and Research	Magnus 12
DTX-0164		NS00035727	NS00035754	Summary Review, Application Number 212154Orig1s000, Center for Drug Evaluation and Research	Magnus 13
DTX-0165		NS00035755	NS00035767	Approval Package for Application Number 212154Orig1s000, Center for Drug Evaluation and Research	Magnus 14
DTX-0166	3/1/2021	NS00035784	NS00035794	Highlights of Prescribing Information of Viltepso, 3/2021	Magnus 15

Sarepta-UWA Tenth Revised Trial Exhibit List

November 25, 2024

Confidential

DTX-0167		NS00035826		2. Summaries; 2.1-2.5 Introduction to Summary	Magnus 16
DTX-0168		NS00035827		2. Summaries; 2.3 Quality Overall Summary	Magnus 17
DTX-0169		NS00035828		Quality Overall Summary, Description and Composition of the Drug Product	Magnus 18
DTX-0170	5/13/2022	NS00041039	NS00041264	Investigator's Brochure 9.0	Magnus 19
DTX-0171	7/30/2018	NS00052639	NS00052759	Clinical Study Report, NS-065/NCNP-01	Magnus 20
DTX-0172	5/30/2019	NS00052760	NS00052938	A Phase II, Dose Finding Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NS-065/NCNP-01 in Boys with Duchenne Muscular Dystrophy (DMD), NS-065/NCNP-01-201	Magnus 21
DTX-0173 DTX-0261	2019-19-20	NS00036928	NS00036934	██████████ Agreement between Nippon Shinyaku and ██████████	Takagaki 17 Toda 15
DTX-0174	9/20/2019	NS00065827	NS00065830	██████████ Agreement between Nippon Shinyaku and ██████████	Takagaki 18
DTX-0175		NS00065426	NS00065468	2. Summaries, Clinical Overview; 2.5 Clinical Overview	Magnus 22 Melia 05
DTX-0176		NS00065541	NS00065553	2.3 Quality Overall Summary, 2.3.P.2 Pharmaceutical Development	Magnus 23
DTX-0177		NS00066000	NS00066108	2.7 Clinical Summary, 2.7.3 Summary of Clinical Efficacy Duchenne Muscular Dystrophy	Magnus 24 Melia 06
DTX-0178	6/28/2023	NS00137710	NS00137980	Ninth Development Safety Update Report for Viltolarsen (NS-065/NCNP-01)	Magnus 26
DTX-0179	1/17/2020	NS00097387		Email from S. Sonohara to A. Latts re: FAQ, ██████████.docx	Magnus 29 Sudovar 25
DTX-0180	6/19/2019	NS00097388	NS00097400	Viltolarsen (NS-065/NCNP-01) FAQ	Magnus 30 Melia 08 Sudovar 26
DTX-0181		NS00056021	NS00056029	Cure Duchenne, Leslie Magnus, MD NS Pharma	Magnus 32

Sarepta-UWA Tenth Revised Trial Exhibit List

November 25, 2024

Confidential

DTX-0182	12/2/2022	NS00096010	NS00096010	E-mail from S. Sudovar to K. Kimura, re: [REDACTED] [REDACTED] [REDACTED] [REDACTED] [REDACTED] [REDACTED] VILTEPSO (viltolarsen) [REDACTED] [REDACTED] (1).docx; NS [REDACTED] [REDACTED].pptm	Gendron 39 Sudovar 11
DTX-0183	4/16/2020	NS00096011	NS00096030	NS Pharma Presentation, [REDACTED] [REDACTED]	Gendron 40 Sudovar 12
DTX-0184		NS00096031	NS00096049	NS Pharma Presentation, [REDACTED] [REDACTED]	Gendron 41 Sudovar 13
DTX-0185	3/24/2020	NS00096050	NS00096060	NS Pharma Presentation, [REDACTED] [REDACTED]	Gendron 42 Sudovar 14
DTX-0186	2/4/2020	NS00096061	NS00096086	NS Pharma Presentation, [REDACTED] [REDACTED]	Gendron 43 Sudovar 15
DTX-0187 DTX-0368	8/12/2020	NS00096087	NS00096092	VILTEPSO (viltolarsen) injection FDA Approval: [REDACTED]	Gendron 44 Sudovar 16
DTX-0188		NS00096093	NS00096163	NS Pharma Presentation, Viltepsos [REDACTED] [REDACTED]	[REDACTED] [REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED] Development Safety Update Report for Viltolarsen (NS-065/NCNP-01)	Melia 03
DTX-0190		NS00041423	NS00041436	An exon-skipping treatment option for DMD patients with an exon 52 deletion	Melia 04
DTX-0191 DTX-0260	9/20/2019	NS00065827	NS00065830	Certified English translation of [REDACTED] Agreement between Nippon Shinyaku and [REDACTED]	Takagaki 19
DTX-0192	8/24/2011	NS00073716	NS00073743	Duchenne muscular dystrophy (DMD) therapeutic agent - [REDACTED] [REDACTED]	Takagaki 20 Toda 21A

Sarepta-UWA Tenth Revised Trial Exhibit List

November 25, 2024

Confidential

DTX-0193	8/24/2011	NS00073716	NS00073743	Certified english translation of Duchenne muscular dystrophy (DMD) therapeutic agent - [REDACTED] [REDACTED]	Takagaki 21 Toda 21
DTX-0194		NS00073427	NS00073427	Viltepso [REDACTED]	Takagaki 23
DTX-0195		NS00073427	NS00073427	Certified english translation of Viltepso [REDACTED] [REDACTED]	Takagaki 24
DTX-0196		NS00073426	NS00073426	Viltepso [REDACTED]	Takagaki 25
DTX-0197		NS00073426	NS00073426	Certified english translation of Viltepso [REDACTED] [REDACTED]	Takagaki 26
DTX-0198				Japanese facilities relating to topic 71	Takagaki 27
DTX-0199		NS00061840	NS00061845	Selective Antisense Array to Skip Exon53	Takagaki 29 Watanabe 15
DTX-0200		NS00061840	NS00061845	Certified english translation of Selective Antisense Array to Skip Exon53	Takagaki 30 Watanabe 15A
DTX-0201	9/15/2009	NS00061097	NS00061098	[REDACTED] from the [REDACTED] [REDACTED] Meeting	Takagaki 31
DTX-0202	9/15/2009	NS00061097	NS00061098	Certified english translation of [REDACTED] from the [REDACTED] Meeting	Takagaki 32
DTX-0203	10/15/2009	NS00091091	NS00091105	[REDACTED]	Takagaki 37
DTX-0204	1/28/2010	NS00063643	NS00063654	[REDACTED] presentation entitled, "Development of DMD Therapies"	Takagaki 38 Satou 09 Watanabe 28
DTX-0205	1/28/2001	NS00063643	NS00063654	Certified english translation of [REDACTED] presentation entitled, "Development of DMD Therapies"	Takagaki 39 Satou 09A Watanabe 28A
DTX-0206	2/25/2010	NS00061582	NS00061586	[REDACTED] presentation entitled, [REDACTED] [REDACTED]	Takagaki 40 Ueda 10 Watanabe 12
DTX-0207	2/25/2010	NS00061582	NS00061586	Certified english translation of [REDACTED] presentation entitled, [REDACTED] [REDACTED]"	Takagaki 41 Ueda 10A Watanabe 12A

Sarepta-UWA Tenth Revised Trial Exhibit List

November 25, 2024

Confidential

DTX-0208	9/27/2010	NS00073610	NS00073653	[REDACTED] meeting materials	Takagaki 42
DTX-0209	9/27/2010	NS00073610	NS00073653	Certified english translation of [REDACTED] [REDACTED] meeting materials	Takagaki 43
DTX-0210		NS00059688	NS00059695	Presentation entitled '[REDACTED] [REDACTED] Material'	Takagaki 44
DTX-0211	8/10/2022	NS00039681	NS00039840	A Phase II, Open-Label, Extension Study to Assess the Safety and Efficacy of NS-065/NCNP-01 in Boys with Duchenne Muscular Dystrophy (DMD)	Melia 11
DTX-0212		NS00059688	NS00059695	Certified english translation of 143 Presentation entitled "DMD [REDACTED] [REDACTED]"	Takagaki 45
DTX-0213	12/27/2012	NS00076300	NS00076300	Email from K. Takagaki to K. Mori; N. Takashi; and Y. Yamashita RE: [REDACTED] [REDACTED]	Takagaki 46
DTX-0214	12/27/2012	NS00076300	NS00076300	Certified english translation of Email from K. Takagaki to K. Mori; N. Takashi; and Y. Yamashita RE: [REDACTED] [REDACTED]	Takagaki 47
DTX-0215	8/4/2021	NS00046479	NS00046486	Study to Assess the Efficacy and Safety of Viltolarsen in Ambulant Boys With DMD (RACER53), ClinicalTrials.gov	Melia 12
DTX-0216	5/26/2020	NS00035339	NS00035348	P. Clemens et al., Safety, tolerability, and efficacy of viltolarsen in boys with duchenne muscular dystrophy amenable to exon 53 skipping: a phase 2 randomized clinical trial, JAMA Neurology (2020)	Satou 01
DTX-0217	12/24/2008	NS00085193	NS00085198	Email from S. Yasufuku to T. Ohgi; K. Takagaki; S. Sonoke; and H. Kitagawa RE: [REDACTED] [REDACTED] with attachment [REDACTED] [REDACTED]_added kuwa.doc'	Takagaki 48

Sarepta-UWA Tenth Revised Trial Exhibit List

November 25, 2024

Confidential

DTX-0218	12/24/2008	NS00085193	NS00085198	Certified english translation of Email from S. Yasufuku to T. Ohgi; K. Takagaki; S. Sonoke; and H. Kitagawa RE: [REDACTED] with attachment [REDACTED]_added kuwa.doc'	Takagaki 49
DTX-0219		NS00000064	NS00000066	US 9,708,361 B2, Claims in Certified Japanese Translation	Satou 02A Takeda 02A Watanabe 02A
DTX-0220	3/9/2009	NS00073545	NS00073547	[REDACTED] [REDACTED]	Takagaki 50
DTX-0221	3/9/2009	NS00073545	NS00073547	Certified english translation of [REDACTED] [REDACTED] [REDACTED]	Takagaki 51
DTX-0222	8/28/2009	NS00085275	NS00085295	Email from Y. Washikita to A. Matsuura; T. Kyoi; M. Matsuoka; M. Hattori; H. Mukai; A. Nakamura; S. Ochi; H. Nishida; K. Kuwabara; S. Mitawaki; K. Kameyama; E. Doi; T. Ohgi; M. Tanaka; K. Mori; Y. Maruyama; T. Asaki; T. Harabe; T. Fujii; Y. Shirouchi; H. Fuki; S. Watanabe; K. Nonaka; S. Hayashi; S. Ishibashi; Y. Yamashita; K. Nawa; S. Sonoke; K. Takagaki RE: [REDACTED] [REDACTED] Sending notes and attachment [REDACTED].doc'	Takagaki 52

Sarepta-UWA Tenth Revised Trial Exhibit List

November 25, 2024

Confidential

DTX-0223	8/28/2009	NS00085275	NS00085295	Certified English translation of Email from Y. Washikita to A. Matsuura; T. Kyoi; M. Matsuoka; M. Hattori; H. Mukai; A. Nakamura; S. Ochi; H. Nishida; K. Kuwabara; S. Mitawaki; K. Kameyama; E. Doi; T. Ohgi; M. Tanaka; K. Mori; Y. Maruyama; T. Asaki; T. Harabe; T. Fujii; Y. Shirouchi; H. Fukiu; S. Watanabe; K. Nonaka; S. Hayashi; S. Ishibashi; Y. Yamashita; K. Nawa; S. Sonoke; K. Takagaki RE: [REDACTED] [REDACTED] Sending notes and attachment [REDACTED] [REDACTED].doc'	Takagaki 53
DTX-0224	11/25/2009	NS00085355	NS00085370	Email from N. Watanabe to K. Takagi RE: [REDACTED] [REDACTED].ppt'	Takagaki 54 Watanabe 32
DTX-0225	11/25/2009	NS00085355	NS00085370	Certified english translation of Email from N. Watanabe to K. Takagaki RE: [REDACTED] [REDACTED].ppt'	Takagaki 55 Watanabe 32A
DTX-0226	1/24/2013	NS00073744	NS00073785	[REDACTED] Meeting Materials	Takagaki 56
DTX-0227	1/24/2013	NS00073744	NS00073785	Certified english translation of [REDACTED] [REDACTED] Meeting Materials	Takagaki 57
DTX-0228	1/24/2013	NS00065611	NS00065616	Minute record of [REDACTED] Meeting	Takagaki 58
DTX-0229	1/24/2013	NS00065611	NS00065616	Certified english translation of [REDACTED] [REDACTED] Meeting	Takagaki 59
DTX-0230 DTX-0321	4/28/2010	NS00061338	NS00061339	[REDACTED] by Hidetoshi Kitagawa	Takagaki 60 Watanabe 13

Sarepta-UWA Tenth Revised Trial Exhibit List

November 25, 2024

Confidential

DTX-0231 DtX-0322	4/22/2010	NS00061338	NS00061339	Certified english translation of [REDACTED] by Hidetoshi Kitagawa	Takagaki 61 Watanabe 13A
DTX-0232 DTX-1146	2021-00-00	NS00053735	NS00053750	S. Takeda et al., Exon-skipping in Duchenne muscular dystrophy, Journal of Neuromuscular Diseases 8: S343-S358 (2021)	Takeda 01
DTX-0233	8/24/2021	NS00000473	NS00000475	Certified Japanese translation of U.S. Patent 10,683,322	Takeda 03A Satou 03A Ueda 02A Watanabe 03A
DTX-0234	3/8/2012			Foreign document entitled "WO 2012/029986"	Takeda 04 Satou 04 Ueda 03 Watanabe 04
DTX-0235	3/8/2012			Certified english translation of foreign document entitled "WO 2012/029986"	Takeda 04A Satou 04A Ueda 03A Watanabe 04A
DTX-0236	2010-02-00			L. Popplewell et al., Comparative analysis of antisense oligonucleotide sequences targeting exon 53 of the human DMD gene: Implications for future clinical trials, Neuromuscular Disorders 2(2): 102-110 (2010)	Takeda 06 Satou 11 Watanabe 33 Wood 34
DTX-0237	7/1/2010			U.S. Patent Application Publication 2010/0168212	Takeda 07 Wood 35
DTX-0238	2011-07-00			E. Hoffman et al., Restoring dystrophin expression in Duchenne muscular dystrophy muscle: Project in exon skipping and stop codon read through, The American Journal of Pathology, 1279(1): 12-22 (2011)	Takeda 08

Sarepta-UWA Tenth Revised Trial Exhibit List

November 25, 2024

Confidential

DTX-0239 DTX-1211	2010-00-00			P. Sazani et al., Safety pharmacology and genotoxicity evaluation of AVI-4658, International Journal of Toxicology 29(2): 143-156 (2010)	Takeda 09 Ueda 07
DTX-0240	8/31/2011			International Application Number PCT/JP2011/070318	Satou 05 Watanabe 14
DTX-0241	2009-08-00			A. Nakamura and S. Takeda, Symposium: Clinicopathological aspects of neuromuscular disorders - A new horizon, Neuropathology 29(4): 494-501 (2009)	Takeda 11
DTX-0242	10/6/2004			Foreign document entitled "WO 2004/048570"	Takeda 12
DTX-0243	9/1/2010			Patent application number JP 2010-196032, En. translated copy of JP Prov.	Satou 05A Watanabe 14A
DTX-0244	11/21/2003			European Patent Application Number 03774151.9 for EP 1,568,769	Takeda 12A
DTX-0245		NS00059735	NS00059976		Satou 06
DTX-0246	2015-00-00			Y. Masaki et al., Enhancement of exon skipping in mdx52 mice by 2'-O-methyl-2-thiobothymidine incorporation into phosphorothioate oligonucleotides, MedChemComm 6: 630-633 (2015)	Takeda 13
DTX-0247		NS00059977	NS00060242		Satou 07
DTX-0248	2023-05-00	NS00102924	NS00102987	Study Number: 936-21-M-0643 - Final Report: The assessment of exon skipping activities by 2'-OMe-S-RNA in myotube using Lipofectin as a transfection reagent	Tanaka 01 Hastings 18 Hastings 106
DTX-0249	2023-05-00	NS00102988	NS00103060	Study Number: 936-21-M-0644 - Final Report: The assessment of exon skipping activities by PMO in myotube using Endo-Porter DMSO as a transfection reagent	Tanaka 02 Hastings 19 Hastings 107

Sarepta-UWA Tenth Revised Trial Exhibit List

November 25, 2024

Confidential

DTX-0250	2023-05-00	NS00103061	NS00103110	Study Number: 936-22-M-0661 - Final Report: The assessment of exon skipping activities by PMO in myotube using Endo-Porter DMSO as a transfection reagent	Tanaka 03 Hastings 20 Hastings 108
DTX-0251	2/17/2010	NS00061181	NS00061182	Foreign document entitled [REDACTED]	Satou 10
DTX-0252 DTX-1413	2/17/2010	NS00061181	NS00061183	[REDACTED]	Satou 10A
DTX-0253	11/20/2022	NS00143952	NS00143956	Email from K. Kobayashi to I. Kazuya RE: [REDACTED]	Tanaka 11
DTX-0254	3/23/2022	NS00090737	NS00090744	Table of [REDACTED] survey results)	Toda 04
DTX-0255	3/23/2022	NS00090737	NS00090744	Foreign translation of document entitled [REDACTED] survey results)"	Toda 04A
DTX-0256	9/20/2019	NS00065810	NS00065821	NS Pharma, Inc. and [REDACTED] Memorandum	Toda 05
DTX-0257	9/20/2022	NS00065810	NS00065821	Foreign translation of document entitled "NS Pharma, Inc. and [REDACTED] Memorandum"	Toda 05A
DTX-0258	9/20/2019	NS00036888	NS00036892	Memorandum [REDACTED] from Nippon Shinyaku Co., Ltd. to NS Pharma, Inc.	Toda 06
DTX-0259	9/20/2019	NS00036888	NS00036892	Foreign translation of document entitled [REDACTED] from Nippon Shinyaku Co., Ltd. to NS Pharma, Inc."	Toda 06A
DTX-0260 DTX-0191	3/16/2020	NS00065827	NS00065830	NS Pharma, Inc. [REDACTED] agreement	Toda 07 Takagaki 18

Sarepta-UWA Tenth Revised Trial Exhibit List

November 25, 2024

Confidential

DTX-0261 DTX-0174	3/16/2020	NS00065827	NS00065830	Foreign translation of document entitled "[REDACTED] [REDACTED] agreement"	Toda 07A Takagaki 19
DTX-0262	4/1/2020	NS00036893	NS00036908	[REDACTED] agreement between Nippon Shinyaku and NS Pharma, Inc.	Toda 08
DTX-0263	4/1/2020	NS00036893	NS00036908	Foreign translation of document entitled "[REDACTED] [REDACTED] agreement between Nippon Shinyaku and NS Pharma, Inc."	Toda 08A Hosfield 09
DTX-0264	4/1/2021	NS00036966	NS00036967	Memorandum [REDACTED] between Nippon Shinyaku and NS Pharma Inc.	Toda 09
DTX-0265	4/1/2021	NS00036966	NS00036967	Foreign translation of document entitled "Memorandum [REDACTED] between Nippon Shinyaku and NS Pharma Inc."	Toda 09A
DTX-0266	1/31/2022	NS00036968	NS00036968	Final [REDACTED] Calendar Year 2021	Toda 10
DTX-0267	7/25/2022	NS00036975	NS00036985	NS Pharma Organization Chart	Sudovar 03 Gendron 04
DTX-0268	1/31/2022	NS00036968	NS00036968	Foreign translation of document entitled " Final [REDACTED] Calendar Year 2021"	Toda 10A
DTX-0269	1/30/2023	NS00091311	NS00091311	Final [REDACTED] Calendar Year 2022	Toda 11
DTX-0270	4/1/2023	NS00091314	NS00091315	Memorandum [REDACTED] between Nippon Shinyaku Co. and NS Pharma, Inc.	Toda 12
DTX-0271		NS00073341	NS00073368	Viltepsom [REDACTED], S. Sudovar	Sudovar 04
DTX-0272 DTX-0877	4/11/2023	NS00091312	NS00091312	Preliminary [REDACTED] Fiscal Year 2023	Gendron 11 Toda 13

Sarepta-UWA Tenth Revised Trial Exhibit List

November 25, 2024

Confidential

DTX-0273	4/15/2021	NS00127938	NS00127940	E-mail from L. Bicknell to D. Quigley, S.Sudovar, Z.To, G. Go, M. Nassar, A. Shih, N. Jones, C. Heaver, A. Timney, Y. Jaramillo. RE: Recap: [REDACTED]. Attachments: [REDACTED]_03042021[1] - Read-Only.pptx; Reference 2 - Clemens 2020.pdf	Sudovar 05
DTX-0274	2/26/2021	NS00127941	NS00127951	[REDACTED] in Context	Sudovar 06
DTX-0275	7/14/2021	NS00059145	NS00059230	NS Pharma [REDACTED] Meeting	Sudovar 07
DTX-0276	11/26/2020			Memorandum on the [REDACTED] between [REDACTED] and Nippon Shinyaku Co.	Toda 14
DTX-0277	9/20/2019			Agreement between [REDACTED] and Nippon Shinyaku Co. re: [REDACTED]	Toda 15
DTX-0278	2022-00-00	NS00090510	NS00090566	[REDACTED] Agreement for [REDACTED] between Nippon Shinyaku Co. and [REDACTED]	Toda 16
DTX-0279	7/14/2021	NS00090573	NS00090696	[REDACTED] Agreement for [REDACTED] between Nippon Shinyaku Co. and [REDACTED]	Today 17
DTX-0280		NS00091313	NS00091313	Excel spreadsheet indicating [REDACTED]	Toda 22
DTX-0281 DTX-0086		NS00091316	NS00091316	Excel spreadsheet relating [REDACTED]	Toda 23
DTX-0282	10/21/2015	SRPT-VYDS-0222265	SRPT-VYDS-0222274	Email from M. Gall to M. Toda RE: [REDACTED]	Toda 27

Sarepta-UWA Tenth Revised Trial Exhibit List

November 25, 2024

Confidential

DTX-0283	10/21/2015	SRPT-VYDS-0222265	SRPT-VYDS-0222274	Foreign translation of Email from M. Gall to M. Toda RE: [REDACTED] [REDACTED]	Toda 27A
DTX-0284	10/13/2017	SRPT-VYDS-0222796	SRPT-VYDS-0222801	Email from M. Toda to M. Gall RE: [REDACTED] [REDACTED]	Toda 29
DTX-0285	10/13/2017	SRPT-VYDS-0222796	SRPT-VYDS-222801	Foreign translation of Email from M. Toda to M. Gall RE: [REDACTED]	Toda 29A
DTX-0286	10/29/2018	SRPT-VYDS-0222970	SRPT-VYDS-0222972	Email from M. Toda to M. Gall RE: [REDACTED] [REDACTED]	Toda 30
DTX-0287	10/29/2018	SRPT-VYDS-0222970	SRPT-VYDS-0222972	Foreign translation of Email from M. Toda to M. Gall RE: [REDACTED]	Toda 30A
DTX-0288	12/5/2018	SRPT-VYDS-0223429	SRPT-VYDS-0223430	Email from M. Toda to M. Gall RE: [REDACTED] [REDACTED]	Toda 31
DTX-0289	12/5/2018	SRPT-VYDS-0223429	SRPT-VYDS-0223430	Foreign translation of Email from M. Toda to M. Gall RE: [REDACTED]	Toda 31A
DTX-0290	11/29/2019	SRPT-VYDS-0223159	SRPT-VYDS-0223159	Email from M. Toda to M. Gall RE: Hello, Gall-san; from Masaya Toda (Nippon Shinyaku)	Toda 32
DTX-0291	11/29/2019	SRPT-VYDS-0223159	SRPT-VYDS-0223159	Foreign translation of Email from M. Toda to M. Gall RE: Hello, Gall-san; from Masaya Toda (Nippon Shinyaku)	Toda 32A
DTX-0292	1/2/2020	SRPT-VYDS-0223074	SRPT-VYDS-0223077	Email from M. TODa to M. Gall RE: [REDACTED] and attachment 'ATT00001.jpg'	Toda 33
DTX-0293	5/6/2020	SRPT-VYDS-0223099	SRPT-VYDS-0223106	Email from M. Toda to M. Gall RE: [REDACTED] [REDACTED] and attachments 'ATT000001.jpg', 'ATT000002.jpg', 'AT000003.jpg', 'ATT000004.jpg', 'ATT000005.jpg'	Toda 34

Sarepta-UWA Tenth Revised Trial Exhibit List

November 25, 2024

Confidential

DTX-0294	5/6/2020	SRPT-VYDS-0223099	SRPT-VYDS-0223106	Foreign translation of Email from M. Toda to M. Gall RE: [REDACTED] and attachments 'ATT000001.jpg', 'ATT000002.jpg', 'AT000003.jpg', 'ATT000004.jpg', 'ATT000005.jpg'	Toda 34A
DTX-0295	6/1/2020			Mutual Confidentiality Agreement between [REDACTED] and [REDACTED]	Toda 35 Maness 07
DTX-0296	4/1/2009	NS0007554	NS00073559	Institutional List, April 2009, Development Headquarters	Ueda 04
DTX-0297	4/1/2009	NS00073554	NS00073559	Certified english translation of Institutional List, April 2009, Development Headquarters	Ueda 04A
DTX-0298				Documents, "Experimental Report" and "Declaration of Mr. Ueda," respectively filed 3/16/18 and 10/27/22, in European Patent 3,018,211	Ueda 05
DTX-0299				Foreign translation of Documents, "Experimental Report" and "Declaration of Mr. Ueda," respectively filed 3/16/18 and 10/27/22, in European Patent 3,018,211	Ueda 05A
DTX-0300	1/13/2011	NS00077554	NS00077563	Email from H. Kitagawa to H. Toyoshiima; K. Takagaki; K. Kuwabara; K. Higashiyama; N. Watanabe; S. Sooke; S. Nagata; S. Nakagawa; T. Ueda; and Y. Enya RE: General Notification: (NDK) GLP Safety Study (January 14, 9:00 a.m. ZE9 Location: 3F Seminar Room) and attachment '101227_NDK Post-Drug Discovery Council GLP study details review memo final.pdf'	Ueda 06

Sarepta-UWA Tenth Revised Trial Exhibit List

November 25, 2024

Confidential

DTX-0301	1/13/2011	NS00077554	NS00077563	Certified english translation of Email from H. Kitagawa to H. Toyoshiima; K. Takagaki; K. Kuwabara; K. Higashiyama; N. Watanabe; S. Sooke; S. Nagata; S. Nakagawa; T. Ueda; and Y. Enya RE: General Notification: (NDK) GLP Safety Study (January 14, 9:00 a.m. ZE9 Location: 3F Seminar Room) and attachment '101227_NDK Post-Drug Discovery Council GLP study details review memo final.pdf'	Ueda 06A
DTX-0302	4/5/2012			Foreign Patent Document - WO 2012/043730	Ueda 08
DTX-0303				English Specification of Foreign Patent Document - WO 2012/043730	Ueda 08A
DTX-0304		NS00137981	NS00138039	[REDACTED]	Ueda 09
DTX-0305		NS00137981	NS00138042	Certified english translation of [REDACTED]	Ueda 09A
DTX-0306		NS00138040	NS00138040	Excel spreadsheet entitled [REDACTED]	Ueda 11
DTX-0307		NS00138040	NS00138040	Excel spreadsheet entitled [REDACTED]	Ueda 12
DTX-0308		NS00138331	NS00138340	[REDACTED] powerpoint	Ueda 13
DTX-0309		NS00138331	NS00138340	Certified english translation of [REDACTED] powerpoint	Ueda 13A
DTX-0310	2010-09-00	NS00074094	NS00074344	[REDACTED]	Watanabe 01
DTX-0311	10/29/2008	NS00063146	NS00063162	Presentation titled [REDACTED]	Watanabe 05
DTX-0312	10/29/2008	NS00063146	NS00063162	Certified english translation of Presentation titled [REDACTED]	Watanabe 05A
DTX-0313	3/18/2009	NS00061802	NS00061805	Mr. Kitagawa's [REDACTED]	Watanabe 07

Sarepta-UWA Tenth Revised Trial Exhibit List

November 25, 2024

Confidential

DTX-0314	3/18/2009	NS00061802	NS00061805	Certified english translation of Mr. Kitagawa's [REDACTED]	Watanabe 07A
DTX-0315	8/26/2009	NS00061604	NS00061607	Mr. Kitagawa's [REDACTED] [REDACTED]	Watanabe 09
DTX-0316	8/26/2009	NS00061604	NS00061607	Certified english translation of Mr. Kitagawa's [REDACTED]	Watanabe 09A
DTX-0317	9/2/2009	NS00061271	NS00061272	Mr. Kitagawa's [REDACTED] [REDACTED]	Watanabe 10
DTX-0318	9/2/2009	NS00061271	NS00061272	Certified english translation of Mr. Kitagawa's [REDACTED] [REDACTED]	Watanabe 10A
DTX-0319	2/17/2010	NS00061427	NS00061429	Mr. Kitagawa's [REDACTED] [REDACTED]	Watanabe 11
DTX-0320	2/17/2010	NS00061427	NS00061429	Certified English translation of Mr. Kitagawa's [REDACTED] [REDACTED]	Watanabe 11A
DTX-0321 DTX-0230	4/28/2010	NS00061338	NS00061339	Mr. Kitagawa's [REDACTED] [REDACTED]	Watanabe 13 Takagaki 60
DTX-0322 DTX-0231	4/28/2010	NS00061338	NS00061339	Certified english translation of Mr. Kitagawa's [REDACTED]	Watanabe 13A Takagaki 61
DTX-0323	6/17/2009	NS00061035	NS00061035	Mr. Watanabe's [REDACTED]	Watanabe 16
DTX-0324	6/17/2009	NS00061035	NS00061035	Certified English translation of Mr. Watanabe's [REDACTED]	Watanabe 16A
DTX-0325	6/17/2009	NS00061118	NS00061118	Mr. Sato's [REDACTED] [REDACTED]	Watanabe 17
DTX-0326	6/17/2009	NS00061118	NS00061118	Certified English translation of Mr. Sato's [REDACTED] [REDACTED]	Watanabe 17A

Sarepta-UWA Tenth Revised Trial Exhibit List

November 25, 2024

Confidential

DTX-0327		NS00061808	NS00061819	Powerpoint presentation entitled [REDACTED] [REDACTED] [REDACTED] [REDACTED] [REDACTED]	Watanabe 18
DTX-0328		NS00061808	NS00061819	Certified English translation of Powerpoint presentation entitled [REDACTED] [REDACTED] [REDACTED] [REDACTED] [REDACTED]	Watanabe 18A
DTX-0329	7/29/2009	NS00060995	NS00060995	Mr. Sato's [REDACTED] [REDACTED]	Watanabe 19
DTX-0330	7/29/2009	NS00060995	NS00060995	Certified English translation of Mr. Sato's [REDACTED] [REDACTED]	Watanabe 19A
DTX-0331	8/5/2009	NS00061119	NS00061120	Mr. Sato's [REDACTED] [REDACTED]	Watanabe 20
DTX-0332	8/5/2009	NS00061119	NS00061120	Certified English translation of Mr. Sato's [REDACTED] [REDACTED]	Watanabe 20A
DTX-0333	8/19/2009	NS00061106	NS00061107	Mr. Sato's [REDACTED] [REDACTED]	Watanabe 21
DTX-0334	8/19/2009	NS00061106	NS00061107	Certified English translation of Mr. Sato's [REDACTED] [REDACTED]	Watanabe 21A
DTX-0335	8/26/2009	NS00061116	NS00061117	Mr. Sato's [REDACTED] [REDACTED]	Watanabe 23
DTX-0336	8/26/2009	NS00061116	NS00061117	Certified English translation of Mr. Sato's [REDACTED] [REDACTED] [REDACTED]	Watanabe 22A
DTX-0337	2009-04-00	NS00066456	NS00066668	[REDACTED]	Watanabe 23

Sarepta-UWA Tenth Revised Trial Exhibit List

November 25, 2024

Confidential

DTX-0338	9/2/2009	NS00061263	NS00061265	Mr. Sato's [REDACTED] [REDACTED]	Watanabe 24
DTX-0339	9/2/2009	NS00061263	NS00061265	Certified English translation of Mr. Sato's [REDACTED] [REDACTED]	Watanabe 24A
DTX-0340	9/9/2009	NS00061379	NS00061382	Mr. Sato's [REDACTED] [REDACTED]	Watanabe 25
DTX-0341	9/9/2009	NS00061379	NS00061382	Certified English translation of Mr. Sato's [REDACTED] [REDACTED]	Watanabe 25A
DTX-0342	10/14/2009	NS00061188	NS00061189	Mr. Sato's [REDACTED] [REDACTED]	Watanabe 26
DTX-0343	10/14/2009	NS00061188	NS00061189	Certified English translation of Mr. Sato's [REDACTED] [REDACTED]	Watanabe 26A
DTX-0344	6/23/2010	NS00062225	NS00062237	Powerpoint presentation entitled [REDACTED] [REDACTED]	Watanabe 34
DTX-0345	6/23/2010	NS00062225	NS00062237	Certified English translation of Powerpoint presentation entitled [REDACTED] [REDACTED]	Watanabe 34A
DTX-0346	7/29/2010	NS00081120	NS00081145	Powerpoint presentation entitled [REDACTED] [REDACTED].ppt'	Watanabe 35
DTX-0347	7/29/2010	NS00081120	NS00081145	Certified English translation of Powerpoint presentation entitled [REDACTED] [REDACTED].ppt'	Watanabe 35A
DTX-0348	8/4/2010	NS00060984	NS00060984	Mr. Watanabe's [REDACTED]	Watanabe 36
DTX-0349	8/4/2010	NS00060984	NS00060984	Certified English translation of Mr. Watanabe's [REDACTED] [REDACTED]	Watanabe 36A
DTX-0350	8/18/2010	NS00061042	NS00061042	Mr. Watanabe's [REDACTED]	Watanabe 37
DTX-0351	8/18/2010	NS00061042	NS00061042	Certified English translation of Mr. Watanabe's [REDACTED] [REDACTED]	Watanabe 37A

Sarepta-UWA Tenth Revised Trial Exhibit List

November 25, 2024

Confidential

DTX-0352	3/5/2010	NS00085390	NS00085439	Email from S. Nakagawa to A. Nakamura; S. Watanabe; K. Nonoka; S. Ochi; S. Ishibashi; Y. Yamashita; and S. Hayashi RE: NKD with attachments [REDACTED].pdf,, [REDACTED].pdf' and [REDACTED].ppt'	Watanabe 39
DTX-0353	3/5/2010	NS00085390	NS00085439	English translation of Email from S. Nakagawa to A. Nakamura; S. Watanabe; K. Nonoka; S. Ochi; S. Ishibashi; Y. Yamashita; and S. Hayashi RE: NKD with attachments [REDACTED].pdf,, [REDACTED].pdf' and [REDACTED].ppt'	Watanabe 39A
DTX-0354	8/15/2016			Experimental Report of Dr. Watanabe in Opposition of EP 2,206,781	Watanabe 41
DTX-0355	8/15/2016			Foreign translation of Experimental Report of Dr. Watanabe in Opposition of EP 2,206,781	Watanabe 41A
DTX-0356	9/26/2017			Experimental Report of Dr. Watanabe DATED 9/26/17	Watanabe 42
DTX-0357	9/26/2017			Foreign translation of Experimental Report of Dr. Watanabe DATED 9/26/17	Watanabe 42A
DTX-0358		NS00091284	NS00091309	[REDACTED]	Watanabe 43
DTX-0359	9/26/2017			Experimental Report of Mr. Tone dated 9/26/17	Watanabe 44
DTX-0360	9/26/2017			Foreign translation of Experimental Report of Mr. Tone dated 9/26/17	Watanabe 44A
DTX-0361	1/19/2015	NS00091317	NS00091318	Report of Dr. Watanabe entitled 'Activity Comparison of Morpholino Described in the Sarepta Patent Document'	Watanabe 45

Sarepta-UWA Tenth Revised Trial Exhibit List

November 25, 2024

Confidential

DTX-0362	1/19/2015	NS00091317	NS00091318	Certified English translation of Report of Dr. Watanabe entitled 'Activity Comparison of Morpholino Described in the Sarepta Patent Document'	Watanabe 45A
DTX-0363		NS00091319	NS00091319	Excel document regarding [REDACTED] [REDACTED]	Watanabe 46
DTX-0364 DTX-0046				Experimental report and declaration of Mr. Ueda for EP 3,018,211 dated 3/16/18 and 10/27/21	Watanabe 47
DTX-0365				Foreign translation of Experimental report and declaration of Mr. Ueda for EP 3,018,211 dated 3/16/18 and 10/27/21	Watanabe 47A
DTX-0366	7/14/2023			Efficacy and Safety. Efficacy data and four-year, long-term, open-label extension study	Sudovar 09
DTX-0367		NS00074851		Excel spreadsheet regarding [REDACTED] [REDACTED] r	Sudovar 10 Magnus 38
DTX-0368 DTX-0187	8/12/2020	NS00096087	NS00096092	VILTEPSO (viltolarsert) injection FDA Approval: Key Messages, Questions & Answers	Gendron 44 Sudovar 16
DTX-0369		NS00097136	NS00097198	Viltepso® 2020 Launch Brand Plan	Sudovar 18
DTX-0370	10/9/2020	NS00098489	NS00098492	E-mail from S. Sudovar to M. Young, RE: PerkinElmer Data Needs, attachments: VILTEPSO_Overview_for_Caregivers.pdf; VILTEPSO_Getting_Started_Overview.pdf; VILTEPSO_Infusion_Overview_Guide.pdf; US-NS65C-0344_48974_ID04B_AffordabilityBrochure-DIGITAL.pdf; USNS65C-0271_48937_O02A_NSSupport_GovHealthPlanOptions-DIGITAL.pdf; US-NS65C-0191_49163ID02C-Pat- Found-Flashcard.pdf	Sudovar 19

Sarepta-UWA Tenth Revised Trial Exhibit List

November 25, 2024

Confidential

DTX-0371		NS00098493	NS00098499	Getting to know VILTEPSO: A new treatment for Duchenne muscular dystrophy (DMD)	Sudovar 20
DTX-0372		NS00098500	NS00098508	Getting Started, Viltepso	Sudovar 21
DTX-0373		NS00098509	NS00098515	Infusion Overview, Viltepso	Sudovar 22
DTX-0374		NS00098516	NS00098523	Helping to provide affordable access to VILTEPSO (vittotarsen) injection	Sudovar 23
DTX-0375		NS00098524	NS00098537	Understanding Government-funded Health Insurance	Sudovar 24
DTX-0376	3/31/2022	NS00042807	NS00042857	NS Pharma Duchenne Muscular Dystrophy (DMD) Virtual Advisory Board	Sudovar 28 Maness 06
DTX-0377	3/19/2021	NS00128010		E-mail from N. Jones to S. Sudovar, D. Quigley, G. Go, B. Kazmi, A. Timney, L. Bicknell, RE: ABM messages - for review, Attachments: [REDACTED] [REDACTED].pdf	Sudovar 30
DTX-0378		NS00128011	NS00128025	VILT21CDNY3712 VILTEPSO [REDACTED] [REDACTED] [REDACTED]	Sudovar 31
DTX-0379	1/9/2020	NS00132160		E-mail from M. Falcicchio to S. Sudovar, S. Soto and D. Quigley, RE: Viltepso Strategy Session, Attachments: Viltepso_Strat Session Jan 9.pptx; Exondys 51 - Vis Aid.pdf	Sudovar 22
DTX-0380	2020-01-00	NS00132161	NS00132212	Viltepso Strategy Session	Sudovar 33 Maness 05 Lu 07
DTX-0381	10/1/2002	SRPT-VYDS-0008639	SRPT-VYDS-0008650	A. Aartsma-Rus et al., Targeted exon skipping as a potential gene correction therapy for Duchenne muscular dystrophy, Neuromuscular Disorders 12:571-577 (2002)	

November 25, 2024

Confidential

DTX-0382	2007-10-00	SRPT-VYDS-0009201	SRPT-VYDS-0009220	A. Aartsma-Rus & G.J. Van Ommen, Antisense-mediated exon skipping: a versatile tool with therapeutic and research applications, RNA: A Publication of the RNA Society 13(10):1609-1624 (2007)	
DTX-0383	2009-10-00	SRPT-VYDS-0009041	SRPT-VYDS-0009045	A. Aartsma-Rus, Less is more: therapeutic exon skipping for Duchenne muscular dystrophy, Lancet Neurology 8(10): 873-875 (2009)	
DTX-0384	2009-03-00	SRPT-VYDS-0008671	SRPT-VYDS-0008680	A. Aartsma-Rus et al., Guidelines for antisense oligonucleotide design and insight into splice-modulating mechanisms, Molecular Therapy 17(3):548-553 (2009)	
DTX-0385	7/2/2007	SRPT-VYDS-0008288	SRPT-VYDS-0008295	A. Adams et al., Antisense oligonucleotide induced exon skipping and the dystrophin gene transcript: cocktails and chemistries, BMC Molecular Biology 8(57) (2007)	
DTX-0386	2002-00-00	SRPT-VYDS-0007858	SRPT-VYDS-0007981	A. Alberts et al., Molecular biology of the cell, Fourth Edition, pp. 191-374 (2002)	
DTX-0387	2006-02-00	SRPT-VYDS-0228703	SRPT-VYDS-0228705	J. Alter et al., Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology, Nature Medicine 12(2):175-177 (2006)	
DTX-0388		SRPT-VYDS-0228706	SRPT-VYDS-0228719	Highlights of Prescribing Information, Amondys 45 Label, Rev. Mar. 2023	
DTX-0389	2010-11-00	SRPT-VYDS-0228720	SRPT-VYDS-0228730	Y. Aoki et al., In-frame dystrophin following exon 51-skipping improves muscle pathology and function in the exon 52-deficient mdx mouse, The American Society of Gene & Cell Therapy 18(11):1995-2005 (2010)	

November 25, 2024

Confidential

DTX-0390	2007-09-00	SRPT-VYDS-0009069	SRPT-VYDS-0009085	V. Arechavala-Gomez et al., Comparative analysis of antisense oligonucleotide sequences for targeted skipping of exon 51 dystrophin pre-mRNA splicing in human muscle, Human Gene Therapy 18(9):798-810 (2007)	
DTX-0391	2004-00-00	SRPT-VYDS-0009289	SRPT-VYDS-0009297	V. Arora et al., Neutrally charged phosphorodiamidate morpholino antisense oligomers: uptake, efficacy and pharmacokinetics, Current Pharmaceutical Biotechnology 5:431-439 (2004)	
DTX-0392	5/31/2016	SRPT-VYDS-0228249	SRPT-VYDS-0228252	BioMarin Announces Withdrawal of Market Authorization Application for Kyndrisa (drisapersen) in Europe; https://investors.biopharm.com/2016-05-31-BioMarin-Announces-Withdrawal-of-Market-Authorization-Application-for-Kyndrisa-drisapersen-in-Europe?... (2023)	
DTX-0393	2004-08-00	SRPT-VYDS-0007386	SRPT-VYDS-0007396	M. Bremmer-Bout et al., Targeted exon skipping in transgenic hDMD mice: a model for direct preclinical screening of human-specific antisense oligonucleotides, The Journal of the American Society of Gene Therapy 10(2):232-240 (2004)	
DTX-0394		SRPT-VYDS-0007616	SRPT-VYDS-0007635	Bushby, Diagnosis and Management of Duchenne Muscular Dystrophy, Part 1: Diagnosis, and Pharmacological and Psychosocial Management, (2010)	

November 25, 2024

Confidential

DTX-0395	6/23/2010	SRPT-VYDS-0007856	SRPT-VYDS-0007857	Business Wire, Prosena and GlaxoSmithKline initiate development of four additional products under existing alliance in Duchenne muscular dystrophy; Broadened program marks key inflexion in Prosensa's progress to a fully integrated specialty-pharma company; Business Wire, Inc. (2010)	
DTX-0396	2006-05-00	SRPT-VYDS-0009046	SRPT-VYDS-0009055	J. Chan et al., Antisense oligonucleotides: from design to therapeutic application, Clinical and Experimental Pharmacology and Physiology 33(5/6): 533-540 (2006)	
DTX-0397 DTX-1734	8/13/2011	SRPT-VYDS-0007646	SRPT-VYDS-0007658	S. Cirak et al., Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study, The Lancet 378(9791):595-605 (2011)	
DTX-0398		SRPT-VYDS-0228731	SRPT-VYDS-0228824	File History for U.S. App. No. 61,591,354	
DTX-0399	4/22/1993	SRPT-VYDS-0007596	SRPT-VYDS-0007602	Z. Dominski & R. Kole, Restoration of correct splicing in thalassemic pre-mRNA by antisense oligonucleotides, Proceedings of the National Academy of Sciences of the United States of America 90(18):8673-8677 (1993)	
DTX-0400	8/15/1994	SRPT-VYDS-0009239	SRPT-VYDS-0009250	Z. Dominski & R. Kole, Identification and characterization of antisense oligonucleotides of exon and intron sequences required for splicing, Molecular and cellular biology 14(11):7445-7454 (1994)	

November 25, 2024

Confidential

DTX-0401	11/24/2015	SRPT-VYDS-0227851	SRPT-VYDS-0228237	FDA Briefing Document, Peripheral and Central Nervous System Drugs Advisory Committee Meeting, NDA 206031 Drisapersen	
DTX-0402	9/2/2017	SRPT-VYDS-0223945	SRPT-VYDS-0223946	EPO Communication, Application No. 15199455	
DTX-0403		SRPT-VYDS-0227342		Exemplary Gel Images, blank document	
DTX-0404		SRPT-VYDS-0228957	SRPT-VYDS-0228968	Highlights of Prescribing Information, Eteplirsen (Revised: 1/22)	
DTX-0405 DTX-0026	8/12/2020	NS00035370	NS00035379	FDA Approval Letter for the use of Viltepso	Magnus 04
DTX-0406	8/12/2020	SRPT-VYDS-0228976	SRPT-VYDS-0228978	FDA Approves Targeted Treatment for Rare Duchenne Muscular Dystrophy Mutation	
DTX-0407	12/12/2019	SRPT-VYDS-0228972	SRPT-VYDS-0228975	FDA Grants Accelerated Approval to First Targeted Treatment for Rare Duchenne Muscular Dystrophy Mutation	
DTX-0408	6/7/2023	SRPT-VYDS-0234614	SRPT-VYDS-0234638	Japanese Yen (JPY) To US Dollar (USO) Exchange Rate History for 2019, https://www.exchange-rates.org/exchange-rate-history/jpy-usd-2019 (2023)	
DTX-0409	6/14/2023	SRPT-VYDS-0234 704	SRPT-VYDS-0234 765	US10227590B2 -Antisense oligonucleotides for inducing exon skipping and methods of use thereof - Google Patents, https://patents.google.com/patent/US10227590B2/en?q=10227590 (2023)	
DTX-0410	6/14/2023	SRPT-VYDS-0234 766	SRPT-VYDS-0234826	US10266827B2 -Antisense oligonucleotides for inducing exon skipping and methods of use thereof - Google Patents, https://patents.google.com/patent/US10266827B2/en?q=10266827 (2023)	
DTX-0411	2/25/2021	SRPT-VYDS-0228979	SRPT-VYDS-0228981	FDA Approves Targeted Treatment for Rare Duchenne Muscular Dystrophy Mutation	

Sarepta-UWA Tenth Revised Trial Exhibit List

November 25, 2024

Confidential

DTX-0412	6/19/2023	SRPT-VYDS-0234827	SRPT-VYDS-0234852	Japanese Yen (JPY) To US Dollar (USO) Exchange Rate History for 2020, https://www.exchange-rates.org/exchange-rate-history/jpy-usd-2020 (2023)	
DTX-0413	9/19/2016	SRPT-VYDS-0228969	SRPT-VYDS-0228971	FDA Grants Accelerated Approval to First Drug for Duchenne Muscular Dystrophy	
DTX-0414	4/6/1989	SRPT-VYDS-0228982	SRPT-VYDS-022898	C. Feener et al., Alternative splicing of human dystrophin mRNA generates isoforms at the carboxy terminus, Letters to Nature 338:509-511 (1989)	
DTX-0415	6/19/2023	SRPT-VYDS-0234853	SRPT-VYDS-0234868	Japanese Yen (JPY) To US Dollar (USO) Exchange Rate History for 2021, https://www.exchange-rates.org/exchange-rate-history/jpy-usd-2021 (2023)	
DTX-0416	6/19/2023	SRPT-VYDS-0234869	SRPT-VYDS-0234882	Japanese Yen (JPY) To US Dollar (USO) Exchange Rate History for 2022, https://www.exchange-rates.org/exchange-rate-history/jpy-usd-2022 (2023)	
DTX-0417	6/22/2023	SRPT-VYDS-0234883	SRPT-VYDS-0234885	Sarepta Therapeutics, Inc. FAQs, https://investorrelations.sarepta.com/faqs (2023)	
DTX-0418	2009-00-00	SRPT-VYDS-0228985	SRPT-VYDS-0229027	K. Flanigan et al., Mutational spectrum of DMD mutations in dystrophinopathy patients: application of modern diagnostic techniques to a large cohort, Human Mutation 30(12):1657-1666 (2009)	
DTX-0419	6/22/2023	SRPT-VYDS-0234886	SRPT-VYDS-0234888	NS Pharma - Contact Us, https://www.nspharma.com/contact (2023)	
DTX-0420	11/14/2005	SRPT-VYDS-0229028	SRPT-VYDS-0229037	S. Fletcher et al., Dystrophin expression in the mdx mouse after localised and systemic administration of a morpholino antisense oligonucleotide, The Journal of Gene Medicine 8:207-216 (2006)	Meloni 01

November 25, 2024

Confidential

DTX-0421	6/23/2023	SRPT-VYDS-0234889	SRPT-VYDS-0234899	US Dollar (USO) to Japanese Yen (JPY) exchange rate history, https://www.exchangerates.org.uk/USD-JPY-exchange-rate-history.html (2023)	
DTX-0422	6/23/2023	SRPT-VYDS-0234900	SRPT-VYDS-0234903	Nippon Shinyaku - Company Overview & News, https://www.forbes.com/companies/nippon-shinyaku/?sh=6938d4f12785 (2023)	
DTX-0423	6/23/2023	SRPT-VYDS-0234904	SRPT-VYDS-0234906	Main Products - Pharmaceuticals Division - Who we are - NIPPON SHINYAKU CO., LTD., https://www.nippon-shinyaku.co.jp/english/company_profile/medical/mainproduct.php (2023)	
DTX-0424	6/23/2023	SRPT-VYDS-0234907	SRPT-VYDS-0234909	NS Pharma - Building A Healthier Future Powered by Science, https://www.nsphanna.com/ (2023)	
DTX-0425	2010-06-00	SRPT-VYDS-0229038	SRPT-VYDS-0229043	S. Fletcher et al., Dystrophin isoform induction in vivo by antisense-mediated alternative splicing, The American Society of Gene & Cell Therapy 18(6):1218-1223 (2010)	
DTX-0426	6/27/2023	SRPT-VYDS-0234910	SRPT-VYDS-0234918	JPY to USO Exchange Rate History for 2023, https://www.exchange-rates.org/exchange-rate-history/jpy-usd-2023 (2023)	
DTX-0427	6/28/2007	SRPT-VYDS-0229044	SRPT-VYDS-0229054	K. Fukushima et al., Activation and localization of matrix metalloproteinase-2 and -9 in the skeletal muscle of the muscular dystrophy dog (CXMDj), BMC Musculoskeletal Disorders 8(54) (2007)	

Sarepta-UWA Tenth Revised Trial Exhibit List

November 25, 2024

Confidential

DTX-0428	6/22/2023	SRPT-VYDS-0234919	SRPT-VYDS-0234928	Sarepta Therapeutics Announces FDA Approval of ELEVIDYS, the First Gene Therapy to Treat Duchenne Muscular Dystrophy, https://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-therapeutics-announces-fda-approval-elevidys-first-gene?ga=2.22... (2023)	
DTX-0429	4/1/2003	SRPT-VYDS-0227840	SRPT-VYDS-0227850	B. Gebiski et al., Morpholino antisense oligonucleotide induced dystrophin exon 23 skipping in mdx mouse muscle, Human Molecular Genetics 12(15):1801-1811 (2003)	Dowdy II 16
DTX-0430	7/5/2023	SRPT-VYDS-0234929	SRPT-VYDS-0234932	Duchenne Muscular Dystrophy Johns Hopkins Medicine, https://www.hopkinsmedicine.org/health/conditions-and-diseases/duchenne-muscular-dystrophy#:~:text=Duchenne muscular dl:'l?roP.h,'{'1,2C or DMD,s... (2023)	
DTX-0431	8/18/2023	SRPT-VYDS-0229055	SRPT-VYDS-0229064	Morpholink History, Production, and Properties - Gene Tools Webpage; https://www.gene-tools.com/history_production_and_properties (2023)	
DTX-0432	7/5/2023	SRPT-VYDS-0234933	SRPT-VYDS-0234945	Research - Duchenne Muscular Dystrophy (DMD) - Diseases - Muscular Dystrophy Association, https://www.mda.org/disease/duchenne-muscular-dystrophy/research (2023)	

Sarepta-UWA Tenth Revised Trial Exhibit List

November 25, 2024

Confidential

DTX-0433	7/5/2023	SRPT-VYDS-0234946	SRPT-VYDS-0234949	Duchenne Muscular Dystrophy (DMD) - Diseases - Muscular Dystrophy Association, https://www.mda.org/disease/duchenne-muscular-dystrophy (2023)	
DTX-0434	4/21/2011	SRPT-VYDS-0229065	SRPT-VYDS-0229076	N. Goemans et al., Systemic administration of PRO051 in Duchenne's muscular dystrophy, The New England Journal of Medicine 364(16):1513-1522 (2011)	
DTX-0435	7/5/2023	SRPT-VYDS-0234950	SRPT-VYDS-0234957	Duchenne muscular dystrophy - About the Disease - Genetic and Rare Diseases Information Center, https://rarediseases.info.nih.gov/diseases/6291/duchenne-muscular-dystrophy (2023)	
DTX-0436	7/6/2023	SRPT-VYDS-0234958	SRPT-VYDS-0234968	Medical Management - Duchenne Muscular Dystrophy (DMD) - Diseases - Muscular Dystrophy Association, https://www.mda.org/disease/duchenne-muscular-dystrophy/medical-management (2023)	
DTX-0437	7/12/2012	SRPT-VYDS-0234969	SRPT-VYDS-0234973	AVI Bio Pharma Announces Corporate Name Change to Sarepta Therapeutics and Stock Ticker Symbol Change to "SRPT" Effective Today, https://investorrelations.sarepta.com/news-releases/news-release-details/avi-biopharma-announces-corporate-name-change-sarepta (2023)	

Sarepta-UWA Tenth Revised Trial Exhibit List

November 25, 2024

Confidential

DTX-0438 DTX-0755	7/10/2023	SRPT-VYDS-0234974	SRPT-VYDS-0234980	Therapeutic Approaches - Parent Project Muscular Dystrophy, https://www.parentprojectmd.org/research/current-research/therapeutic-approaches/ (2023)	
DTX-0439	2007-01-00	SRPT-VYDS-0229263	SRPT-VYDS-0229272	P.L. Harding et al., The influence of antisense oligonucleotide length on dystrophin exon skipping, <i>Molecular Therapy</i> 15(1):157-166 (2007)	
DTX-0440	7/18/2023	SRPT-VYDS-0234981	SRPT-VYDS-0234982	FDA Search Orphan Drug Designations and Approvals, https://www.accessdata.fda.gov/scripts/opdlisting/loop/detailedIndex.cfm?cfgridkey=636818 (2023)	
DTX-0441	11/29/2022	SRPT-VYDS-0234983	SRPT-VYDS-0234990	A 48-Week, Open Label, Study to Evaluate the Efficacy and Safety of Casimersen, Eteplirsen and Golodirsen in Subjects With Duchenne Muscular Dystrophy Carrying Eligible DMD Duplications, https://clinicaltrials.gov/study/NCT04179409?intr=SRP-4053&rank=4 (2022)	
DTX-0442	2013-05-00	SRPT-VYDS-0229273	SRPT-VYDS-0229292	M. Havens et al., Targeting RNA splicing for disease therapy, <i>WIREs RNA</i> 4:247-266 (2013)	
DTX-0443	7/10/2023	SRPT-VYDS-0234991	SRPT-VYDS-0234998	A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)(EMBARC), https://clinicaltrials.gov/study/NCT05096221?intr=srp-9001&rank=3 118 (2023)	

Sarepta-UWA Tenth Revised Trial Exhibit List

November 25, 2024

Confidential

DTX-0444	7/5/2023	SRPT-VYDS-0234999	SRPT-VYDS-0235007	A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Non-Ambulatory and Ambulatory Participants With Duchenne Muscular Dystrophy (DMD) (ENVISION), https://clinicaltrials.gov/study/NCT05881408?intr=srp-9001&rank=2 (2023)	
DTX-0445	7/11/2023	SRPT-VYDS-0235008	SRPT-VYDS-0235015	A Gene Transfer Therapy Study to Evaluate the Safety of Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD), https://clinicaltrials.gov/study/NCT03375164?intr=srp-9001&rank=5 (2023)	
DTX-0446	1/25/2016	SRPT-VYDS-0229293	SRPT-VYDS-0229307	M. Havens & M. Hastings, Splice-switching antisense oligonucleotides as therapeutic drugs, <i>Nucleic Acids Research</i> 44(14):6549-6563 (2016)	
DTX-0447	7/1/2022	SRPT-VYDS-0235016	SRPT-VYDS-0235023	A Randomized, Double-blind, Placebo-controlled Study of SRP-9001 (Delandistrogene Moxeparvovec) for Duchenne Muscular Dystrophy (DMD), https://clinicaltrials.gov/study/NCT03769116?intr=srp-9001&rank=1 (2022)	
DTX-0448	2/26/2020	SRPT-VYDS-0235024	SRPT-VYDS-0235032	Exploratory Study of NS-065/NCNP-01 in DMD, https://clinicaltrials.gov/study/NCT02081625?intr=NS-065%2FNCNP-01&rank=2 (2020)	
DTX-0449		NS00040046	NS00040047	Helping You Support Your Patients, NS Pharma Webpage	

Sarepta-UWA Tenth Revised Trial Exhibit List

November 25, 2024

Confidential

DTX-0450	12/28/2022	SRPT-VYDS-0235033	SRPT-VYDS-0235044	Extension Study of NS-065/NCNP-01 in Boys With Duchenne Muscular Dystrophy (DMD), https://clinicaltrials.gov/study/NCT03167255?intr=NS-065%2FNCNP-01 &rank=1 (2022)	
DTX-0451	9/4/2003	SRPT-VYDS-0007659	SRPT-VYDS-0007687	U.S. Patent Application Publication No. 2003/0166588 A1	Wood 109
DTX-0452	10/19/2020	SRPT-VYDS-0235045	SRPT-VYDS-0235060	Phase 1/11 Study of SRP-4053 in DMD Patients, https://clinicaltrials.gov/study/NCT02310906?intr=SRP-4053&rank=1 (2023)	
DTX-0453 DTX-1735	2009-10-00	SRPT-VYDS-0007820	SRPT-VYDS-0007833	M. Kinali et al., Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study, Lancet Neurology 8(10):918-928 (2009)	
DTX-0454	4/22/1988	SRPT-VYDS-0229308	SRPT-VYDS-0229317	M. Koenig et al., The complete sequence of dystrophin predicts a rod-shaped cytoskeletal protein, Cell Press 53:219-228 (1988)	
DTX-0455 DTX-1283	4/18/2018	SRPT-VYDS-0183317	SRPT-VYDS-0183328	H. Komaki, Systemic Administration of the Antisense Oligonucleotide NS-065/NCNP-01 for Skipping of Exon 53 on Patients with Duchenne Muscular Dystrophy, (2018)	
DTX-0456	5/18/1977	SRPT-VYDS-0007713	SRPT-VYDS-0007717	M. MacCoss & D. Cameron, Facile detritylation of nucleoside derivatives by using trifluoroacetic acid, Carbohydrate Research 60:206-209 (1978)	

Sarepta-UWA Tenth Revised Trial Exhibit List

November 25, 2024

Confidential

DTX-0457	2002-00-00	SRPT-VYDS-0008356	SRPT-VYDS-0008364	C. Mann et al., Improved antisense oligonucleotide induced exon skipping in the mdx mouse model of muscular dystrophy, The Journal of Gene Medicine 4:644-654 (2002)	
DTX-0458	2005-00-00	SRPT-VYDS-0227830	SRPT-VYDS-0227835	G. McClorey et al., Splicing intervention for Duchenne muscular dystrophy, Current Opinion in Pharmacology 5:529-534 (2005)	
DTX-0459	20203-08-09	SRPT-VYDS-0227836	SRPT-VYDS-0227838	Muscular Dystrophy Association Celebrates FDA Approval of Viltolarsen for Treatment of Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping, MDA Press Release	
DTX-0460	4/1/2020	NS00036879	NS00036881	Memorandum [REDACTED] between Nippon Shinyaku and NS Pharma	
DTX-0461	12/7/2021	SRPT-VYDS-0235061	SRPT-VYDS-0235071	Safety and Dose Finding Study of NS-065/NCNP-01 in Boys With Duchenne Muscular Dystrophy (DMD), https://clinicaltrials.gov/study/NCT02740972?intr=NS-065%2FNCNP-01&rank=3 (2021)	
DTX-0462	2/21/2023	SRPT-VYDS-0235072	SRPT-VYDS-0235080	Study of SRP-4045 (Casimersen) and SRP-4053 (Golodirsen) in Participants With Duchenne Muscular Dystrophy (DMD) (ESSENCE), https://clinicaltrials.gov/study/NCT02500381?intr=SRP-4053&rank=2 (2023)	Sehinovych 04
DTX-0463	3/25/2009	SRPT-VYDS-0008651	SRPT-VYDS-0008670	J. Moulton & S. Jiang, Gene knockdowns in adult animals: PPMOs and vivo-morpholinos, Molecules 14:1304-1323 (2009)	

Sarepta-UWA Tenth Revised Trial Exhibit List

November 25, 2024

Confidential

DTX-0464	5/25/2022	SRPT-VYDS-0235081	SRPT-VYDS-0235090	Study to Assess the Efficacy and Safety of Viltolarsen in Ambulant Boys With DMD (RACER53), https://clinicaltrials.gov/study/NCT04060199?intr=NS-065%2FNCNP-01&rank=5 (2022)	
DTX-0465	5/26/2022	SRPT-VYDS-0235091	SRPT-VYDS-0235098	Study to Assess the Safety and Efficacy of Viltolarsen in Ambulant Boys With DMD (RACER53-X), https://clinicaltrials.gov/study/NCT04768062?intr=NS-065%2FNCNP-01&rank=4 (2022)	
DTX-0466	8/18/2020	SRPT-VYDS-0235099	SRPT-VYDS-0235105	The Expanded Access Use of Viltolarsen in Duchenne Muscular Dystrophy With Confirmed Exon 53 Amenable Mutation, https://clinicaltrials.gov/study/NCT04337112?intr=NS-065%2FNCNP-01&rank=7 (2020)	
DTX-0467	2019-12-00	SRPT-VYDS-0235106	SRPT-VYDS-0235110	FDA Approves Vyondys 53 (golodirsen) Injection for the Treatment of Duchenne Muscular Dystrophy (DMD) in Patients Amenable to Skipping Exon 53, https://www.drugs.com/newdrugs/fda-approves-vyondys-53-golodirsen-duchenne-muscular-dystrophy-dmd-patients-amenable-s10?P.in.911xon-5119.html (2019)	
DTX-0468		NS00039941	NS00039987	Navigating Insurance Processes and Programs for VILTEPSO (viltolarsen) Injection, NS Pharma Access Solutions Presentation	

Sarepta-UWA Tenth Revised Trial Exhibit List

November 25, 2024

Confidential

DTX-0469	2019-08-00	SRPT-VYDS-0235111	SRPT-VYDS-0235112	Sarepta Therapeutics Receives Complete Response Letter from the US Food and Drug Administration for Golodirsén New Drug Application, https://www.drugs.com/nda/golodirsén_190819.html (2019)	
DTX-0470	7/25/2018	SRPT-VYDS-0235113	SRPT-VYDS-0235116	Sarepta Therapeutics Announces that Phase 1/2a Duchenne Muscular Dystrophy (DMD) MicroDystrophin Gene Therapy Trial Placed on Clinical Hold Due to an Out-of-Specification Production Lot; No Observed Safety Events, https://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-therapeutics-announces-phase-12a-duchenne-muscular (2018)	
DTX-0471	8/12/2020	SRPT-VYDS-0235117	SRPT-VYDS-0235121	NS Pharma's VILTEPSO™ (viltolarsén) injection Now FDA-Approved in the U.S. for the Treatment of Duchenne Muscular Dystrophy in Patients Amenable to Exon 53 Skipping Therapy (2020)	
DTX-0472	11/29/2022	SRPT-VYDS-0235122	SRPT-VYDS-0235129	A 48-Week, Open Label, Study to Evaluate the Efficacy and Safety of Casimersén, Eteplirsén and Golodirsén in Subjects With Duchenne Muscular Dystrophy Carrying Eligible DMD Duplications, https://clinicaltrials.gov/study/NCT04179409?intr=avi-4658&limit=25&page=1&rank=11 (2022)	

Sarepta-UWA Tenth Revised Trial Exhibit List

November 25, 2024

Confidential

DTX-0473	7/5/2023	SRPT-VYDS-0235130	SRPT-VYDS-0235140	A Study to Compare Safety and Efficacy of a High Dose of Eteplirsen in Participants With Duchenne Muscular Dystrophy (DMD) (MIS51 ON), https://clinicaltrials.gov/study/NCT03992430?intr=avi-4658&limit=25&page=1&rank=B(2023)	
DTX-0474	10/3/2022	SRPT-VYDS-0235141	SRPT-VYDS-0235147	A Study to Evaluate Safety, Tolerability, and Efficacy of Eteplirsen in Participants With Duchenne Muscular Dystrophy (DMD) Who Have Completed Study 4658-102 (NCT03218995), https://clinicaltrials.gov/study/NCT03985878?intr=avi-4658&limit=25&page=1&rank=4(2022)	
DTX-0475	2002-00-00	SRPT-VYDS-0229330	SRPT-VYDS-0229336	S. Nelson et al., Emerging genetic therapies to treat Duchenne muscular dystrophy, Current Opinion in Neurology 22:532-538 (2002)	
DTX-0476	10/6/2015	SRPT-VYDS-0235148	SRPT-VYDS-0235157	Dose-Ranging Study of AVI-4658 to Induce Dystrophin Expression in Selected Duchenne Muscular Dystrophy (DMD) Patients, https://clinicaltrials.gov/study/NCT00844597?intr=avi-4658&limit=25&page=1&rank=5(2015)	
DTX-0477	3/30/2020	SRPT-VYDS-0235158	SRPT-VYDS-0235168	Efficacy Study of AVI-4658 to Induce Dystrophin Expression in Selected Duchenne Muscular Dystrophy Patients, https://clinicaltrials.gov/study/NCT01396239?intr=avi-4658&limit=25&page=1&rank=2(2020)	
DTX-0478		SRPT-VYDS-0010597	SRPT-VYDS-0010607	Nippon Shinyaku Exhibit 2067-1 in IPR2021-01140	

November 25, 2024

Confidential

DTX-0479		SRPT-VYDS-0225302	SRPT-VYDS-0225326	Opposition to EP3018211B Nippon Shinyaku Co., Ltd. and National Center of Neurology and Psychiatry by Sarepta Therapeutics, Inc.	
DTX-0480		SRPT-VYDS-0223972	SRPT-VYDS-0223989	Antisense Nucleic Acids European Patent 3 018 211 Nippon Shinyaku, Opposed by James Poole	
DTX-0481		SRPT-VYDS-0226797		Nippon Shinyaku's Notice of Abandonment	
DTX-0482	3/30/2020	SRPT-VYDS-0235169	SRPT-VYDS-0235176	Efficacy, Safety, and Tolerability Rollover Study of Eteplirsén in Subjects With Duchenne Muscular Dystrophy, https://clinicaltrials.gov/study/NCT01540409?intr=avi-4658&limit=25&page=1&rank=1 (2020)	
DTX-0483	12/5/2019	SRPT-VYDS-0235177	SRPT-VYDS-0235190	Safety and Efficacy Study of Antisense Oligonucleotides in Duchenne Muscular Dystrophy, https://clinicaltrials.gov/study/NCT00159250?intr=avi-4658&limit=25&page=1&rank=3 (2019)	
DTX-0484	3/30/2020	SRPT-VYDS-0235191	SRPT-VYDS-0235201	Safety Study of Eteplirsén to Treat Advanced Stage Duchenne Muscular Dystrophy, https://clinicaltrials.gov/study/NCT02286947?intr=avi-4658&limit=25&page=1&rank=6 (2020)	
DTX-0485 DTX-1214	8/25/2016	SRPT-VYDS-0229337	SRPT-VYDS-0229351	Nippon Shinyaku's Notice of Opposition	
DTX-0486	1/25/2021	SRPT-VYDS-0235202	SRPT-VYDS-0235210	Safety Study of Eteplirsén to Treat Early Stage Duchenne Muscular Dystrophy, https://clinicaltrials.gov/study/NCT02420379?intr=avi-4658&limit=25&page=1&rank=10 (2021)	

Sarepta-UWA Tenth Revised Trial Exhibit List

November 25, 2024

Confidential

DTX-0487	1/25/2021	SRPT-VYDS-0235211	SRPT-VYDS-0235220	Study of Eteplirsen in DMD Patients {PROMOVI}, https://clinicaltrials.gov/study/NCT02255552?intr=avi-4658&limit=25&page=1&rank=9 (2021)	
DTX-0488	12/9/2021	SRPT-VYDS-0235221	SRPT-VYDS-0235231	Study of Eteplirsen in Young Participants With Duchenne Muscular Dystrophy (DMD) Amenable to Exon 51 Skipping, https://clinicaltrials.gov/study/NCT03218995?intr=avi-4658&limit=25&page=1&rank=7 (2021)	
DTX-0489	7/19/2023	SRPT-VYDS-0235232	SRPT-VYDS-0235233	Search Orphan Drug Designations and Approvals, https://www.accessdata.fda.gov/scripts/odp/listing/loopdldetailedIndex.cfm?cfgridkey=248407 (2023)	
DTX-0490	6/22/2023	SRPT-VYDS-0235234	SRPT-VYDS-0235235	FDA Approves First Gene Therapy for Treatment of Certain Patients with Duchenne Muscular Dystrophy, https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapy-treatment-certain-patients-duchenne-muscular-dystrophy (2023)	
DTX-0491	7/24/2023	SRPT-VYDS-0235236	SRPT-VYDS-0235237	What is Gene Therapy?, https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/what-gene-therapy (2023)	
DTX-0492	7/26/2023	SRPT-VYDS-0235238	SRPT-VYDS-0235238	SRP-5053 Sarepta Therapeutics, https://www.sarepta.com/srp-5053 (2023)	

Sarepta-UWA Tenth Revised Trial Exhibit List

November 25, 2024

Confidential

DTX-0493	12/12/2019	SRPT-VYDS-0235239	SRPT-VYDS-0235242	FDA grants accelerated approval to first targeted treatment for rare Duchenne muscular dystrophy mutation, <a href="https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-first-targeted-treatment-rare-duchenne-muscular-<t:stro,e!Jy-...">https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-first-targeted-treatment-rare-duchenne-muscular-<t:stro,e!Jy- ... (2019)	
DTX-0494	9/9/2016	SRPT-VYDS-0235243	SRPT-VYDS-0235250	Sarepta Therapeutics Announces FDA Accelerated Approval of EXONDYS 51™ (eteplirsen) injection, an Exon Skipping Therapy to Treat Duchenne Muscular Dystrophy (DMD) Patients Amenable to Skipping Exon 51, http s://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-therapeutics-announces-fda-accelerated-approval-exondys (2016)	
DTX-0495	12/12/2019	SRPT-VYDS-0235251	SRPT-VYDS-0235259	Sarepta Therapeutics Announces FDA Approval of VYONDYS 53™ (golodirsen) Injection for the Treatment of Duchenne Muscular Dystrophy (DMD) in Patients Amenable to Skipping Exon 53, https://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-therapeutics-announces-fda-approval-v'yond~53tm (2019)	
DTX-0496	8/4/2023	SRPT-VYDS-0235260	SRPT-VYDS-0235265	Seroprevalence: What patients should know about pre-existing antibodies to gene therapy, https://www.sarepta.com/newsroom/seroprevalence-what-patients-should-know-about-pre-existing-antibodies-gene-therap (2023)	

Sarepta-UWA Tenth Revised Trial Exhibit List

November 25, 2024

Confidential

DTX-0497	8/11/2022	SRPT-VYDS-0235266	SRPT-VYDS-023526	CRD's Gene Editing Therapy Planned for DMD Patient After FDA Approval, https://muscular dystrophy news.com/news/crd-gene-editing-therapy-planned-dmd-patient-fda-approval/ (2022)	
DTX-0498	8/8/2023	SRPT-VYDS-0235268	SRPT-VYDS-0235269	Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, https://www.accessdata.fda.gov/scripts/cder/obl/patent_info.cfm (2023)	
DTX-0499	8/8/2023	SRPT-VYDS-0235270	SRPT-VYDS-0235275	CureDuchenne I Exon skipping research, https://www.cureduchenne.org/cure/exon-skipping/ (2023)	
DTX-0500		NS00041528	NS00041574	NS Pharma Banner, Indication and Important Safety Information	
DTX-0501		NS00041712	NS00041755	NS Pharma Banner 2, Indication and Important Safety Information	
DTX-0502		NS00041524	NS00041527	NS Pharma Banner 3, Jordan (12 year old), a real VILTEPSO patient and compensated spokesperson	
DTX-0503		NS00041498	NS00041502	Duchenne Diaries January Social Post	
DTX-0504	8/12/2020	NS00043966	NS00043969	NS Pharma Press Release, NS Pharma VILTEPSO (viltolarsen) injection Now FDA-Approved in the U.S. for the Treatment of Duchenne Muscular Dystrophy in Patients Amenable to Exon 53 Skipping Therapy	
DTX-0505	8/19/2020	NS00043970	NS00043972	NS Pharma Press Release, VILTEPSO (viltolarsen) injection Now Commercially Available in the U.S.	
DTX-0506		NS00041304	NS00041306	NS Pharma's Promotional Email Templates for Viltepso (viltolarsen), In the pivotal study for VILTEPSO, Secondary Endpoint Results Provided Additional Evidence of Dystrophin Production	

November 25, 2024

Confidential

DTX-0507	2/25/2021	SRPT-VYDS-0235276	SRPT-VYDS-0235278	Exon Skipping Dominates DMD Treatment, But What's on Horizon?, https://muscular dystrophy news.com/news/exon-skipping-dominates-duchenne-gene-therapy-horizon/ (2021)	
DTX-0508		NS00041302	NS00041303	NS Pharma's Promotional Email Templates for Viltepso (viltolarsen), An exon 53-skipping therapy designed for your patients with DMD	
DTX-0509	8/8/2023	SRPT-VYDS-0235279	SRPT-VYDS-0235280	Products Sarepta Therapeutics, https://www.sarepta.com/products-pipeline/products (2023)	
DTX-0510	8/8/2023	SRPT-VYDS-0235284	SRPT-VYDS-0235288	RNA Technologies for Rare Diseases Sarepta Therapeutics, https://www.sarepta.com/science/rna-platform (2023)	
DTX-0511	8/3/2023	SRPT-VYDS-0235289	SRPT-VYDS-0235291	Sarepta offers early look at closely watched gene therapy launch BioPharm Dive, https://www.biopharmadive.com/news/sarepta-elevidys-duchenne-gene-therapy-launch-sales/6898271 (2023)	
DTX-0512	2/26/2022	NS00041307	NS00041308	NS Pharma's Promotional Email Templates for Viltepso (viltolarsen), Rare Disease Day	
DTX-0513	8/1/2023	SRPT-VYDS-0235292	SRPT-VYDS-0235342	Pfizer (PFE) Q2 2023 Earnings Call Transcript The Motley Fool, https://www.fool.com/earnings/call-transcripts/2023/08/01/pfizer-pfe-q2-2023-earnings-call-transcript/ (2023)	
DTX-0514		NS00041316	NS00041317	NS Pharma's Promotional Email Templates for Viltepso (viltolarsen), Comprehensive support for patients, caregivers, and you	

November 25, 2024

Confidential

DTX-0515	4/13/2023	SRPT-VYDS-0235343	SRPT-VYDS-0235352	Microdystrophin Gene Transfer Study in Adolescents and Children With DMD (IGNITE DMD) ClinicalTrials.gov, https://clinicaltrials.gov/study/NCT03368742?intr=SGT-001&rank=1 (2023)	
DTX-0516	2/18/2022	SRPT-VYDS-0235353	SRPT-VYDS-0235358	SGT-001 Muscular Dystrophy News How SGT-001 works, https://musculardystrophynews.com/sgt-001 (2022)	
DTX-0517	10/13/2022	SRPT-VYDS-0235359	SRPT-VYDS-0235362	Solid Biosciences Presents New SGT-001 IGNITE DMD Study Results at World Muscle Society 2022 Congress Demonstrating improvements in Ambulatory Function, https://www.solidbio.com/about/media/press-releases/solid-biosciences-presents-new-sgt-001-ignite-dmd-study-results-at-world-muscle-society-2022-congress-demonstrating-improvements-in-ambulatory-function (2022)	
DTX-0518	8/2/2023	SRPT-VYDS-0235363	SRPT-VYDS-0235379	Sarepta Therapeutics, Inc. (SRPT) Q2 2023 Earnings Call Transcript _ Seeking Alpha, https://seekingalpha.ccn/article/4623070-sarepta-therapeutics-inc-srpt-q2-2023-earnings-call-transcript (2023)	
DTX-0519	9/19/2016	SRPT-VYDS-0235380	SRPT-VYDS-0235382	FDA grants accelerated approval to first drug for Duchenne muscular dystrophy, https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-first-drug-duchenne-muscular-dystrophy (2016)	
DTX-0520	10/27/2020	SRPT-VYDS-0224423	SRPT-VYDS-0224444	Nippon Shinyaku's Reply to Oppositions filed against EP 3018211	

November 25, 2024

Confidential

DTX-0521	3/9/2017	SRPT-VYDS-0229352	SRPT-VYDS-0229363	Foreign document entitled 'Written Opinion' to reference number P12-0190-B and its english translation	
DTX-0522	11/10/2016	SRPT-VYDS-0226291	SRPT-VYDS-0226293	Nippon Shinyaku's Response dated November 10, 2016	
DTX-0523	9/27/2017	SRPT-VYDS-0229364	SRPT-VYDS-0229381	Nippon Shinyaku's Response to the Summons to Attend Oral Proceedings	
DTX-0524	3/16/2018	SRPT-VYDS-0224892	SRPT-VYDS-0224893	Nippon Shinyaku's Response to the Communications dated September 8th, 2017	
DTX-0525	10/31/2019	SRPT-VYDS-0235383	SRPT-VYDS-0235383	Allievex to Continue BioMarin's Clinical Program Testing Tralesinidase Alfa for Sanfilippo T, https://www.allievex.com/post/allievex-to-continue-biomarin-s-clinical-program-testing-tralesinidase-alfa-for-sanfilippo-t (2019)	
DTX-0526		NS00039857	NS00039860	NS Support Patient Assistance Program Application	
DTX-0527	8/25/2023	SRPT-VYDS-0235384	SRPT-VYDS-0235434	LICENSE AGREEMENT I BIOMARIN PHARMACEUTICAL INC I Business Contracts I Justia, https://contracts.justia.com/companies/biomarin-pharmaceutical-inc-1771/contract/1209811/ (2023)	
DTX-0528	2000-00-00	SRPT-VYDS-0229382	SRPT-VYDS-0229409	T. Pon, Solid-phase supports for oligonucleotide synthesis, Current Protocols in Nucleic Acid Chemistry 3.1.1-3.1.28 (2000)	
DTX-0529	2009-00-00	SRPT-VYDS-0008344	SRPT-VYDS-0008355	L. Popplewell et al., Design of Phosphorodiamidate morpholino oligomers (PMOs) for the induction of exon skipping of the human DMD gene, Molecular Therapy 17(3):554-561 (2009)	Wood 111

Sarepta-UWA Tenth Revised Trial Exhibit List

November 25, 2024

Confidential

DTX-0530	8/21/2023	SRPT-VYDS-0229410	SRPT-VYDS-0229420	Comparative analysis of antisense oligonucleotide sequences targeting exon 53 of the human DMD gene: Implications for future clinical trials; https://www.nmd-journal.com/article/S0960-8966(09)00666-X/fulltext# (2023)	
DTX-0531		NS00041402	NS00041422	Resource Guide Helping with Patient Access to VILTEPSO (viltolarsen)	
DTX-0532	8/25/2023	SRPT-VYDS-0235435	SRPT-VYDS-0235448	BioMarin Pharmaceutical Inc. LinkedIn, https://www.linkedin.com/company/biomarin (2023)	
DTX-0533	8/25/2023	SRPT-VYDS-0235449	SRPT-VYDS-0235468	Sarepta Therapeutics LinkedIn, https://www.linkedin.com/company/sarepta-therapeutics (2023)	
DTX-0534	8/25/2023	SRPT-VYDS-0235464	SRPT-VYDS-0235466	Commercialise or license our world-class research, https://www.royalholloway.ac.uk/about-us/more/business-and-industry/commercialisation-and-licensing/ (2023)	
DTX-0535 DTX-0114	2022-00-00	SRPT-VYDS-0229421	SRPT-VYDS-0229431	L. Servais et al., Long-term safety and efficacy data of golodirsen in ambulatory patients with Duchenne muscular dystrophy amenable to exon 53 skipping: a first-in-human, multicenter, two-part, open-label, phase 1/2 trial, Nucleic Acid Therapeutics 32(1):29-39 (2022)	Strober 13
DTX-0536	8/29/2023	SRPT-VYDS-0235467	SRPT-VYDS-0235472	National Center of Neurology and Psychiatry, https://www.ncnp.go.jp/en/ (2023)	
DTX-0537	8/29/2023	SRPT-VYDS-0235473	SRPT-VYDS-0235477	Pipeline Developments - NS Pharma, https://www.nspharma.com/pipeline/ (2023)	

Sarepta-UWA Tenth Revised Trial Exhibit List

November 25, 2024

Confidential

DTX-0538	9/1/2023	SRPT-VYDS-0235478	SRPT-VYDS-0235479	European Medicines Agency (EMA), https://european-union.europa.eu/institutions-law-budget/institutions-and-bodies/search-all-eu-institutions-and-bodies/european-medicines-agency-ema_en (2023)	
DTX-0539	2007-04-00	SRPT-VYDS-0227059	SRPT-VYDS-0227068	Y. Shiba et al., Chemical synthesis of a very long oligoribonucleotide with 2-cyanoethoxymethyl (CEM) as the 2'-O-protecting group: structural identification and biological activity of a synthetic 110mer precursor-microRNA candidate, Nucleic Acids Research 35(10):3287-3296 (2007)	
DTX-0540	11/18/1996	SRPT-VYDS-0007357	SRPT-VYDS-0007363	H. Sierakowska et al., Repair of thalassemic human B-globin mRNA in mammalian cells by antisense oligonucleotides, Proceedings of the National Academy of Sciences of The United States of America 93(23):12840-12844 (1996)	
DTX-0541		NS00039853	NS00039853	NS Pharma, Specialty Distribution Network Information Sheet	
DTX-0542	1997-00-00	SRPT-VYDS-0229432	SRPT-VYDS-0229445	J. Summerton & D. Weller, Morpholino antisense oligomers: design, preparation, and properties, Antisense & Nucleic Acid Drug Development 7:187-195 (1997)	Wood 118 Hastings 105
DTX-0543	5/18/1999	SRPT-VYDS-0008296	SRPT-VYDS-0008313	J. Summerton, Morpholino antisense oligomers: the case for an RNase H-independant structural type, Biochimica et Biophysica Acta 1489:141-158 (1999)	
DTX-0544	2003-00-000	SRPT-VYDS-0007834	SRPT-VYDS-0007855	J. Summerton, Morpholinos and PNAs compared, Letters in Peptide Science 10:215-236 (2003)	Wood 107

November 25, 2024

Confidential

DTX-0545	2005-00-00	SRPT-VYDS-0229446	SRPT-VYDS-0229459	J. Summerton, A novel reagent for safe, effective delivery of substances into cells, Annals New York Academy of Sciences 1058:62-75 (2005)	Wood 105
DTX-0546	10/6/2016	SRPT-VYDS-0235480	SRPT-VYDS-0235482	First Commercial Duchenne Muscular Dystrophy Therapy in US Administered at UF Health - UF Health, https://ufhealth.org/news/2016/first-commercial-duchenne-muscular-dystrophy-therapy-us-administered-uf-health (2016)	
DTX-0547	10/31/2018	SRPT-VYDS-0229590	SRPT-VYDS-0229591	Statement on a Nonproprietary Name Adopted by the USAN Council, Golodirsén	
DTX-0548	8/1/2023	SRPT-VYDS-0235483	SRPT-VYDS-0235494	A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD) (ENDEAVOR), https://clinicaltrials.gov/study/NCT04626674?int=r=SRP-9001&rank=3 (2023)	
DTX-0549	9/26/2018	SRPT-VYDS-0229592	SRPT-VYD-0229592	Statement on a Nonproprietary Name Adopted by the USAN Council, Viltolarsén	
DTX-0550	8/1/2023	SRPT-VYDS-0235495	SRPT-VYDS-0235505	A Long-term Follow-up Study of Participants Who Received Delandistrogene Moxeparvovec (SRP-9001) in a Previous Clinical Study (EXPEDITION), https://clinicaltrials.gov/study/NCT05967351?int=r=SRP-9001&rank=2 (2023)	
DTX-0551	8/21/2023	SRPT-VYDS-0235506	SRPT-VYDS-0235512	An Extension Study to Evaluate Casimersén or Golodirsén in Patients With Duchenne Muscular Dystrophy, https://clinicaltrials.gov/study/NCT03532542?int=r=srp-4053&rank=4 (2023)	

November 25, 2024

Confidential

DTX-0552	12/15/2019	SRPT-VYDS-0235513	SRPT-VYDS-0235529	Safety and Efficacy Study of Antisense Oligonucleotides in Duchenne Muscular Dystrophy, https://clinicaltrials.gov/study/NCT00159250?int=r=AVI-4658&rank=1 (2019)	
DTX-0553	7/19/2023	SRPT-VYDS-0235530	SRPT-VYDS-0235542	Study to Assess the Safety, Tolerability, and Efficacy of Viltolarsen in Ambulant and Non-Ambulant Boys With DMD (Galactic53), https://clinicaltrials.gov/study/NCT04956289?int=r=NS-065&rank=6 (2023)	
DTX-0554	9/5/2023	SRPT-VYDS-0235543	SRPT-VYDS-023554 7	The University of Western Australia - Commercialisation, https://www.uwa.edu.au/Industry/Commercialisation (2023)	
DTX-0555	9/6/2023	SRPT-VYDS-0235548	SRPT-VYDS-0235563	Russian Ruble (RUB) To US Dollar (USO) Exchange Rate History for 2022, https://www.exchange-rates.org/exchange-rate-history/rub-usd-2022 (2023)	
DTX-0556	9/6/2023	SRPT-VYDS-0235564	SRPT-VYDS-0235565	University of Western Australia available technologies I Powered by IN-PART, https://1/uwa.portals.in-part.com (2023)	
DTX-0557	10/1/2020	SRPT-VYDS-0235566	SRPT-VYDS-0235569	Pfizer Receives FDA Fast Track Designation for Duchenne Muscular Dystrophy investigational Gene Therapy, https://www.pfizer.com/news/press-release/press-release-detail/pfizer-receives-fda-fast-track-designation-duchenne (2020)	
DTX-0558	9/6/2023	SRPT-VYDS-0235570	SRPT-VYDS-0235587	Royal Holloway - Business and Industry, https://www.royalholloway.ac.uk/about-us/more/business-and-industry/ (2023)	

November 25, 2024

Confidential

DTX-0559	10/31/2017	SRPT-VYDS-0235588	SRPT-VYDS-0235593	Sarepta Therapeutics Signs Exclusive Global Collaboration with Duke University for Gene Editing CRISPR/Cas9 Technology to Develop New Treatments for Duchenne Muscular Dystrophy (DMD), https://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-therapeutics-signs-exclusive-global-collaboration-duke?ga=2.4607... (2017)	
DTX-0560	1/28/2023	SRPT-VYDS-0235594	SRPT-VYDS-0235606	DMD treatment: Exon-skipping therapies Muscular Dystrophy News, https://muscular dystrophy news.com/exon-skipping-for-duchenne-muscular-dystrophy?cn-reloaded=1&cn-reloaded=1 (2023)	
DTX-0561	12/27/2007	SRPT-VYDS-0229593	SRPT-VYDS-0229603	J. van Deutekom et al., Local dystrophin restoration with antisense oligonucleotide PRO051, The New England Journal of Medicine 357(26):2677-2686 (2007)	
DTX-0562	2/1/2022	SRPT-VYDS-0235607	SRPT-VYDS-0235609	Sarepta Therapeutics and GenEdit Share Progress on Research Collaboration and Announce Agreement to Develop Gene Editing Therapeutics for Neuromuscular Diseases, https://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-therapeutics-and-genedit-share-progress-research (2022)	
DTX-0563	9/5/2023	SRPT-VYDS-0235610	SRPT-VYDS-0235613	United States Corporate Tax Rate 2023. Take-profit.org, https://take-profit.org/en/statistics/corporate-tax-rate/united-states/ (2023)	

Sarepta-UWA Tenth Revised Trial Exhibit List

November 25, 2024

Confidential

DTX-0564	9/5/2023	SRPT-VYDS-0235614	SRPT-VYDS-0235615	Marginal Corporate Tax Rates Tax Policy Center, https://www.taxpolicycenter.org/statistics/marginal-corporate-tax-rates (2023)	
DTX-0565	1/26/2000	SRPT-VYDS-0007729	SRPT-VYDS-0007740	T. Vickers et al., Effects of RNA secondary structure on cellular antisense activity, Nucleic Acids Research 28(6):1340-1347 (2000)	
DTX-0566		NS00039875	NS00039876	Viltepso (Viltolarsen) Request Form	
DTX-0567		NS00035328	NS00035338	Highlights of Prescribing Information, Viltepso (Revised: 8/2020)	
DTX-0568	8/28/2023	SRPT-VYDS-0229604	SRPT-VYDS-0229605	Viltepso Main Website; https://www.viltepso.com/ (2023)	
DTX-0569	8/28/2023	SRPT-VYDS-0229606	SRPT-VYDS-0229610	Viltepso Patient Website; https://www.viltepso.com/patient/about-viltepso (2023)	
DTX-0570		NS00035829	NS00035831	Viltolarsen NDA Section 2.3.S.1	
DTX-0571		NS00073509	NS00073521	Viltolarsen NDA Section 2.3.S.2	
DTX-0572		NS00066412	NS00066419	Viltolarsen NDA Section 2.6.1	
DTX-0573		NS00066669	NS00066746	Foreign Document, [REDACTED] [REDACTED] and its Certified english translation	
DTX-0574		NS00041491	NS00041495	Viltepso Webpage, What to Expect on Your Path to Treatment	
DTX-0575	2022-00-00	SRPT-VYDS-0229621	SRPT-VYDS-0229638	D. Wilson et al., The role of the dystrophin glycoprotein complex in muscle cell mechanotransduction, Communications Biology 5(1022) (2022)	
DTX-0576	1999-00-00	SRPT-VYDS-0229761	SRPT-VYDS-0229769	S. Wilton et al., Specific removal of the nonsense mutation for the mdx dystrophin mRNA using antisense oligonucleotides, Neuromuscular Disorders 9:330-338 (1999)	

Sarepta-UWA Tenth Revised Trial Exhibit List

November 25, 2024

Confidential

DTX-0577	2007-07-00	SRPT-VYDS-0007603	SRPT-VYDS-0007615	S. Wilton et al., Antisense oligonucleotide-induced exon skipping across the human dystrophin gene transcript, Molecular Therapy 15(7):1288-1296 (2007)	
DTX-0578	2008-06-00	SRPT-VYDS-0007702	SRPT-VYDS-0007712	S. Wilton & S. Fletcher, Exon skipping and Duchenne muscular dystrophy: Hope, hype and how feasible?, Neurology India 56(3):254-262 (2008)	
DTX-0579	1/5/2006	SRPT-VYDS-0229639	SRPT-VYDS-0229760	WO2006/000057 A1	
DTX-0580	5/19/2011	SRPT-VYDS-0228438	SRPT-VYDS-0228539	WO2011/057350 to Wilton et. al.	Adams 26 Meloni 10 Wood 37
DTX-0581		WILTON0009927	WILTON0009948	S. Wilton and S. Fletcher Presentation, Australasian AO: DMD Clinical Trials Participation Criteria: Safety, Incidence, or Responsiveness	
DTX-0582	10/24/2018	NS00035380	NS00035403	Center for Drug Eval. and Research - Application Number: 212154Orig1s000 - Administrative and Correspondence Documents - Correspondence between E. Hastings and Dr. Stover.	Magnus 05
DTX-0583	7/6/2021	SRPT-VYDS-0223211	SRPT-VYDS-0223214	Foreign translation of Email from J. Zenkus to M. Toda RE: Draft note to NS	Toda 36A Luedtke 06
DTX-0584 DTX-0025	2020-08-00	NS00035358	NS00035369	Highlights of Prescribing Information of VILTEPSO (Revised: 08/2020)	Magnus 03
DTX-0585		NS00041300	NS00041301	Email from noreply@NSPharma.com (Marketing Email)	
DTX-0586	6/28/2005	SRPT-VYDS-0228825	SRPT-VYDS-0228874	European Patent Specification 2,206,781	
DTX-0587	8/31/2011	SRPT-VYDS-0228875	SRPT-VYDS-0228956	European Patent Specification 3,018,211	
DTX-0588	1/12/2011	SRPT-VYDS-0229077	SRPT-VYDS-0229262	WO2011/150408 to Gunnar et al.	
DTX-0589	11/25/2003	SRPT-VYDS-0229318	SRPT-VYDS-0229329	U.S. Patent No. 6,653,467 to Matsuo et. al.	
DTX-0590	2022-02-00	NS00042012	NS00042029	Powerpoint presentation from NS Pharma entitled 'Objection Handler'	
DTX-0591	5/22/2009	SRPT-VYDS-0007297	SRPT-VYDS-0007345	WO2009/064471 to Reeves et al.	

Sarepta-UWA Tenth Revised Trial Exhibit List

November 25, 2024

Confidential

DTX-0592	5/21/2009	SRPT-VYDS-0007785	SRPT-VYDS-0007808	U.S. Appl. Publ. No. 2009/0131624 to Reeves et al.	
DTX-0593	4/29/2010	SRPT-VYDS-0228276	SRPT-VYDS-0228437	WO2010/048586 to Sazani et al.	Dowdy 11 Wood 36 Wood 113
DTX-0594	2022-09-00	NS00043079	NS00043122	Powerpoint presentation from NS Pharma entitled [REDACTED]	
DTX-0595	2/9/1993	SRPT-VYDS-0009167	SRPT-VYDS-0009200	U.S. Patent 5,185,444 to Summerton et al.	
DTX-0596	2022-00-00	NS00044112	NS00044174	Powerpoint presentation from NS Pharma entitled [REDACTED]	
DTX-0597	7/14/2015	SRPT-VYDS-0229460	SRPT-VYDS-0229523	U.S. Patent No. 9,079,934 to Watanabe et al.	
DTX-0598	2020-00-00	NS00056035	NS00056062	Powerpoint presentation from NS Pharma entitled [REDACTED]	
DTX-0599		SRPT-VYDS-0229524	SRPT-VYDS-0229589	U.S. Patent No. 11,028,122 to Watanabe et al.	
DTX-0600 DTX-0154	8/2/2022	NS00057814	NS00057855	Presentation from NS Pharma entitled [REDACTED]	
DTX-0601	9/12/2020	NS00058280	NS00058321	Powerpoints presentation from NS Pharma entitled [REDACTED]	
DTX-0602	2021-10-00	NS00073249	NS00073340	Powerpoint presentation from NS Pharma entitled [REDACTED]	
DTX-0603	7/6/2012	NS00073402	NS00073408	Foreign Document entitled [REDACTED] Agreement' between Nippon Shinyaku and [REDACTED]	

November 25, 2024

Confidential

DTX-0604	2/13/2017	NS00073409	NS00073418	Foreign document entitled [REDACTED] contract' between Nippon Shinyaku and [REDACTED]	
DTX-0605	8/30/2019	NS00073428	NS00073441	Foreign document entitled [REDACTED] Agreement [REDACTED] between Nippon Shinyaku, GeneDesign Inc., and [REDACTED]	
DTX-0606	7/12/2018	NS00073451	NS00073459	Foreign document entitled [REDACTED] contract' between Nippon Shinyaku and [REDACTED]	
DTX-0607	2/13/2017	NS00073460	NS00073466	Foreign document entitled [REDACTED] Agreement	
DTX-0608	8/20/2014	NS00073467	NS00073478	Foreign document entitled [REDACTED] Agreement between Nippon Shinyaku, [REDACTED]	
DTX-0609	6/26/2020	NS00073811	NS00073823	Foreign document entitled [REDACTED] and its certified english translation	
DTX-0610	8/30/2019	NS00073849	NS00073862	Foreign document entitled [REDACTED] ' between Nippon Shinyaku, GeneDesign [REDACTED]	
DTX-0611	9/9/2019	NS00073866	NS00073875	Foreign document entitled [REDACTED] contract' between Nippon Shinyaku and [REDACTED]	
DTX-0612	2022-05-00	NS00074351	NS00074368	Powerpoint presentation from NS Pharma and [REDACTED]	
DTX-0613	10/29/2021	NS00090456	NS00090489	[REDACTED] Agreement between [REDACTED] and Nippon Shinyaku	

Sarepta-UWA Tenth Revised Trial Exhibit List

November 25, 2024

Confidential

DTX-0614	8/26/2022	NS00090749	NS00090750	[REDACTED] Agreement [REDACTED] Agreement between Nippon Shinyaku and Joint [REDACTED] [REDACTED]	
DTX-0615	1/24/2022	NS00090767	NS00090820	[REDACTED] Agreement between [REDACTED] tics and Nippon Shinyaku	
DTX-0616	11/26/2020	NS00090904	NS00090913	Foreign document entitled [REDACTED] [REDACTED] [REDACTED] and Nippon Shinyaku' and it's certified english translation	
DTX-0617	3/3/2015	NS00091117	NS00091119	Foreign document entitled [REDACTED] [REDACTED] [REDACTED] and Nippon Shinyaku and it's certified english translation	
DTX-0618	6/16/2014	NS00091193	NS00091197	Foreign document entitled [REDACTED] [REDACTED] [REDACTED] and Nippon Shinyaku and its certified english translation	
DTX-0619		NS00140986	NS00140986	Excel showing [REDACTED] [REDACTED] [REDACTED]	
DTX-0620	10/28/2015	SRPT-VYDS-0190737	SRPT-VYDS-0190825	Powerpoint presentation from Sarepta Therapeutics entitled [REDACTED] [REDACTED]	
DTX-0621	20136-07-15	SRPT-VYDS-0200990	SRPT-VYDS-0200991	Letter agreement between [REDACTED] [REDACTED] with resepct to the Amended and Restated Exclusive License Agreement between Sarepta and UWA, effective as of November 24, 2008 (the "UWA Agreement")	

Sarepta-UWA Tenth Revised Trial Exhibit List

November 25, 2024

Confidential

DTX-0622 DTX-0038 DTX-1321		SRPT-VYDS-0201524	SRPT-VYDS-0201588	Sarepta Therapeutics Research Report entitled [REDACTED]	
DTX-0623	11/3/2021	SRPT-VYDS-0203061	SRPT-VYDS-0203144	Sarepta Therapeutics, Inc. form 10-Q for the Q3 2021	
DTX-0624	3/1/2022	SRPT-VYDS-0203561	SRPT-VYDS-0203725	Sarepta Therapeutics, Inc. form 10-K for the fiscal year 2021	
DTX-0625	2/26/2020	SRPT-VYDS-0204595	SRPT-VYDS-0205034	Sarepta Therapeutics, Inc. form 10-K for the fiscal year 2019	
DTX-0626	8/4/2021	SRPT-VYDS-0205673	SRPT-VYDS-0205760	Sarepta Therapeutics, Inc. form 10-Q for Q2 2021	
DTX-0627 DTX-0144	12/5/2013	SRPT-VYDS-0206683	SRPT-VYDS-0206707	Non-Exclusive License Agreement between Royal Holloway and Bedford New College and Sarepta Therapeutics	
DTX-0628 DTX-0142	4/19/2019	SRPT-VYDS-0207088	SRPT-VYDS-0207091	Amendment No 1 to License Agreement between Sarepta Therapeutics and BioMarin Leiden and its subsidiaries	
DTX-0629 DTX-0134		SRPT-VYDS-0208199	SRPT-VYDS-0208200	Spreadsheet regarding [REDACTED]	
DTX-0630 DTX-0037	6/8/2021	SRPT-VYDS-0209787	SRPT-VYDS-0209791	Powerpoint presentation from Sarepta Therapeutics entitled [REDACTED]	Forsa 09
DTX-0631 DTX-0035		SRPT-VYDS-0210679	SRPT-VYDS-0210695	Powerpoints presentation from Sarepta [REDACTED]	
DTX-0632	2021-02-00	SRPT-VYDS-0212450	SRPT-VYDS-0212462	Highlights of Prescribing Information of Vyondys 53 (Revised: 02/2021)	
DTX-0633		SRPT-VYDS-0213311	SRPT-VYDS-0213311	Excel showing [REDACTED] Exondys 51, Vyondys 53, and Vyondys 45	
DTX-0634 DTX-0132		SRPT-VYDS-0213320	SRPT-VYDS-0213322	Quarterly [REDACTED] of VYONDYS 53 (golodirsen) Injection 2ml	

Sarepta-UWA Tenth Revised Trial Exhibit List

November 25, 2024

Confidential

DTX-0635	5/18/2018	SRPT-VYDS-0213330	SRPT-VYDS-0213332	Fifth Amendment to Commercial Supply Agreement between [REDACTED] and [REDACTED]	
DTX-0636	5/18/2017	SRPT-VYDS-0213393	SRPT-VYDS-0213403	First Amendment to Commercial Supply Agreement between [REDACTED] and [REDACTED]	
DTX-0637	11/1/2019	SRPT-VYDS-0219822	SRPT-VYDS-0219825	Second Amendment to Commercial Outsourcing Services Agreement between [REDACTED] and [REDACTED]	
DTX-0638	8/18/2018	SRPT-VYDS-0220244	SRPT-VYDS-0220244	Email from T. Truesdal to B. Cumbo; J. White; and B. Forsa RE: [REDACTED] [REDACTED] [REDACTED] and attachment [REDACTED] [REDACTED] [REDACTED]	
DTX-0639	2/10/2022	SRPT-VYDS-0220334	SRPT-VYDS-0220358	Powerpoint presentation from Nippon Shinyaku entitled 'Outline of Consolidated Financial Results for the 3rd Quarter Ended December 31, 2021	
DTX-0640	2/21/2020	SRPT-VYDS-0220696	SRPT-VYDS-0220698	Email from B. Cumbo to D. Kumiega and D. Murray RE: [REDACTED]	
DTX-0641	2/5/2019	SRPT-VYDS-0220923	SRPT-VYDS-0220924	Email from D. Kumiega to B. Forsa; J. Fiorelli; C. Calabro; and S. Foley RE: Golodirsen [REDACTED] [REDACTED]	

Sarepta-UWA Tenth Revised Trial Exhibit List

November 25, 2024

Confidential

DTX-0642	6/19/2020	SRPT-VYDS-0221066	SRPT-VYDS-0221066	Email from A. Annis to T. Boutwell; B. Forsa; S. Marlow; P. Moss; P. Cogan; J. Bratica; B. Cumbo; M. Hurley; C. Wahden-Rothman; E. Jacoby; J. White; D. Madden; S. Mahatme; M. O'Neil; G. O'Neill; M. Gilbert; M. Tornsen; J. Fiorelli; and E. Smith RE: [REDACTED] [REDACTED]	
DTX-0643		SRPT-VYDS-0221056	SRPT-VYDS-0221056	Excel showing three scenarios of [REDACTED] [REDACTED]	
DTX-0644	10/19/2022	SRPT-VYDS-0227481	SRPT-VYDS-0227529	Powerpoint presentation from Sarepta Therapeutics entitled [REDACTED]	
DTX-0645	6/14/2023	SRPT-VYDS-0234766	SRPT-VYDS-0234826	US10266827B2 -Antisense oligonucleotides for inducing exon skipping and methods of use thereof - Google Patents, https://patents.google.com/patent/US10266827B2/en?q=10266827 (2023)	
DTX-0646	9/1/2023	SRPT-VYDS-0235616	SRPT-VYDS-0235616	Production page for Board of Gov's Fed Reserve Release H.15	
DTX-0647	9/1/2023	SRPT-VYDS-0235616	SRPT-VYDS-0235616	Board of Gov's Fed. Reserve Release H.15	
DTX-0648	10/13/2021	SRPT-VYDS-0231451	SRPT-VYDS-0231462	J. Broomfield et al., Life expectancy in Duchenne muscular dystrophy, Neurology: 2304-2314 (2021)	
DTX-0649	2009-00-00	SRPT-VYDS-0231463	SRPT-VYDS-0231469	B. Butler, Patent Infringement: Compensation and damages, Law Journal Press 5: 4-1 - 4-5 (2009)	
DTX-0650	2009-00-00	SRPT-VYDS-0231470	SRPT-VYDS-0231487	R. Cauley, Winning the Patent Damages, Oxford University Press: 3-13 (2009)	
DTX-0651	5/12/2009	SRPT-VYDS-0231488	SRPT-VYDS-0231532	M. Chapman, Using settlement licenses in reasonable royalty determinations, The Intellectual Property Law Reviews 49(3): 313-357 (2009)	

November 25, 2024

Confidential

DTX-0652	2/23/2018	SRPT-VYDS-0230277	SRPT-VYDS-0230304	Credit Suisse, Sarepta Therapeutics, Inc. (SRPT) - DMD gene therapy: the next big innovation? (2018)	
DTX-0653	2020-00-00	SRPT-VYDS-0231533	SRPT-VYDS-0231552	S. Crisafulli et al., Global epidemiology of Duchenne muscular dystrophy: an updated systematic review and meta-analysis, Orphanet Journal of Rare Diseases 15(141): 1-20 (2020)	
DTX-0654	2016-00-00	SRPT-VYDS-0231553	SRPT-VYDS-0231553	CureDuchenne, Duchenne population potentially amenable to exon skipping (2016)	
DTX-0655	2019-12-00	SRPT-VYDS-0231554	SRPT-VYDS-0231559	M. Edwards, Recent trends in effective royalty rate4s of biopharma alliances, Digitales Archiv: 244-249 (2019)	
DTX-0656	2023-06-00	SRPT-VYDS-0230261	SRPT-VYDS-0230276	Highlights of Prescribing Information of Elevidys (Revised: 6/2023)	
DTX-0657	7/14/2022	SRPT-VYDS-0231560	SRPT-VYDS-0231570	G. Eser and H. Topaloglu, Current outline of exon skipping trials in Duchenne muscular dystrophy, Genes 13(1241): 1-11 (2022)	
DTX-0658	2022-01-00	SRPT-VYDS-0232087	SRPT-VYDS-0232098	Highlights of Prescribing Information of Exondys 51 (Revised 1/2022)	
DTX-0659	8/4/2020	SRPT-VYDS-0231249	SRPT-VYDS-0231258	Center for Drug Evaluation and Research - Application Number: 212154Orig1s000 - Risk Assessment and Risk Mitigation Review(s)	
DTX-0660	6/21/2023	SRPT-VYDS-0231421	SRPT-VYDS-0231450	Summary Basis for Regulatory Action of ELEVIDYS	
DTX-0661	2022-12-00	SRPT-VYDS-0231571	SRPT-VYDS-0231581	L. Gan et al., A cell-penetrating peptide enhances delivery and efficacy of phosphorodiamidate morpholino oligomers in mdx mice, Muscular Therapy Nucleic Acids 30: 17-27 (2022)	

Sarepta-UWA Tenth Revised Trial Exhibit List

November 25, 2024

Confidential

DTX-0662	9/23/2020	SRPT-VYDS-0231582	SRPT-VYDS-0231589	V. Himic and K. Davies, Evaluating the potential of novel genetic approaches for the treatment of Duchenne muscular dystrophy, European Journal of Human Genetics 29: 1369-1376 (2021)	
DTX-0663	2022-00-00	SRPT-VYDS-0233605	SRPT-VYDS-0233648	Booklet from Nippon Shinyaku entitled 'A New Way of Life'	
DTX-0664	1993-00-00	SRPT-VYDS-0231590	SRPT-VYDS-0231625	P. Janicke, 42 Am. U.L. Rev. 691, The American University Law Review (1993)	
DTX-0665	2013-00-00	SRPT-VYDS-0231626	SRPT-VYDS-0231689	J. Jarosz and M. Chapman, The hypothetical negotiation and reasonable royalty damages: the tail wagging the dog, Stanford Technology Law Review 16(3): 769-832 (2013)	
DTX-0666	2021-00-00	SRPT-VYDS-0231690	SRPT-VYDS-0231696	C. Kupatt et al., Genome editing for Duchenne muscular dystrophy: a glimpse of the future?, Gene Therapy 28: 542-548 (2021)	
DTX-0667	2015-03-00	SRPT-VYDS-0230360	SRPT-VYDS-0230674	Licensing Exec Society - Global Life Sciences Rate and Terms Survey 2014 - 2015	
DTX-0668	2017-02-00	SRPT-VYDS-0230675	SRPT-VYDS-0230971	Licensing Exec Society - Global Life Sciences Rate and Terms Survey 2016 - 2017	
DTX-0669	2019-03-00	SRPT-VYDS-0230972	SRPT-VYDS-0231248	Licensing Exec Society - Global Life Sciences Rate and Terms Survey 2018 - 2019	
DTX-0670	2022-04-00	SRPT-VYDS-0231261	SRPT-VYDS-0231420	Licensing Exec Society - Global Life Sciences Rate and Terms Survey 2021 - 2022	
DTX-0671	2020-00-00	SRPT-VYDS-0231697	SRPT-VYDS-0231700	Muscular Dystrophy Association DMD Fact Sheet 2020	
DTX-0672	8/3/2023	SRPT-VYDS-0230350	SRPT-VYDS-0230359	Needham - 2Q23 Update - August 3, 2023	

November 25, 2024

Confidential

DTX-0673	8/20/2020	SRPT-VYDS-0231259	SRPT-VYDS-0231260	Nippon Shinyaku - VILTEPSO Injection Now Commercially Available 2020	
DTX-0674	5/11/2023	SRPT-VYDS-0233594	SRPT-VYDS-0233604	Outline of Consolidated Financial Results for the Year Ended March 31, 2023 (IFRS)	
DTX-0675	2000-00-00	SRPT-VYDS-0231701	SRPT-VYDS-0231856	S. Pratt et al., Valuing a business: the analysis and appraisal of closely held companies, McGraw Hill : 151-303 (2000)	
DTX-0676	8/2/2023	SRPT-VYDS-0230340	SRPT-VYDS-0230349	RBC Capital Markets - 2Q23 - Aug 2, 2023	
DTX-0677	1999-00-00	SRPT-VYDS-0231857	SRPT-VYDS-0231966	R. Reilly and R. Schweihs, Valuing intangible assets, McGraw Hill : 95-202 (1999)	
DTX-0678	6/23/2023	SRPT-VYDS-0231967	SRPT-VYDS-0231967	Sarepta - Our Pipeline 2023	
DTX-0679	1998-00-00	SRPT-VYDS-0235642	SRPT-VYDS-0235673	M. Schankerman, How valuable is patent protection? Estimates by Technology Field, The RAND Journal of Economics 29(1): 77-107 (1998)	
DTX-0680	11/1/2011	SRPT-VYDS-0231968	SRPT-VYDS-0232036	C. Seaman, Reconsidering the Georgia-Pacific standard for reasonable royalty patent damages, BYU Law Review 2010(5) : 1661-1728 (2011)	
DTX-0681	3/31/2023	SRPT-VYDS-0232037	SRPT-VYDS-0232057	P. Shah et al., Comparing the economic terms of biotechnology licenses from academic institutions with those between commercial firms, PLoS ONE 18(3) (2023)	
DTX-0682	2004-00-00	SRPT-VYDS-0235674	SRPT-VYDS-0235686	E. Sherry and D. Teece, Royalties, evolving patent rights, and the value of innovation, Research Policy 33: 179-191 (2004)	
DTX-0683	6/29/2012	SRPT-VYDS-0232058	SRPT-VYDS-0232061	G. Sidak, Apple V. Motorola: implications for patent damages, Law 360 (2012)	
DTX-0684	2000-00-00	SRPT-VYDS-0232062	SRPT-VYDS-0232086	G. Smith and R. Parr, Valuation of intellectual property and intangible assets, John Wiley & Sons, Inc. : 151- 173 (2000)	

Sarepta-UWA Tenth Revised Trial Exhibit List

November 25, 2024

Confidential

DTX-0685	2020-12-00	SRPT-VYDS-0235687	SRPT-VYDS-0235707	R. Vigil and X. Zhang, Apportioning value in patent portfolio license and sale agreements, Les Nouvelles : 241-261 (2020)	
DTX-0686	2019-12-00	SRPT-VYDS-0232110	SRPT-VYDS-0232122	Highlights of Prescribing Information of Vyondys 53 (Revised 12/2019)	Wood 17
DTX-0687 DTX-0888	2021-03-00	SRPT-VYDS-0232099	SRPT-VYDS-0232109	Highlights of Prescribing Information of VILTEPSO (Revised 3/2021)	Wood 19
DTX-0688		SRPT-VYDS-0018028	SRPT-VYDS-0018142	Declaration of D. Corey for IPR2021-01134 (U.S. Patent No. 9,708,361)	
DTX-0689		SRPT-VYDS-0080843	SRPT-VYDS-0080954	Declaration of D. Corey for IPR2021-01135 (U.S. Patent No. 10,385,092)	
DTX-0690		SRPT-VYDS-0084573	SRPT-VYDS-0084682	Declaration of D. Corey for IPR2021-01136 (U.S. Patent No. 10,407,461)	
DTX-0691		SRPT-VYDS-0077680	SRPT-VYDS-0077789	Declaration of D. Corey for IPR2021-01137 (U.S. Patent No. 10,487,106)	
DTX-0692		SRPT-VYDS-0016374	SRPT-VYDS-0016489	Declaration of D. Corey for IPR2021-01138 (U.S. Patent No. 10,647,741)	
DTX-0693		SRPT-VYDS-0090621	SRPT-VYDS-0090737	Declaration of D. Corey for IPR2021-01139 (U.S. Patent No. 10,662,217)	
DTX-0694		SRPT-VYDS-0010130	SRPT-VYDS-0010264	Declaration of D. Corey for IPR2021-01140 (U.S. Patent No. 10,683,322)	
DTX-0695	1/20/2022	SRPT-VYDS-0017505	SRPT-VYDS-0017549	Decision Granting Institution of IPR2021-01134 (U.S. Patent No. 9,708,361)	
DTX-0696	1/12/2022	SRPT-VYDS-0079288	SRPT-VYDS-0079335	Decision Granting Institution of IPR2021-01135 (U.S. Patent No. 10,385,092)	Esau 04
DTX-0697	1/13/2022	SRPT-VYDS-0083148	SRPT-VYDS-0083195	Decision Granting Institution of IPR2021-01136 (U.S. Patent No. 10,407,461)	
DTX-0698	3/1/2018	SRPT-VYDS-0233649	SRPT-VYDS-0233795	Sarepta SEC Form 10-K for year end Dec 31, 2017	
DTX-0699	2/28/2019	SRPT-VYDS-0233796	SRPT-VYDS-0233923	Sarepta SEC Form 10-K for year end December 31, 2018	
DTX-0700	2/26/2020	SRPT-VYDS-0233924	SRPT-VYDS-0234107	Sarepta SEC Form 10-K for year end December 31, 2019	

Sarepta-UWA Tenth Revised Trial Exhibit List

November 25, 2024

Confidential

DTX-0701	3/1/2021	SRPT-VYDS-0234108	SRPT-VYDS-0234296	Sarepta SEC Form 10-K for year end December 31, 2020	
DTX-0702	3/1/2022	SRPT-VYDS-0234297	SRPT-VYDS-0234447	Sarepta SEC Form 10-K for year end December 31, 2021	
DTX-0703	2/28/2023	SRPT-VYDS-0234448	SRPT-VYDS-0234613	Sarepta SEC Form 10-K for year end December 31, 2022	
DTX-0704	8/7/2018	SRPT-VYDS-0232693	SRPT-VYDS-0232772	Sarepta SEC Form 10-Q for year end June 30, 2019	
DTX-0705	8/8/2018	SRPT-VYDS-0232263	SRPT-VYDS-0232490	Sarepta SEC Form 10-Q for year end June 30, 2018	
DTX-0706	8/5/2020	SRPT-VYDS-0232919	SRPT-VYDS-0233004	Sarepta SEC Form 10-Q for year end June 30, 2020	
DTX-0707	8/4/2021	SRPT-VYDS-0233170	SRPT-VYDS-0233257	Sarepta SEC Form 10-Q for year end June 30, 2021	
DTX-0708	8/2/2022	SRPT-VYDS-0233426	SRPT-VYDS-0233508	Sarepta SEC Form 10-Q for year end June 30, 2022	
DTX-0709	5/3/2018	SRPT-VYDS-0232123	SRPT-VYDS-0232262	Sarepta SEC Form 10-Q for year end March 31, 2018	
DTX-0710	5/8/2019	SRPT-VYDS-0232596	SRPT-VYDS-0232692	Sarepta SEC Form 10-Q for year end March 31, 2019	
DTX-0711	5/6/2020	SRPT-VYDS-0232845	SRPT-VYDS-0232918	Sarepta SEC Form 10-Q for year end March 31, 2020	
DTX-0712	5/5/2021	SRPT-VYDS-0233096	SRPT-VYDS-0233169	Sarepta SEC Form 10-Q for year end March 31, 2021	
DTX-0713	5/4/2022	SRPT-VYDS-0233342	SRPT-VYDS-0233425	Sarepta SEC Form 10-Q for year end March 31, 2022	
DTX-0714	10/31/2018	SRPT-VYDS-0232491	SRPT-VYDS-0232595	Sarepta SEC Form 10-Q for year end Sept 30, 2018	
DTX-0715	11/7/2019	SRPT-VYDS-0232773	SRPT-VYDS-0232844	Sarepta SEC Form 10-Q for year end Sept 30, 2019	
DTX-0716	11/5/2020	SRPT-VYDS-0233005	SRPT-VYDS-0233095	Sarepta SEC Form 10-Q for year end Sept 30, 2020	
DTX-0717	11/3/2021	SRPT-VYDS-0233258	SRPT-VYDS-0233341	Sarepta SEC Form 10-Q for year end Sept 30, 2021)	

Sarepta-UWA Tenth Revised Trial Exhibit List

November 25, 2024

Confidential

DTX-0718	11/2/2022	SRPT-VYDS-0233509	SRPT-VYDS-0233593	Sarepta SEC Form 10-Q for year end Sept 30, 2022	
DTX-0719	1/13/2022	SRPT-VYDS-0075788	SRPT-VYDS-0075833	Decision Granting Institution of IPR2021-01137 (U.S. Patent 10,487,106)	
DTX-0720	1/13/2022	SRPT-VYDS-0013445	SRPT-VYDS-0013493	Decision Granting Institution of IPR2021-01138 (U.S. Patent 10,647,741)	
DTX-0721	1/13/2022	SRPT-VYDS-0086867	SRPT-VYDS-0086907	Decision Granting Institution of IPR2021-01139 (U.S. Patent 10,662,217)	
DTX-0722	1/12/2022	SRPT-VYDS-0090964	SRPT-VYDS-0091016	Decision Granting Institution of IPR2021-01140 (U.S. Patent 10,683,322)	
DTX-0723	7/3/2023			Memorandum Opinion on Claim Construction	Esau 05 Hastings 07
DTX-0724	7/3/2023			Memorandum Opinion, Order on Claim Construction	Esau 06
DTX-0725				List of Oligonucleotide Sequences	Esau 07
DTX-0726	2/6/2023			Declaration of M. Hastings	Esau 08 Hastings 06 Wood 117 Hastings 104
DTX-0727	9/16/2004			C. Esau et al., MicroRNA-143 regulates adipocyte differentiation, The Journal of Biological Chemistry 279(50):52631-52365 (2004)	Esau 09
DTX-0728	4/1/2005			G. Jiang et al., Prevention of obesity in mice by antisense oligonucleotide inhibitors of stearyl-CoA desaturase-1, The Journal of Clinical Investigation 115(4):1030-1038 (2005)	Esau 10

Sarepta-UWA Tenth Revised Trial Exhibit List

November 25, 2024

Confidential

DTX-0729	1997-05-02ds			B. Baker et al., 2'-O-(2-methoxy)ethyl-modified anti-intercellular adhesion molecule 1 (ICAM-1) oligonucleotides selectively increase the ICAM-1 mRNA level and inhibit formation of the ICAM-1 translation initiation complex in human umbilical vein endothelial cells, The Journal of Biological Chemistry 272(18):11994-12000 (1997)	Esau 11
DTX-0730	3/23/2006			S. Davis et al., Improved targeting of miRNA with antisense oligonucleotides, Nucleic Acids Research 34(8):2294-2304 (2006)	Esau 12
DTX-0731	2/15/2006			E. Koller et al., Use of a chemically modified antisense oligonucleotide library to identify and validate Eg5 (kinesin-like 1) as a target for antineoplastic drug development, Cancer Research 66(4):2059-2066 (2006)	Esau 13
DTX-0732	2004-11-00			R. Kramer & D. Cohen, Functional Genomics to new drug targets, Nature Reviews - Drug Discovery 3:965-972 (2004)	Esau 14
DTX-0733	2017-00-00	SRPT -VYDS-0236527	SRPT -VYDS-0236528	S. Robey & F. David, Drug launch curves in the modern era, Nature Reviews - Drug Discovery (2017)	Hosfield 06
DTX-0734		SRPT-VYDS-0213542	SRPT-VYDS-0213543	Patient Information	Hosfield 08
DTX-0735	3/23/2018			26 U.S.C.A. § 482, I.R.C. § 482 § 482. Allocation of Income and Deductions Among Taxpayers	Hosfield 11
DTX-0736 DTX-0141	7/17/2017	SRPT-VYDS-0207092	SRPT-VYDS-0207177	License Agreement between [REDACTED] [REDACTED]	Hosfield 12 Zenkus 09

Sarepta-UWA Tenth Revised Trial Exhibit List

November 25, 2024

Confidential

DTX-0737		WILTON0025140	WILTON0025145	Neuromuscular Disorders Letter from S. Wilton and S. Fletcher,, Antisense Oligonucleotides and DMD: Where are we now?	
DTX-0738	2/24/2006	WILTON0026361	WILTON0026367	E-mail from P. Harding to S. Wilton, re: Paper	Meloni 02
DTX-0739	6/26/2014	SRPT-VYDS-0228540	SRPT-VYDS-0228610	PCT/WO2014/100714 A1	
DTX-0740	9/25/2014	SRPT-VYDS-0228611	SRPT-VYDS-0228702	PCT/WO2014/153240 A2	
DTX-0741	7/3/1984	SRPT-VYDS-0235712	SRPT-VYDS-0235727	U.S. Patent No. 4,458,066 to Caruthers et al.	
DTX-0742	8/31/2005			European Patent Specification No. EP 1 568 769 A1	
DTX-0743	4/12/2007	SRPT-VYDS-0008113	SRPT-VYDS-0008287	U.S. Patent Application Publication 2007/0082861 A1 to Matsuo et al.	Hastings 44
DTX-0744		SRPT-VYDS-0228268	SRPT-VYDS-0228275	Declaration of F. Schnell in the matter of Appeal No. T518/18	
DTX-0745		SRPT-VYDS-0228257	SRPT-VYDS-0228267	Declaration of F. Schnell in the matter of European Patent No. 2206781	Schnell 03
DTX-0746	9/30/2004	SRPT-VYDS-0009096	SRPT-VYDS-0009166	PCT/WO2004/083432 A1	
DTX-0747		FLETCHER0000043	FLETCHER0000088	Grant Application, [REDACTED] [REDACTED]	Fletcher 11
DTX-0748	9/30/2007	FLETCHER0000009	FLETCHER0000018	Grant Progress Report	
DTX-0749	9/30/2007	FLETCHER0000027	FLETCHER0000034	Grant Progress Report, [REDACTED]	Fletcher 12
DTX-0750		SRPT-VYDS-0162285	SRPT-VYDS-0162461	Laboratory Notebook to [REDACTED]	
DTX-0751		SRPT-VYDS-0161650	SRPT-VYDS-0161826	Laboratory Notebook issued to [REDACTED] [REDACTED]	Adams 13
DTX-0752	3/11/2009	SRPT-VYDS-0161337	SRPT-VYDS-0161480	Laboratory Notebook issued to [REDACTED] [REDACTED]	Adams 20

November 25, 2024

Confidential

DTX-0753	1981-00-00	SRPT-VYDS-0235708	SRPT-VYDS-0235711	S. Beaucage & M. Caruthers, Deoxynucleoside phosphoramidites - A new class of key intermediates for deoxypolynucleotide synthesis, Tetrahedron Letters 22(20):1859-1862 (1981)	
DTX-0754	2001-00-00	NS00143520	NS00143526	D. Braasch & D. Corey, Locked nucleic acid (LNA): fine-tuning the recognition of DNA and RNA, Chemistry & Biology 8:1-7 (2001)	
DTX-0755 DTX-0438	7/10/2023	SRPT-VYDS-0234974	SRPT-VYDS-0234980	Therapeutic Approaches - Parent Project Muscular Dystrophy, https://www.parentprojectmd.org/research/current-research/therapeutic-approaches/ (2023)	
DTX-0756	6/14/2023	SRPT-VYDS-0235856	SRPT-VYDS-0235894	US10385092B2 -Antisense nucleic acids - Google Patents, https://patents.google.com/patent/US10385092B2/en?q=10385092 (2023)	
DTX-0757	6/14/2023	SRPT-VYDS-0235895	SRPT-VYDS-0235932	US10407461B2 -Antisense nucleic acids - Google Patents, https://patents.google.com/patent/US10407461B2/en?q=10407461 (2023)	
DTX-0758	6/14/2023	SRPT-VYDS-0235933	SRPT-VYDS-0235970	US10487106B2 -Antisense nucleic acids - Google Patents, https://patents.google.com/patent/US10487106B2/en?q=10487106 (2023)	
DTX-0759	6/14/2023	SRPT-VYDS-0235971	SRPT-VYDS-0236012	US10647741B2 -Antisense nucleic acids - Google Patents, https://patents.google.com/patent/US10647741B2/en?q=10647741 (2023)	
DTX-0760	12/9/2019	SRPT-VYDS-0211304	SRPT-VYDS-0211333	Center for Drug Evaluation and Research, Application No. 211970Orig1s000, Summary Review	

Sarepta-UWA Tenth Revised Trial Exhibit List

November 25, 2024

Confidential

DTX-0761	6/14/2023	SRPT-VYDS-0236013	SRPT-VYDS-0236052	US10662217B2 -Antisense nucleic acids - Google Patents, https://patents.google.com/patent/US10662217B2/en?q=10662217 (2023)	
DTX-0762	6/14/2023	SRPT-VYDS-0236053	SRPT-VYDS-0236093	US10683322B2 -Antisense nucleic acids - Google Patents, https://patents.google.com/patent/US10683322B2/en?q=10683322 (2023)	
DTX-0763	7/20/2023	SRPT-VYDS-0236094	SRPT-VYDS-0236120	Gene-Based Therapy for Duchenne Muscular Dystrophy (DMD) - Medical Clinical Policy Bulletins I Aetna, https://www.aetna.com/cpb/medical/data/900_999/0911.html (2023)	
DTX-0764	9/25/2023	SRPT-VYDS-0236121	SRPT-VYDS-0236126	Overcoming Launch Access Barriers with Patient Support Programs - IQVIA, https://www.iqvia.com/locations/united-states/blogs/2022/01/overcoming-launch-access-baniers-with-patient-support-programs (2023)	
DTX-0765	9/26/2023	SRPT-VYDS-0236127	SRPT-VYDS-0236131	Pipeline, https://www.dyne-tx.com/pipeline/ (2023)	
DTX-0766	2022-00-00	SRPT-VYDS-0235728	SRPT-VYDS-0235743	J. Centa & M. Hastings, Targeting alternative splicing for therapeutic interventions, Methods in Molecular Biology 2537:21-36 (2022)	
DTX-0767	9/26/2023	SRPT-VYDS-0236132	SRPT-VYDS-0236166	US9079934B2 - Antisense nucleic acids - Google Patents, https://patents.google.com/patent/US9079934B2/en?q=9079934 (2023)	
DTX-0768	9/26/2023	SRPT-VYDS-0236167	SRPT-VYDS-0236207	US10870676B2 -Antisense nucleic acids - Google Patents, https://patents.google.com/patent/US10870676B2/en?q=10870676 (2023)	

November 25, 2024

Confidential

DTX-0769	9/26/2023	SRPT-VYDS-0236208	SRPT-VYDS-0236209	Pipeline I PepGen, https://www.pepgen.com/pipeline/ (2023)	
DTX-0770	9/26/2023	SRPT-VYDS-0236210	SRPT-VYDS-0236211	Pipeline - Wave Life Sciences, https://wavelifesciences.com/pipeline/ (2023)	
DTX-0771	10/9/2023	SRPT-VYDS-0236212	SRPT-VYDS-0236230	JPY to USO Exchange Rate History for 2018, https://www.exchange-rates.org/exchange-rate-history/jpy-usd-2018 (2023)	
DTX-0772	2002-00-00	SRPT-VYDS-0235744	SRPT-VYDS-0235746	P. Juo, Concise Dictionary of Biomedicine and Molecular Biology, Second Edition, p. 99 (2002)	
DTX-0773	10/10/2023	SRPT-VYDS-0236231	SRPT-VYDS-0236232	FDA Grants Breakthrough Therapy Designation to First Exon 44 Skipping Drug for Duchenne Muscular Dystrophy - Practical Neurology, https://practicalneurology.com/news/fda-grants-breakthrough-therapy-designation-to-first-exon-44-skipping-drug-for-duchenne-muscular-dystrophy (2023)	
DTX-0774	12/23/2019	SRPT-VYDS-0236233	SRPT-VYDS-0236238	Sarepta Therapeutics Announces Partnership with Roche in Territories Outside the United States for its investigational Micro-dystrophin Gene Therapy for Duchenne Muscular Dystrophy, SRP-9001, https://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-therapeutics-announces-partnership-roche-territories (2019)	
DTX-0775	9/26/2023	SRPT-VYDS-0237832	SRPT-VYDS-0237833	Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, https://www.accessdata.fda.gov/scripts/cder/ob/patent_info.cfm?Product_No=001&Appl_No=212154&Appl_type=N (2023)	

November 25, 2024

Confidential

DTX-0776	8/12/2020	SRPT-VYDS-0237918	SRPT-VYDS-0237920	FDA Approves Targeted Treatment for Rare Duchenne Muscular Dystrophy Mutation I FDA, https://www.fda.gov/news-events/press-announcements/fda-approves-targeted-treatment-rare-duchenne-muscular-dystrophy-mutation (2023)	
DTX-0777	2002-00-00	SRPT-VYDS-0235747	SRPT-VYDS-0235750	G. Dickson et al., Screening for antisense modulation of dystrophin pre-mRNA splicing, Neuromuscular Disorder 12:S67-S70 (2002)	
DTX-0778	4/28/2013	SRPT-VYDS-0009272	SRPT-VYDS-0009288	A. Douglas & M. Wood, Splicing therapy for neuromuscular disease, Molecular and Cellular Neuroscience 53:169-185 (2013)	
DTX-0779 DTX-1313	1/21/2003	NS00035839	NS00035848	S. Errington et al., Target selection for antisense oligonucleotide induced exon skipping in the dystrophin gene, The Journal of Gene Medicine 5:518-527 (2003)	
DTX-0780	8/9/2023	SRPT-VYDS-0228248	SRPT-VYDS-0228248	FDA Orphan Designation of PRO053; https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=384612 (2023)	
DTX-0781	8/7/2019	SRPT-VYDS-0236346	SRPT-VYDS-0236351	NS Outline of Cons. Fin. Results for the 1st Quart Ended June 30, 2019	
DTX-0782	6/29/2010	SRPT-VYDS-0161827	SRPT-VYDS-0161956	Laboratory Notebook of [REDACTED]	
DTX-0783	8/11/2020	SRPT-VYDS-0236374	SRPT-VYDS-0236379	NS Outline of Cons. Fin. Results for the 1st Quart Ended June 30, 2020	
DTX-0784	8/10/2021	SRPT-VYDS-0236402	SRPT-VYDS-0236407	NS Outline of Cons. Fin. Results for the 1st Quart Ended June 30, 2021	
DTX-0785	2/20/2011	SRPT-VYDS-0161292	SRPT-VYDS-0161336	Laboratory Notebook issued to [REDACTED]	
DTX-0786	8/7/2018	SRPT-VYDS-0236318	SRPT-VYDS-0236323	NS Outline of Cons. Fin. Results for the 1st Quarter Ended June 30, 2018	

Sarepta-UWA Tenth Revised Trial Exhibit List

November 25, 2024

Confidential

DTX-0787	11/6/2018	SRPT-VYDS-0236324	SRPT-VYDS-0236330	NS Outline of Cons. Fin. Results for the 2nd Quart Ended Sep 30, 2018	
DTX-0788	10/6/2019	SRPT-VYDS-0236352	SRPT-VYDS-0236358	NS Outline of Cons. Fin. Results for the 2nd Quart Ended Sep 30, 2019	
DTX-0789	11/5/2020	SRPT-VYDS-0236380	SRPT-VYDS-0236386	NS Outline of Cons. Fin. Results for the 2nd Quart Ended Sep 30, 2020	
DTX-0790	11/10/2021	SRPT-VYDS-0236408	SRPT-VYDS-0236414	NS Outline of Cons. Fin. Results for the 2nd Quart Ended Sep 30, 2021	
DTX-0791	2/6/2019	SRPT-VYDS-0236331	SRPT-VYDS-0236336	NS Outline of Cons. Fin. Results for the 3rd Quart Ended Dec 31, 2018	
DTX-0792	2/5/2020	SRPT-VYDS-0236359	SRPT-VYDS-0236364	NS Outline of Cons. Fin. Results for the 3rd Quart Ended Dec 31, 2019	
DTX-0793	2/8/2021	SRPT-VYDS-0236387	SRPT-VYDS-0236392	NS Outline of Cons. Fin. Results for the 3rd Quart Ended Dec 31, 2020	
DTX-0794	2/10/2022	SRPT-VYDS-0236415	SRPT-VYDS-0236420	NS Outline of Cons. Fin. Results for the 3rd Quart Ended Dec 31, 2021	
DTX-0795	5/13/2020	SRPT-VYDS-0236337	SRPT-VYDS-0236345	NS Outline of Cons. Fin. Results for the Year Ended March 31, 2020	
DTX-0796	5/14/2021	SRPT-VYDS-0236365	SRPT-VYDS-0236373	NS Outline of Cons. Fin. Results for the Year Ended March 31, 2021	
DTX-0797	5/11/2022	SRPT-VYDS-0236393	SRPT-VYDS-0236401	NS Outline of Cons. Fin. Results for the Year Ended March 31, 2022	
DTX-0798	5/13/2019	SRPT-VYDS-0236309	SRPT-VYDS-0236317	NS Outline of Cons. Fin. Results for the Year Ended Marrch 31, 2019	
DTX-0799		NS00073522	NS00073535	2.3 Quality Overall Summary - 2.3.S.2 Manufacturer	
DTX-0800	6/15/2021	NS00138041	NS00138045	Morgan Lewis Invoice and Summary of Services for the period ended May 31, 2021	
DTX-0801		NS00141003	NS00141003	Actual Shipping Costs to the United States	
DTX-0802		SRPT-VYDS-0164361	SRPT-VYDS-0164584	AVI BioPharma Lab Notebook Labeled [REDACTED] [REDACTED]	Schnell 16

Sarepta-UWA Tenth Revised Trial Exhibit List

November 25, 2024

Confidential

DTX-0803	5/11/2004	SRPT-VYDS-0235751	SRPT-VYDS-0235755	S. Fox et al., High-throughput screening: searching for higher productivity, Journal of Biomolecular Screening 9(4):354-358 (2004)	
DTX-0804		SRPT-VYDS-0159343	SRPT-VYDS-0159420	Laboratory notebook issued to [REDACTED]	
DTX-0805	9/19/2022	SRPT-VYDS-00236239	SRPT-VYDS-0236241	Medical Drug Clinical Criteria for Viltapso (viltolarsen)	
DTX-0806	1/9/2017	SRPT-VYDS-0236242	SRPT-VYDS-0236255	J. Ascher et al., How to successfully launch a rare disease drug in patient-centric world, McKinsey & Company (2017)	
DTX-0807	2022-08-00	SRPT-VYDS-0236256	SRPT-VYDS-0236258	Blue Cross Blue Shield Requests for Prior Authorization for Duchenne Muscular Dystrophy Antisense Oligonucleotides	
DTX-0808	2019-05-00	SRPT-VYDS-0236270	SRPT-VYDS-0236279	Charles River Associates - Is today's pharmaceutical commercial model going extinct? 7 ways one-time therapies disrupt drug commercialization	
DTX-0809	1/15/2023	SRPT-VYDS-0236266	SRPT-VYDS-0236269	Cigna Drug and Biologic Coverage Policy for Viltolarsen	
DTX-0810	8/2/2004	SRPT-VYDS-0235756	SRPT-VYDS-0235757	Gene Tools Price List, 2005	Wood 104
DTX-0811	2003-07-00	SRPT-VYDS-0236280	SRPT-VYDS-0236308	R. Epstein & A. Marcus, Economic analysis of the reasonable royalty: simplification and extension of the Georgia-Pacific factors, Journal of the Patent and Trademark Office Society 85(7): 555-583 (2003)	
DTX-0812		SRPT-VYDS-0236421	SRPT-VYDS-0236426	Profit Split - Contribution analyses under the profit split method	
DTX-0813	10/18/2010	SRPT-VYDS-0160521	SRPT-VYDS-0160639	Laboratory Notebook issued to [REDACTED]	
DTX-0814	2011-00-00	SRPT-VYDS-0236427	SRPT-VYDS-0236450	T. Heberden, Intellectual property valuation and royalty determination, Wolters Kluwer Law & Business (2011)	

Sarepta-UWA Tenth Revised Trial Exhibit List

November 25, 2024

Confidential

DTX-0815	12/1/2013	SRPT-VYDS-0236451	SRPT-VYDS-0236483	M. Lemley & C. Shapiro, A simple approach to setting reasonable royalties for standard-essential patents, Berkeley Technology Law Review 28(2): 1134-1166 (2013)	
DTX-0816	12/19/2019	SRPT-VYDS-0228239	SRPT-VYDS-0228242	MDA Press Release, MDA Celebrates FDA Approval of Vyondys 53 for Treatment of DMD Amenable to Exon 53 Skipping, Dec. 13, 2019; https://www.mda.org/press-releases/mda-celebrates-fda-approval-vyondys-53-treatment-dmd-amenable-exon-53-skipping	
DTX-0817	2016-06-00	SRPT-VYDS-0236484	SRPT-VYDS-0236487	D. McDuff, Splitting the atom: economic methodologies for profit sharing in reasonable royalty analysis, Les Nouvelles (2016)	
DTX-0818	7/28/2021	SRPT-VYDS-0236488	SRPT-VYDS-0236496	Molina Healthcare Drug and Biological Coverage Criteria for Viltropso (viltolarsen) MNR	
DTX-0819	2012-00-00	SRPT-VYDS-0236497	SRPT-VYDS-0236526	W. Murphy et al., Patent valuation: improving decision making through analysis, John Wiley & Sons, Inc.: 189- 218 (2012)	
DTX-0820	2/19/2007	SRPT-VYDS-0159885	SRPT-VYDS-0160000	Laboratory Notebook issued to [REDACTED]	Meloni 06
DTX-0821	8/23/2010	SRPT-VYDS-0159207	SRPT-VYDS-0159342	Laboratory Notebook issued to [REDACTED]	Meloni 09
DTX-0822	2/11/2003	SRPT-VYDS-0235758	SRPT-VYDS-0235773	K. Morita et al., Synthesis and properties of 2'-O,4'-C-ethylene-bridged nucleic acids (ENA) as effective antisense oligonucleotides, Bioorganic & Medicinal Chemistry 11:2211-2226 (2003)	
DTX-0823	2005-00-00	SRPT-VYDS-0007364	SRPT-VYDS-0007374	S. Wilton & S. Fletcher, Antisense oligonucleotides, exon skipping and the dystrophin gene transcript, Acta Myologica 24:222-229 (2005)	

Sarepta-UWA Tenth Revised Trial Exhibit List

November 25, 2024

Confidential

DTX-0824	2005-00-00	SRPT-VYDS-0235852	SRPT-VYDS-0235855	S. Wilton & S. Fletcher, Antisense oligonucleotides in the treatment of Duchenne muscular dystrophy: where are we now?, Neuromuscular Disorders 15:399-402 (2005)	Mandragouras 11 Wilton 03
DTX-0825	2006-00-00	SRPT-VYDS-0235774	SRPT-VYDS-0235797	J. Moulton, Using Morpholinos to Control Gene Expression, Current Protocols in Nucleic Acid Chemistry 4.30.1-4.30.24 (2006)	
DTX-0826	10/5/2023	SRPT-VYDS-0235798	SRPT-VYDS-0235805	NCBI Gene Information for RFC1, https://www.ncbi.nlm.nih.gov/gene/5981 (2023)	
DTX-0827	10/5/2023	SRPT-VYDS-0235806	SRPT-VYDS-0235815	NCBI Gene Information for SOCS2; https://www.ncbi.nlm.nih.gov/gene/8835 (2023)	
DTX-0828	10/5/2023	SRPT-VYDS-0235816	SRPT-VYDS-0235823	NCBI Gene Information for STS; https://www.ncbi.nlm.nih.gov/gene?Db=gene&Cmd=DetailsSearch&Term=412 (2023)	
DTX-0829	10/5/2023	SRPT-VYDS-0235824	SRPT-VYDS-0235830	NCBI Gene Information for SYNE3; https://www.ncbi.nlm.nih.gov/gene/161176 (2023)	
DTX-0830	8/9/2023	SRPT-VYDS-0228243	SRPT-VYDS-0228247	NCT01957059 Clinical Trial; https://classic.clinicaltrials.gov/ct2/show/NCT01957059 (2023)	
DTX-0831	2001-00-00	SRPT-VYDS-0235831	SRPT-VYDS-0235848	P. Rakoczy, Antisense DNA technology, Methods in Molecular Medicine - Vision Research Protocols, pp. 89-104 (2001)	
DTX-0832	12/12/2019	SRPT-VYDS-0228253	SRPT-VYDS-0228256	Sarepta Press Release, Sarepta Therapeutics Announces FDA Approval of VYONDYS53 Injection for the Treatment of Duchenne Muscular Dystrophy in Patients Amenable to Skipping Exon 53	
DTX-0833		SRPT-VYDS-0235849	SRPT-VYDS-0235851	The New Oxford American Dictionary, Second Edition, p. 68 2005	

Sarepta-UWA Tenth Revised Trial Exhibit List

November 25, 2024

Confidential

DTX-0834		SRPT-VYDS-0158291	SRPT-VYDS-0158435	Laboratory Notebook issued to [REDACTED]	
DTX-0835	2/22/2021	SRPT-VYDS-0225833	SRPT-VYDS-0225840	Preliminary Opinion, Application No. 15199455.5	
DTX-0836		SRPT-VYDS-0224313	SRPT-VYDS-0224314	Opponent 2's Response to the Opposition Division's Preliminary Opinion Dated 22nd February 2021	
DTX-0837	10/11/2019	SRPT-VYDS-0241561	SRPT-VYDS-0241572	M. Aung-Htut et al., Systematic approach to developing splice modulating antisense oligonucleotides, International Journal of Molecular Sciences 20(5030) (2019)	
DTX-0838		SRPT-VYDS-0155595	SRPT-VYDS-0155713	Laboratory Notebook issued to [REDACTED]	
DTX-0839 DtX-1759	5/22/2009	SRPT-VYDS-0007809	SRPT-VYDS-0007819	A. Nakamura & S. Takeda, Exon-skipping therapy for Duchenne muscular dystrophy, Neuropathology 29:494-501 (2009)	
DTX-0840		SRPT-VYDS-0243348		Popplewell 2009 Table 1	
DTX-0841	10/6/2004			WO2004/048570 A1 to Matsuo et al., Foreign Document	
DTX-0842	2/27/2013	SRPT-VYDS-0241573	SRPT-VYDS-0243347	Prosecution History of U.S. Patent Application No. 13819520 to Watanabe et al.	
DTX-0843	7/26/2012	SRPT-VYDS-0012496	SRPT-VYDS-0012538	U.S. Patent Application Publication No. 2012/0190728 A1 to Bennett et al.	
DTX-0844	8/15/2013	SRPT-VYDS-0243449	SRPT-VYDS-0243512	U.S. Patent Application Publication No. 2013/0211062 A1 to Watanabe et al, NS's US publication version	
DTX-0845	3/27/2008	SRPT-VYDS-0243584	SRPT-VYDS-0243751	WO2008/036127 A2 to Weller et al.	
DTX-0846	2/3/2011	WILTON0017612	WILTON0017617	Correspondence between S. Wilton and M. Wood	
DTX-0847	2000-00-00	SRPT-VYDS-0245355	SRPT-VYDS-0245403	D. Rubinfeld, Reference guide on multiple regression, Reference Guide on Scientific Evidence, pp. 179-227 (2000)	

Sarepta-UWA Tenth Revised Trial Exhibit List

November 25, 2024

Confidential

DTX-0848	2018-00-00	SRPT-VYDS-0245410	SRPT-VYDS-0246071	R. Paar, Intellectual property - valuation, exploitation, and infringement damages, Fifth Edition (2018)	
DTX-0849	2017-00-00	SRPT-VYDS-0243947	SRPT-VYDS-0245354	R. Weil et al., Litigation services handbook - the role of the financial expert, Sixth Edition (2017)	
DTX-0850	2003-00-00	SRPT-VYDS-0243940	SRPT-VYDS-0243943	W. Greene, Econometric analysis, Fifth Edition, pp. 19, 31, & 33 (2003)	
DTX-0851	2003-00-00	SRPT-VYDS-0243944	SRPT-VYDS-0243946	W. Greene, Econometric analysis, Fifth Edition, pp. 19, 278, & 345 (2003)	
DTX-0852 DTX-1320	12/12/2019	NS00048946	NS00048949	FDA News Release, FDA grants accelerated approval to first targeted treatment for rare Duchenne muscular dystrophy mutation; https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-first-targeted-treatment-rare-duchenne-muscular-dystrophy-... (2020)	
DTX-0853	3/1/2021	SRPT-VYDS-0009669	SRPT-VYDS-0009678	Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2020 Financial Results and Recent Corporate Developments	
DTX-0854		SRPT-VYDS-0206469	SRPT-VYDS-0206474	Sarepta Therapeutics announces FDA approval of VYONDYS 53 (golodirsen) injection for the treatment of Duchenne muscular dystrophy (DMD) in patients amenable to skipping exon 53	
DTX-0855	5/2/2023	SRPT-VYDS-0229855	SRPT-VYDS-0229863	P. Clemens et al., Efficacy and safety of Viltolarsen in boys with Duchenne muscular dystrophy: results from the phase 2, open-label, 4-year extension study, Journal of Neuromuscular Diseases 10:439-447 (2023)	

Sarepta-UWA Tenth Revised Trial Exhibit List

November 25, 2024

Confidential

DTX-0856 DTX-0113	5/26/2020	SRPT-VYDS-0229866	SRPT-VYDS-0229878	D. Frank et al., Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy, <i>Neurology</i> 94(21):e2270-e2282 (2020)	
DTX-0857	5/24/2022	SRPT-VYDS-0235633	SRPT-VYDS-0235641	P. Clemens et al., Long-term functional efficacy and safety of viltolarsen in patients with Duchenne muscular dystrophy, <i>Journal of Neuromuscular Diseases</i> 9:493-501 (2022)	
DTX-0858	10/25/2023	SRPT-VYDS-0245404	SRPT-VYDS-0245409	Incremental Cost: Definition, How to Calculate, and Examples by The Investopedia Team; https://www.investopedia.com/terms/i/incrementalcost.asp#:~:text=Since incremental costs are the costs of manufacture,are the costs that fluctuate... (2023)	
DTX-0859	2019-01-00	SRPT-VYDS-0229770	SRPT-VYDS-0229792	AM Aartsma-Rus et al., Evidence-based consensus and systematic review on reducing the time to diagnosis of Duchenne muscular dystrophy, <i>The Journal of Pediatrics</i> 204:305-3313e14 (2019)	
DTX-0860	2019-00-00	SRPT-VYDS-0229793	SRPT-VYDS-0229805	A. Aartsma-Rus et al., Report of TREAT-NMD/world Duchenne organisation meeting on dystrophin quantification methodology, <i>Journal of Neuromuscular Diseases</i> 6:147-159 (2019)	
DTX-0861	11/25/2014	SRPT-VYDS-0229806	SRPT-VYDS-0229813	K. Anthony et al., Dystrophin quantification - biological and translational research implications, <i>Neurology</i> 83:2062-2069 (2014)	

Sarepta-UWA Tenth Revised Trial Exhibit List

November 25, 2024

Confidential

DTX-0862	12/18/2019	SRPT-VYDS-0229814	SRPT-VYDS-0229823	F. Barthelemy et al., Targeting RyR activity boosts antisense exon 44 and 45 skipping in human dmd skeletal or cardiac muscles culture models, Molecular Therapy: Nucleic Acids 18:580-589 (2019)	
DTX-0863	8/6/2020	SRPT-VYDS-0229824	SRPT-VYDS-0229834	F. Barthelemy, A Well-Tolerated Core Needle Muscle Biopsy Process Suitable for Children and Adults, (2020)	
DTX-0864	1/21/2015	SRPT-VYDS-0229835	SRPT-VYDS-0229842	C. Bladen et al., The TREAT-NMD DMD global database: analysis of more than 7,000 Duchenne muscular dystrophy mutations, Human Mutation 36(4):395-402 (2015)	
DTX-0865	6/25/2019	SRPT-VYDS-0209753	SRPT-VYDS-0209763	C. Brogna et al., Long-term natural history data in Duchenne muscular dystrophy ambulant patients with mutations amenable to skip exons 44, 45, 51 and 53, PLOS ONE (2019)	
DTX-0866	6/12/2018	SRPT-VYDS-0229843	SRPT-VYDS-0229854	J. Charleston et al., Eteplirsen treatment for Duchenne muscular dystrophy - exon skipping and dystrophin production, Neurology 90(24):e2146-e2154 (2018)	
DTX-0867	6/22/2023	SRPT-VYDS-0229864	SRPT-VYDS-0229865	FDA News Release, FDA approves first gene therapy for treatment of certain patients with Duchenne muscular dystrophy; https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapy-treatment-certain-patients-duchenne-muscular-dystrophy (2023)	

Sarepta-UWA Tenth Revised Trial Exhibit List

November 25, 2024

Confidential

DTX-0868	9/19/2016	NS00056716	NS00056718	FDA News Release, FDA grants accelerated approval to first drug for Duchenne muscular dystrophy; https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-first-drug-duchenne-muscular-dystrophy (2016)	
DTX-0869	4/21/2011	SRPT-VYDS-0007773	SRPT-VYDS-0007784	N. Goemans et al., Systemic administration of PRO051 in Duchenne's muscular dystrophy, The New England Journal of Medicine 364(16):1513-1522 (2011)	
DTX-0870	2013-12-00	SRPT-VYDS-0229879	SRPT-VYDS-0229887	N. Goemans et al., Six-minute walk test: reference values and prediction equation in healthy boys aged 5 to 12 years, PLOS ONE 8(12) (2013)	
DTX-0871	10/13/2016	SRPT-VYDS-0229888	SRPT-VYDS-0229902	N. Goemans et al., Individualized prediction of changes in 6-minute walk distance for patients with Duchenne muscular dystrophy, PLOS ONE (2016)	
DTX-0872	9/8/2020	SRPT-VYDS-0229903	SRPT-VYDS-0229913	N. Goemans et al., Suitability of external controls for drug evaluation in Duchenne muscular dystrophy, Neurology 95(10):e1381-e1391 (2020)	
DTX-0873	2018-00-00	SRPT-VYDS-0229914	SRPT-VYDS-0229925	T. Kinane et al., Long-term pulmonary function in Duchenne muscular dystrophy: comparison of eteplirsen-treated patients to natural history, Journal of Neuromuscular Diseases 5:47-58 (2018)	
DTX-0874	5/27/2020	SRPT-VYDS-0235617	SRPT-VYDS-0235632	H. Komaki et al., Viltolarsen in Japanese Duchenne muscular dystrophy patients: a phase 1/2 study, Annals of Clinical and Translational Neurology 7(12):2393-2408 (2020)	

Sarepta-UWA Tenth Revised Trial Exhibit List

November 25, 2024

Confidential

DTX-0875	3/28/2002	SRPT-VYDS-0230031	SRPT-VYDS-0230073	PCT/WO02/024906 A1	
DTX-0876	9/30/2004	SRPT-VYDS-0230074	SRPT-VYDS-0230144	International Publication Number WO2004/083432 A1	Hastings 45
DTX-0877	11/30/2018	SRPT-VYDS-0229926	SRPT-VYDS-0229945	P. Magrath, Cardiac MRI Biomarkers for Duchenne Muscular Dystrophy, (2018)	
DTX-0878	7/17/2013	NS00051789	NS00051799	J. Mendell et al., Eteplirsen for the treatment of Duchenne muscular dystrophy, Annals of Neurology 74(5):637-647 (2013)	
DTX-0879	2016-02-00	NS00051764	NS00051778	J. Mendell et al., Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy, Annals of Neurology 79(2):257-271 (2016)	
DTX-0880	2/19/2021	SRPT-VYDS-0229946	SRPT-VYDS-0229956	J. Mendell, Comparison of Long-Term Ambulatory Function in Patients with Duchenne Muscular Dystrophy Treated with Eteplirsen and Matched Natural History Controls, (2021)	
DTX-0881	5/24/2016	NS00104095	NS00104102	E. Mercuri et al., Categorizing natural history trajectories of ambulatory function measured by the 6-minute walk distance in patients with Duchenne muscular dystrophy, Neuromuscular Disorders 26:576-583 (2016)	
DTX-0882	9/3/2019	SRPT-VYDS-0229957	SRPT-VYDS-0229977	F. Muntoni et al., Categorising trajectories and individual item changes of the North Star Ambulatory assessment in patients with Duchenne muscular dystrophy, PLOS ONE (2019)	
DTX-0883	4/30/2009	SRPT-VYDS-0230145	SRPT-VYDS-0230258	PCT/WO2009/054725 A2	

Sarepta-UWA Tenth Revised Trial Exhibit List

November 25, 2024

Confidential

DTX-0884	4/17/2017	SRPT-VYDS-0229978	SRPT-VYDS-0229990	F. Schnell et al., Development of a validated western blot method for quantification of human dystrophin protein used in phase II and III clinical trials of eteplirsen for the treatment of Duchenne muscular dystrophy (DMND) (P5.105); https://n.neurology.org/content/88/16_Supplement/P5.105 (2017)	
DTX-0885	3/29/2019	SRPT-VYDS-0229991	SRPT-VYDS-0229997	F. Schnell et al., Challenges of interpreting dystrophin content by western blot, US Neurology 15(1):40-46 (2019)	
DTX-0886	2022-00-00	SRPT-VYDS-0229998	SRPT-VYDS-0220011	D. Scripture-Adams et al., Single nuclei transcriptomics of muscle reveals intra-muscular cell dynamics linked to dystrophin loss and rescue, Communications Biology 5(989) (2022)	
DTX-0887	12/27/2007	SRPT-VYDS-0007718	SRPT-VYDS-0007728	J. van Deutekom et al., Local dystrophin restoration with antisense oligonucleotide PRO051, The New England Journal of Medicine 357(26):2677-2686 (2007)	
DTX-0888		NS00054113	NS00054123	Highlights of Prescribing Information of Viltepso (Revised 3/2021)	Strober 12
DTX-0889		SRPT-VYDS-0211390	SRPT-VYDS-0211402	Highlights of Prescribing Information of VYONDYS 53 (Revised 12/2019)	
DTX-0890	2015-00-00	SRPT-VYDS-0230012	SRPT-VYDS-0230018	R. Wang & S. Nelson, What can Duchenne connect teach us about treating Duchenne muscular dystrophy, Co Neurology 28(5):535-541 (2015)	

Sarepta-UWA Tenth Revised Trial Exhibit List

November 25, 2024

Confidential

DTX-0891	5/31/2018	NS00054224	NS00054233	R. Wang et al., DMD genotype correlations from the Duchenne registry: endogenous exon skipping is a factor in prolonged ambulation for individuals with a defined mutation subtype, Human Mutation 39:1193-1202 (2018)	
DTX-0892	2018-06-00	SRPT-VYDS-0230019	SRPT-VYDS-0230030	D. Wang et al., Repurposing dantrolene for long-term combination therapy to potentiate antisense-mediated DMD exon skipping in the mdx mouse, Molecular Therapy: Nucleic Acids 11:180-191 (2018)	
DTX-0893	7/14/2016	NS00040281	NS00040382	Investigator's Brochure 3.1	
DTX-0894	4/5/2017	NS00040050	NS00040151	Investigator's Brochure 4.0	
DTX-0895	5/18/2018	NS00040152	NS00040280	Investigator's Brochure 5.0	
DTX-0896	6/28/2019	NS00040608	NS00040817	Investigator's Brochure 6.0	
DTX-0897		NS00040818	NS00041038	Investigator's Brochure 7.0	
DTX-0898	6/25/2021	NS00040383	NS00040607	Investigator's Brochure 8.0	
DTX-0899		NS00065469	NS00065540	Viltolarsen NDA Section 2.4	
DTX-0900		NS00065939	NS00065957	Viltolarsen NDA Section 2.7.1	
DTX-0901		NS00065958	NS00065999	Viltolarsen NDA Section 2.7.2	
DTX-0902		NS00066109	NS00066219	Viltolarsen NDA Section 2.7.4 1	
DTX-0903		NS00066228	NS00066342	Viltolarsen NDA Section 2.7.4 2	
DTX-0904		NS00041378	NS00041379	A Quick Guide for the Dosing of Viltepso	
DTX-0905		NS00041318	NS00041321	NS Pharma's Promotional Email Templates for Viltepso (Viltolarsen), Viltepso is Approved for the Treatment of Duchenne Muscular Dystrophy (DMD) in Patients Amenable to Exon 53 Skipping	
DTX-0906		NS00041324	NS00041325	NS Pharma's Promotional Email Templates for Viltepso (viltolarsen), How Would You Help a Patient With No Prior Treatment	

Sarepta-UWA Tenth Revised Trial Exhibit List

November 25, 2024

Confidential

DTX-0907		NS00041326	NS00041327	NS Pharma's Promotional Email Templates for Viltepso (Viltolarsen), Look for a Patient in Your Practice Who is Amenable to Exon 53 Skipping	
DTX-0908		NS00041328	NS00041329	NS Pharma's Promotional Email Templates for Viltepso (Viltolarsen), When You Think of VILTEPSO, Think Dystrophin	
DTX-0909		NS00041330	NS00041331	NS Pharma's Promotional Email Templates for Viltepso (Viltolarsen), VILTEPSO May Be the Next Chapter For Patients with Duchenne Muscular Dystrophy (DMD)	
DTX-0910		NS00041332	NS00041333	NS Pharma's Promotional Email Templates for Viltepso (Viltolarsen), Helping a Patient with DMD and Limited Ambulation	
DTX-0911		NS00039867		Alternate Resources for Patients and Caregivers	
DTX-0912		NS00039874		Alternate Resources for Patients and Caregivers, Spanish document	
DTX-0913		NS00039891		Announcing Permanent J-code for VILTEPSO (viltolarsen)	
DTX-0914		NS00040048	NS00040049	Bridge Program Application	
DTX-0915		NS00039892	NS00039903	Coding and Billing Guide, Coding Information and Sample CMS-1500 and UB-04 Claims for VILTEPSO (Viltolarsen)	
DTX-0916		NS00041346	NS00041347	NS Pharma's Promotional Email Templates for Viltepso (Viltolarsen), Comprehensive Support for Patients, Caregivers, and You	
DTX-0917		NS00041445	NS00041446	NS Pharma's Promotional Email Templates for Viltepso (Viltolarsen), How Does VILTEPSO Work to Treat DMD	

Sarepta-UWA Tenth Revised Trial Exhibit List

November 25, 2024

Confidential

DTX-0918		NS00041447	NS00041448	NS Pharma's Promotional Email Templates for Viltepso (Viltolarsen), Taking VILTEPSO	
DTX-0919		NS00041457	NS00041458	NS Pharma's Promotional Email Templates for Viltepso (Viltolarsen), Announcing Data from a 4-Year Long-Term Extension Study	
DTX-0920		NS00041459		NS Pharma's Promotional Email Templates for Viltepso (Viltolarsen), Estimating Cost for Treating Patients with DMD	
DTX-0921		NS00041470	NS00041481	NS Pharma's Promotional Email Templates for Viltepso (Viltolarsen), Thank You for Meeting About VILTEPSO	
DTX-0922		NS00041482		NS Pharma's Promotional Email Templates for Viltepso (Viltolarsen), A Resource for You: VILTEPSO Infusion In-Service	
DTX-0923		NS00041484	NS00041487	NS Pharma's Promotional Email Templates for Viltepso (Viltolarsen), Meeting Request to Discuss VILTEPSO	Strober 20
DTX-0924		NS00041488	NS00041490	NS Pharma's Promotional Email Templates for Viltepso (Viltolarsen), Follow-Up Discussion About VILTEPSO	
DTX-0925		NS00041519	NS00041520	NS Pharma's Promotional Email Templates for Viltepso (Viltolarsen), We Have Some Additional Data to Share About VILTEPSO	
DTX-0926		NS00039930	NS00039940	Considerations for the Exception and Appeals Process	
DTX-0927		NS00039863	NS00039864	Co-pay Assistance Program Card	

Sarepta-UWA Tenth Revised Trial Exhibit List

November 25, 2024

Confidential

DTX-0928	7/1/2021	NS00043185	NS00043187	NS Pharma Press Release, VILTEPSO Injection: Long-Term Efficacy and Safety Data Presented at the PPMD 2021 Virtual Annual Conference	
DTX-0929	5/12/2021	NS00043177	NS00043178	NS Pharma Press Release, VILTEPSO Injection Long-Term Clinical Trial Data to be Presented at the PPMD 2021 Virtual Annual Conference	
DTX-0930	5/26/2020	NS00042593	NS00042595	NS Pharma Press Release, NS Pharma Announces Publication for Clinical Trial Data	
DTX-0931		NS00039868	NS00039869	Co-pay Assistance Program for VILTEPSO Claim Submission Instruction	
DTX-0932		NS00039865	NS00039866	Co-pay Assistance Program Patient Reimbursement Form	
DTX-0933		NS00038774	NS00038804	Third Development Safety Update Report, NS-065/NCNP-01	
DTX-0934	7/6/2018	NS00038805	NS00038837	Fourth Development Safety Update Report, NS-065/NCNP-01	
DTX-0935	7/11/2019	NS00038838	NS00038882	Fifth Development Safety Update Report, NS-065/NCNP-01	
DTX-0936	5/14/2013	NS00038883	NS00038939	Sixth Development Safety Update Report, NS-065/NCNP-01	
DTX-0937	5/14/2013	NS00038940	NS00039215	Seventh Development Safety Update Report, NS-065/NCNP-01	
DTX-0938	10/26/2022	SRPT-VYDS-0207979	SRPT-VYDS-0208198	Eighth Development Safety Update Report to Golordisen	
DTX-0939	12/19/2018	SRPT-VYDS-0211244	SRPT-VYDS-0211254	FDA Approval Letter to P. O'Malley	
DTX-0940		NS00039988	NS00040044	Navigating Insurance Processes and Programs for VILTEPSO (viltolarsen) Injection, NS Pharma Presentation	
DTX-0941		NS00039855		Provider Office Staff Exception and Appeals Checklist	
DTX-0942		NS00039905	NS00039925	Resource Guide, NS Pharma Presentation	

Sarepta-UWA Tenth Revised Trial Exhibit List

November 25, 2024

Confidential

DTX-0943		NS00039928	NS00039929	Sample Appeal Letter for VILTEPSO (Viltolarsen)	
DTX-0944		NS00039926	NS00039927	Sample Exception Letter for VILTEPSO	
DTX-0945		NS00039904		Sample Letter of Medical Necessity	
DTX-0946		NS00039870	NS00039873	Viltepso Presentation, Starting Your Patient on VILTEPSO	
DTX-0947		NS00054102	NS00054112	Highlights of Prescribing Information of VILTEPSO (Revised 08/2020)	
DTX-0948		NS00041588	NS00041591	Viltepso Dosing Pocket Guide	
DTX-0949		NS00039877	NS00039890	VILTEPSO (Viltolarsen) Injection, An Exon-Skipping Treatment Option for DMD Patients with an Exon 52 Deletion	
DTX-0950		NS00041592	NS00041612	VILTEPSO (viltolarsen) Injection, Viltepso An FDA-Approved Treatment for Patients with DMD Amenable to Exon 53 Skipping	
DTX-0951		NS00041355	NS00041375	VILTEPSO (Viltolarsen) Injection, Viltepso for Patients with DMD Amenable to Exon 53 Skipping Dosing and Administration Guide	
DTX-0952	12/22/2020	SRPT-VYDS-0236990	SRPT-VYDS-0237055	U.S. Patent No. 10,870,676 B2 to Watanabe et al.	
DTX-0953	4/11/2023	SRPT-VYDS-0237056	SRPT-VYDS-0237056	REGENXBIO Press Release, REGENXBIO Receives FDA Fast Track Designation for RGX-202, a Novel Gene Therapy Candidate for the Treatment of Duchenne Muscular Dystrophy	
DTX-0954	8/3/2023	SRPT-VYDS-0237058	SRPT-VYDS-0237060	BioPharmaDive Article, Sarepta Offers Early Look at Closely Watched Gene Therapy Launch; https://www.biopharmadive.com/news/sarepta-elevidys-duchenne-gene-therapy-launch-sales/689827/ (2023)	

Sarepta-UWA Tenth Revised Trial Exhibit List

November 25, 2024

Confidential

DTX-0955	10/9/2023	SRPT-VYDS-0237061	SRPT-VYDS-0237064	Solid Biosciences Press Release, Solid Biosciences Provides Second Quarter Business Update and Financial Results; https://www.solidbio.com/about/media/press-releases/solid-biosciences-provides-second-quarter-business-update-and-financial-results (2023)	
DTX-0956	2021-00-00	SRPT-VYDS-0237065	SRPT-VYDS-0237075	D. Bishop et al., Quantitative immuno-mass spectrometry imaging of skeletal muscle dystrophin, Scientific Reports 11:1128 (2021)	
DTX-0957	9/3/2019	SRPT-VYDS-0237076	SRPT-VYDS-0237085	E. Canessa et al., Absolute quantification of dystrophin protein in human muscle using parallel reaction monitoring (PRM), J Mass Spectrum 55:e4437 (2020)	
DTX-0958	2014-00-00	SRPT-VYDS-0237086	SRPT-VYDS-0237096	A. Degasperi et al., Evaluating strategies to normalise biological replicates of western blot data, PLOS ONE 9(1):e87293 (2014) A. Degasperi, Evaluating Strategies to Normalise Biological Replicates of Western Blot Data, (2014)	
DTX-0959	6/22/2023	SRPT-VYDS-0237097	SRPT-VYDS-0237098	FDA Press Release, FDA Approves First Gene Therapy for Treatment of Certain Patients with Duchenne Muscular Dystrophy	
DTX-0960	5/8/2023	SRPT-VYDS-0237099	SRPT-VYDS-0237101	Ultragenyx Press Release, Ultragenyx Announces Upcoming Data Presentations at American Society of Gene & Cell Therapy (ASGCT) 2023 Annual Meeting	
DTX-0961	5/24/2023	SRPT-VYDS-0237102	SRPT-VYDS-0237103	Sarepta Press Release, Sarepta Therapeutics Announces Update on Regulatory Review of SRP-9001	

November 25, 2024

Confidential

DTX-0962	10/1/2012	SRPT-VYDS-0237104	SRPT-VYDS-0237110	C. Moorwood et al., A cell-based high-throughput screening assay for posttranscriptional utrophin upregulation, Journal of Biomolecular Screening 8(4):400-406 (2012)	
DTX-0963	2011-08-00	SRPT-VYDS-0237111	SRPT-VYDS-0237127	F. Muntoni & M. Wood, Targeting RNA to treat neuromuscular disease, Nature Reviews - Drug Discovery 10:621-637 (2011)	
DTX-0964		SRPT-VYDS-0130130	SRPT-VYDS-0130693	Certified copy of U.S. Patent Application No. 13,741,150	Kamholz 04
DTX-0965	10/8/2021			Patent Owner Preliminary Response, Patent No. 9,708,361	
DTX-0966	10/1/2020	SRPT-VYDS-0237128	SRPT-VYDS-0237131	Pfizer Press Release, Pfizer Receives FDA Fast Track Designation for Duchenne Muscular Dystrophy Investigational Gene Therapy	
DTX-0967	6/30/2023	SRPT-VYDS-0237132	SRPT-VYDS-0237182	Pfizer Q2 2023 Earnings Call Transcript	
DTX-0968		NS00043220	NS00043247	NS Pharma Presentation, [REDACTED]	
DTX-0969	8/2/2023	SRPT-VYDS-0237183	SRPT-VYDS-0237215	Sarepta Q2 2023 Earnings Call Transcript	
DTX-0970		SRPT-VYDS-0212478	SRPT-VYDS-0212479	Treat the Underlying Cause, Marketing Material	
DTX-0971		SRPT-VYDS-0213053	SRPT-VYDS-0213081	Vyondys 53 Brochure	
DTX-0972	5/21/2010	NS00083858	NS00083911	Foreign document entitled 'Duchenne Muscular Dystrophy (DMD) Therapeutic Agents - Nucleic Acids Drugs (NDKs) - Manager Materials	
DTX-0973	7/20/1963	SRPT-VYDS-0227053	SRPT-VYDS-0227058	R. Merrifield, Solid phase peptide synthesis, Synthesis of a Tetrapeptide 85:2149-2154 (1963)	
DTX-0974	2/24/2011	NS00081507	NS00081560	Foreign presentation entitled 'Nucleic Acid Drugs (NDK) for Duchenne Muscular Dystrophy	

November 25, 2024

Confidential

DTX-0975	6/29/1989	SRPT-VYDS-0227069	SRPT-VYDS-0227081	E. Stirchak et al., Uncharged stereoregular nucleic acid analogs: 2. Morpholino nucleoside oligomers with carbamate internucleoside linkages, Nucleic Acid Research 17(15):6129-6141 (1989)	
DTX-0976	7/31/1991	SRPT-VYDS-0227225	SRPT-VYDS-0227262	U.S. Patent No. 5,034,506 to Summerton et al.	
DTX-0977	8/25/1992	SRPT-VYDS-0008729	SRPT-VYDS-0008752	U.S. Patent No. 5,142,047 to Summerton et al.	
DTX-0978	6/8/1993	SRPT-VYDS-0008681	SRPT-VYDS-0008723	U.S. Patent No. 5,217,866 to Summerton et al.	
DTX-0979	5/3/2011	SRPT-VYDS-0007741	SRPT-VYDS-0007772	U.S. Patent No. 7,935,816 to Li	
DTX-0980	4/2/2009	SRPT-VYDS-0008365	SRPT-VYDS-0008509	U.S. Patent Appl. Publication No. 2009/0088562 A1 to Weller et al.	
DTX-0981	5/21/2009	SRPT-VYDS-0009056	SRPT-VYDS-0009068	U.S. Patent Appl. Publication No. 2009/0131632 A1 to Fox et al.	
DTX-0982	10/30/2012	SRPT-VYDS-0227263	SRPT-VYDS-0227276	U.S. Patent No. 8,299,206 B2 to Fox et al.	
DTX-0983	10/18/2022	SRPT-VYDS-0227107	SRPT-VYDS-0227224	U.S. Patent No. 11,472,824 B2 to Cai et al.	
DTX-0984		SRPT-VYDS-0155070	SRPT-VYDS-0155184	3.2.S.2 Manufacture [Golodirsen, ██████████] - 3. CONTROL OF MATERIALS	
DTX-0985		NS00073895	NS00073934	3.2.S.2.2 Description of Manufacturing Process and Process Controls	
DTX-0986		NS00073935	NS00074004	3.2.S.2.6 Manufacturing Process Development	
DTX-0987	1/24/2013	NS00088350	NS00088366	Foreign document, ██████████	
DTX-0988		SRPT-VYDS-0239426	SRPT-VYDS-0239469	Nippon Shinyaku's Integrated Report of 2022	
DTX-0989	3/31/2022	SRPT-VYDS-0239417	SRPT-VYDS-0239425	Nippon Shinyaku's Outline of Consolidated Financial Results for the Year Ended March 31, 2022	

November 25, 2024

Confidential

DTX-0990	3/31/2023	SRPT-VYDS-0239470	SRPT-VYDS-0239480	Nippon Shinyaku's Outline of Consolidated Financial Results for the Year Ended March 31, 2023	
DTX-0991	7/12/2012	SRPT-VYDS-0239481	SRPT-VYDS-0239490	Sarepta Therapeutics Form 8-K for the fiscal year ended July 10, 2012	
DTX-0992	12/31/2019	SRPT-VYDS-0239491	SRPT-VYDS-0239930	Sarepta Therapeutics Form 10-K for the fiscal year ended Dec. 31, 2019	
DTX-0993	12/31/2020	SRPT-VYDS-0239931	SRPT-VYDS-0240093	Sarepta Therapeutics Form 10-K for the fiscal year ended Dec. 31, 2020	
DTX-0994	12/31/2021	SRPT-VYDS-0240094	SRPT-VYDS-0240258	Sarepta Therap. Form 10-K for the fiscal year ended Dec. 31, 2021	
DTX-0995	12/31/2022	SRPT-VYDS-0240259	SRPT-VYDS-0240424	Sarepta Therapeutics Form 10-K for the fiscal year ended Dec. 31, 2022	
DTX-0996	6/30/2022	SRPT-VYDS-0240425	SRPT-VYDS-0240642	Sarepta Therapeutics Form 10-Q for the Quarterly period ended June 30, 2022	
DTX-0997		SRPT-VYDS-0238080	SRPT-VYDS-0238113	Biotechnology Innovation Organization, Clinical Development Success Rates and Contributing Factors 2011-2020	Lu 09
DTX-0998	10/1/2020	SRPT-VYDS-0239334	SRPT-VYDS-0239337	Pfizer Receives FDA Fast Track Designation for Duchenne Muscular Dystrophy Investigational Gene Therapy	
DTX-0999	4/11/2023	SRPT-VYDS-0241551	SRPT-VYDS-0241556	REGENXBIO Receives FDA Fast Track Designation for RGX-202, a Novel Gene Therapy Candidate for the Treatment of Duchenne Dystrophy (2023)	
DTX-1000	8/19/2010	SRPT-VYDS-0238246	SRPT-VYDS-0238282	Horizontal Merger Guidelines, U.S. Department of Justice and the Federal Trade Commission	Lu 08
DTX-1001		NS00041668	NS00041711	NS Pharma Presentation, VILTEPSO Considerations for Payers	Strober 09
DTX-1002		SRPT-VYDS-0210792		Spreadsheet, PMO	

Sarepta-UWA Tenth Revised Trial Exhibit List

November 25, 2024

Confidential

DTX-1003		SRPT-VYDS-0210800		Excel [REDACTED] [REDACTED] [REDACTED] [REDACTED] (Heavily Redacted)	
DTX-1004	6/21/2021	SRPT-VYDS-0210802	SRPT-VYDS-0210836	Sarepta Therapeutics Presentation, [REDACTED] [REDACTED]	
DTX-1005		SRPT-VYDS-0213174	SRPT-VYDS-0213189	VYONDYS 53 (golodirsen) Injection, Getting Started On VYONDYS 53	
DTX-1006		SRPT-VYDS-0219883		[REDACTED] Medicine Spreadsheet	
DTX-1007	1/1/2023	SRPT-VYDS-0227702	SRPT-VYDS-0227728	Sarepta Therapeutics Presentation, Integrated Customer Insights, Covering Q4 2022	
DTX-1008	6/30/2022	SRPT-VYDS-0227788		Sarepta Therapeutics Presentation, [REDACTED] [REDACTED], Commercial Insights and Analysis	
DTX-1009		SRPT-VYDS-0227826		COGS Estimates	
DTX-1010		SRPT-VYDS-0227829		COGS Spreadsheet, Financial Reports	
DTX-1011	9/27/2023	SRPT-VYDS-0241322	SRPT-VYDS-0241327	Group Companies, Company Information, Who We Are, Nippon Shinyaku; https://www.nippon-shinyaku.co.jp/english/company_profile/profile/group.php (2023)	
DTX-1012	2/18/2022	SRPT-VYDS-0241426	SRPT-VYDS-0241430	SGT-001, Muscular Dystrophy News How SGT-001 works; https://musculardystrophynews.com/sgt-001/ (2023)	

November 25, 2024

Confidential

DTX-1013	10/13/2022	SRPT-VYDS-0241431	SRPT-VYDS-0241434	Solid Biosciences Presents New SGT-001 IGNITE DMD Study Results at World Muscle Society 2022 Congress Demonstrating Improvements in Ambulatory Function ; https://www.solidbio.com/about/media/press-releases/solid-biosciences-presents-new-sgt-001-ignite-dmd-study-results-at-world-muscle-society-2022-congress-demonstrating-improvements-in-ambulatory-function (2023)	
DTX-1014	11/24/2005	WILTON0012316	WILTON0012316	Email from A. Fall to P. Iversen RE: Exon 51 and 53	Adams 08
DTX-1015	2007-05-00	SRPT-VYDS-0162960	SRPT-VYDS-0163132	Collins 3880 Account Book Labeled [REDACTED] [REDACTED]	Adams 09
DTX-1016	9/4/2009	WILTON0005884	WILTON0005899	Email from A. Adams to S. Wilton with attachment 'Abbie lab book pages.pdf' and 'AVI information.docx'	Adams 17
DTX-1017	9/23/2009	WILTON0006355	WILTON0006355	Email from A. Adams to S. Wilton	Adams 18
DTX-1018	2009-03-00	SRPT-VYDS-0160640	SRPT-VYDS-0160819	Collins 3880 Account Book labeled [REDACTED] [REDACTED]	Adams 19
DTX-1019	4/22/2010	WILTON0018576	WILTON0018579	Email from A. Adams to S. Wilton	Adams 21
DTX-1020	1/4/2010	SRPT-VYDS-0159054	SRPT-VYDS-0159206	Laboratory Notebook of [REDACTED] [REDACTED]	Adams 22
DTX-1021	8/11/2009	SRPT-VYDS-0161119	SRPT-VYDS-0161291	Laboratory Notebook [REDACTED]	Meloni 07
DTX-1022	6/22/2010	SRPT-VYDS-0162229	SRPT-VYDS-0162284	Laboratory Notebook [REDACTED] [REDACTED]	Meloni 08
DTX-1023		SRPT-VYDS-0007020	SRPT-VYDS-0007040	2.3.S Drug Substance (Golodirsén, Bachem) [REDACTED]	
DTX-1024	1/11/2010	SRPT-VYDS-0159754	SRPT-VYDS-0159884	Laboratory Notebook from [REDACTED] [REDACTED]	
DTX-1025	2008-06-00	SRPT-VYDS-0160001	SRPT-VYDS-0160170	Collins 3880 Account Book about [REDACTED] [REDACTED]	

November 25, 2024

Confidential

DTX-1026	2008-01-00	SRPT-VYDS-0160947	SRPT-VYDS-0161118	Collins 3880 Account Book from [REDACTED]	
DTX-1027	11/1/2012	SRPT-VYDS-0162089	SRPT-VYDS-0162228	Laboratory Notebook issued to Sudarsan Krishnaswamy from [REDACTED]	
DTX-1028	2007-11-00	SRPT-VYDS-0201251	SRPT-VYDS-0201392	Collins 3880 Account Book from [REDACTED]	
DTX-1029	11/10/2014	SRPT-VYDS-0206934	SRPT-VYDS-0207063	Seventh Framework Programme Grant Agreement for: Collaborative Project Project Summary	
DTX-1030	2020-00-00	SRPT-VYDS-0213312	SRPT-VYDS-0213312	Excel showing sales of Exondys 51 and Vyondys 53 in Q4 2020	
DTX-1031	2020-00-00	SRPT-VYDS-0213313	SRPT-VYDS-0213315	Quarterly [REDACTED] for VYONDYS 53 (golodirsén) Injection 2ml	
DTX-1032	2021-00-00	SRPT-VYDS-0213316	SRPT-VYDS-0213316	Excel showing sales of Exondys 51, Vyondys 53, and Amondys 45 in Q3 2021	
DTX-1033	2021-00-00	SRPT-VYDS-0213317	SRPT-VYDS-0213317	Excel showing sales of Exondys 51, Vyondys 53, and Amondys 45 in Q2 2021	
DTX-1034	2022-00-00	SRPT-VYDS-0213318	SRPT-VYDS-0213318	Excel showing sales of Exondys 51, Vyondys 53, and Amondys 45 for Q2 2022	
DTX-1035	2021-00-00	SRPT-VYDS-0213319	SRPT-VYDS-0213319	Excel showing sales of Exondys 51, Vyondys 53, and Amondys 45 in Q4 2021	
DTX-1036	2019-00-00	SRPT-VYDS-0213323	SRPT-VYDS-0213325	Quarterly [REDACTED] for VYONDYS 53 (golodirsén) Injection 2ml	
DTX-1037	2021-00-00	SRPT-VYDS-0213326	SRPT-VYDS-0213326	Excel showing sales of Exondys 51, Vyondys 53, and Amondys 45 in Q2 2021	
DTX-1038	2020-00-00	SRPT-VYDS-0213327	SRPT-VYDS-0213327	Excel showing sales in Q3 2020	
DTX-1039	2022-00-00	SRPT-VYDS-0213328	SRPT-VYDS-0213328	Excel showing sales of Exondys 51, Vyondys 53, and Amondys 45 in Q3 2022	
DTX-1040	2022-00-00	SRPT-VYDS-0213329	SRPT-VYDS-0213329	Excel showing sales of Exondys 51, Vyondys 53, and Amondys 45 in Q1 2022	

November 25, 2024

Confidential

DTX-1041	1/8/2016	SRPT-VYDS-0219826	SRPT-VYDS-0219873	Commercial Packaging Agreement between [REDACTED] and [REDACTED] [REDACTED]	
DTX-1042	4/8/2020	SRPT-VYDS-0220068	SRPT-VYDS-0220069	Amendment to Commercial Packaging Agreement between [REDACTED] and [REDACTED]	
DTX-1043		SRPT-VYDS-0007094	SRPT-VYDS-0007097	3.2.P.3 Manufacture (Golodirsén, Injection) - 3. DESCRIPTION OF MANUFACTURING PROCESS AND PROCESS CONTROLS	
DTX-1044		NS00088569	NS00088575	Foreign Document entitled 'Future development of nucleic acid drugs'	
DTX-1045	6/21/2013	NS00090249	NS00090251	Foreign document entitled 'NS-065 Derivation Policy Review Meeting Notes'	
DTX-1046		SRPT-VYDS-0154902	SRPT-VYDS-0154929	3.2.P.2 Pharmaceutical Development (Golodirsén, [REDACTED]) - 3. MANUFACTURING PROCESS DEVELOPMENT	
DTX-1047		SRPT-VYDS-0210696	SRPT-VYDS-0210696	Excel showing [REDACTED] and other highly redacted pages	
DTX-1048		SRPT-VYDS-0210697	SRPT-VYDS-0210697	Excel showing [REDACTED] and other highly redacted pages	
DTX-1049		SRPT-VYDS-0210698	SRPT-VYDS-0210698	Excel showing [REDACTED] and other highly redacted pages	
DTX-1050		SRPT-VYDS-0154931	SRPT-VYDS-0154934	3.2.P.3 Manufacture (Golodirsén, Injection, [REDACTED]) - 3. DESCRIPTION OF MANUFACTURING PROCESS AND PROCESS CONTROLS	
DTX-1051		SRPT-VYDS-0154935	SRPT-VYDS-0154946	3.2.P.3 Manufacture (Golodirsén, Injection, [REDACTED]) - 5. PROCESS VALIDATION AND/OR EVALUATION	
DTX-1052		SRPT-VYDS-0154947	SRPT-VYDS-0154947	3.2.P.3 Manufacture (Golodirsén, Injection) - 1. MANUFACTURERS	
DTX-1053		SRPT-VYDS-0210699	SRPT-VYDS-0210699	Excel showing COGS Estimates (Highly Redacted)	

Sarepta-UWA Tenth Revised Trial Exhibit List

November 25, 2024

Confidential

DTX-1054		SRPT-VYDS-0210700	SRPT-VYDS-0210700	Excel showing COGS Estimates (Highly Redacted)	
DTX-1055	11/23/2020	SRPT-VYDS-0210701	SRPT-VYDS-0210725	Sarepta Therapeutics powerpoint entitled [REDACTED]	
DTX-1056		SRPT-VYDS-0210726	SRPT-VYDS-0210726	Excel showing COGS Estimates (Highly Redacted)	
DTX-1057		SRPT-VYDS-0210793	SRPT-VYDS-0210793	Excel showing [REDACTED] (Highly Redacted)	
DTX-1058		SRPT-VYDS-0210794	SRPT-VYDS-0210794	Excel showing DMD statistics in [REDACTED] (Highly Redacted)	
DTX-1059	2019-00-00	SRPT-VYDS-0210795	SRPT-VYDS-0210795	Excel showing 2019 Strat Plan (Highly Redacted)	
DTX-1060	2019-00-00	SRPT-VYDS-0210796	SRPT-VYDS-0210796	Excel showing 2019 Strat Plan (Highly Redacted)	
DTX-1061	2019-00-00	SRPT-VYDS-0210797	SRPT-VYDS-0210797	Excel showing 2019 Strat Plan (Highly Redacted)	
DTX-1062	2020-00-00	SRPT-VYDS-0210798	SRPT-VYDS-0210798	Excel showing Executive Summary of 2020 (Highly Redacted)	
DTX-1063		SRPT-VYDS-0210799	SRPT-VYDS-0210799	Excel showing COGS Estimates (Highly Redacted)	
DTX-1064		SRPT-VYDS-0210801	SRPT-VYDS-0210801	Excel showing COGS Estimates (Highly Redacted)	
DTX-1065		SRPT-VYDS-0219874	SRPT-VYDS-0219874	Excel showing [REDACTED]	
DTX-1066	2022-10-00	SRPT-VYDS-0227530	SRPT-VYDS-0227559	Sarepta Therapeutics powerpoints presentation entitled 'Integrated Customer Insights - October 2022 - Data presented a of end of August 2022'	
DTX-1067	2022-10-00	SRPT-VYDS-0227560	SRPT-VYDS-0227585	Sarepta Therapeutics powerpoints presentation entitled 'Integrated Customer Insights - October 2022 - Data presented a of end of September 2022'	

November 25, 2024

Confidential

DTX-1068	2022-08-00	SRPT-VYDS-0227586	SRPT-VYDS-0227615	Sarepta Therapeutics powerpoints presentation entitled 'Integrated Customer Insights - October 2022 - Data presented a of end of July 2022'	
DTX-1069	2022-11-00	SRPT-VYDS-0227616	SRPT-VYDS-0227642	Sarepta Therapeutics powerpoints presentation entitled 'Integrated Customer Insights - October 2022 - Data presented a of end of October 2022'	
DTX-1070	2022-12-00	SRPT-VYDS-0227643	SRPT-VYDS-0227669	Sarepta Therapeutics powerpoints presentation entitled 'Integrated Customer Insights - December 2022'	
DTX-1071	2022-07-00	SRPT-VYDS-0227670	SRPT-VYDS-0227701	Sarepta Therapeutics powerpoints presentation entitled 'Integrated Customer Insights - July 2022'	
DTX-1072	2023-04-00	SRPT-VYDS-0227729	SRPT-VYDS-0227748	Sarepta Therapeutics powerpoints presentation entitled 'Integrated Customer Insights - Published April 2023'	
DTX-1073	2023-03-00	SRPT-VYDS-0227749	SRPT-VYDS-0227766	Sarepta Therapeutics powerpoints presentation entitled 'Integrated Customer Insights - Published March 2023'	
DTX-1074	2023-02-00	SRPT-VYDS-0227767	SRPT-VYDS-0227787	Sarepta Therapeutics powerpoints presentation entitled 'Integrated Customer Insights - Published February 2023'	
DTX-1075		SRPT-VYDS-0227827	SRPT-VYDS-0227827	Excel showing DMD US Commercial Demand	
DTX-1076		SRPT-VYDS-0227828	SRPT-VYDS-0227828	Excel showing DMD US Commercial Demand	
DTX-1077		SRPT-VYDS-0154948	SRPT-VYDS-0154948	3.2.P.3 Manufacture (Golodirsén, Injection) - 2. BATCH FORMULA	
DTX-1078		SRPT-VYDS-0154949	SRPT-VYDS-0154989	3.2.S.2 Manufacture (Golodirsén, [REDACTED]) - 2. DESCRIPTION OF MANUFACTURING PROCESS AND PROCESS CONTROLS	

Sarepta-UWA Tenth Revised Trial Exhibit List

November 25, 2024

Confidential

DTX-1079		SRPT-VYDS-0154996	SRPT-VYDS-0155024	3.2.P.2 Pharmaceutical Development (Golodirsén, Injection) - 3. MANUFACTURING PROCESS DEVELOPMENT	
DTX-1080		SRPT-VYDS-0155069	SRPT-VYDS-0155069	3.2.S.2 Manufacture (Golodirsén, ██████████) - 1. MANUFACTURERS	
DTX-1081		SRPT-VYDS-0155269	SRPT-VYDS-0155288	3.2.P.2 Manufacture (Golodirsén, Injection) - 3. MANUFACTURING PROCESS DEVELOPMENT	
DTX-1082		SRPT-VYDS-0155289	SRPT-VYDS-0155326	3.2.S.2 Manufacture (Golodirsén, ██████████.)	
DTX-1083		SRPT-VYDS-0155410	SRPT-VYDS-0155440	3.2.P.2 Pharmaceutical Development (Golodirsén, Injection) - 3. MANUFACTURING PROCESS DEVELOPMENT	
DTX-1084		SRPT-VYDS-0155442	SRPT-VYDS-0155445	3.2.P.3 Manufacture (Golodirsén, Injection) - 3. DESCRIPTION OF MANUFACTURING PROCESS AND PROCESS CONTROLS	
DTX-1085	6/21/2021	SRPT-VYDS-0013628	SRPT-VYDS-0013710	Petition for Inter Partes Review for Patent No. 10,647,741 (IPR2021-01138)	
DTX-1086	6/21/2021	SRPT-VYDS-0017213	SRPT-VYDS-0017293	Petition for Inter Partes Review for Patent No. 9,708,361 (IPR2021-01134)	
DTX-1087	6/21/2021	SRPT-VYDS-0075712	SRPT-VYDS-0075787	Petition for Inter Partes Review for Patent No. 10,487,106 (IPR2021-01137)	
DTX-1088	6/21/2021	SRPT-VYDS-0079336	SRPT-VYDS-0079413	Petition for Inter Partes Review for Patent No. 10,385,092 (IPR2021-01135)	
DTX-1089	6/21/2021	SRPT-VYDS-0082992	SRPT-VYDS-0083065	Petition for Inter Partes Review for Patent No. 10,407,461 (IPR2021-01136)	
DTX-1090	6/21/2021	SRPT-VYDS-0086942	SRPT-VYDS-0087025	Petition for Inter Partes Review for Patent No. 10,662,217 (IPR2021-01139)	
DTX-1091	8/9/2023	SRPT-VYDS-0228238		Prosensa Initiates First Patient Dosing in Phase I/II trial for PRO053 ; https://www.sec.gov/Archives/edgar/data/1574111/000117184313003639/newsrelease.htm (2023)	

Sarepta-UWA Tenth Revised Trial Exhibit List

November 25, 2024

Confidential

DTX-1092		WILTON0023491		Introduction to the Revised Application	
DTX-1093		SRPT-VYDS-0158885	SRPT-VYDS-0159001	Jiminy Laboratory Notebook [REDACTED]	Fletcher 03
DTX-1094	2/4/2005	WILTON0009239		S. Wilton Presentation, Exon Skipping: From a Party Trick to Planning Clinical Trials with GlaxoSmithKline	
DTX-1095	1/12/2005	WILTON0026218		E-mail from F. Muntoni to S. Wilton, RE: DMD Cell Lines	
DTX-1096	2/18/2005	WILTON0026224	WILTON0026226	E-mail from F. Muntoni to S. Wilton, RE: ENMC Workshop	
DTX-1097	2021-00-00	NS00036987		Excel related to [REDACTED]	
DTX-1098	5/31/2020	NS00060243	NS00060480	[REDACTED] [REDACTED] [REDACTED]	Satou 08
DTX-1099	5/29/2020	NS00060481	NS00060718	[REDACTED] 4	
DTX-1100	2/13/2020	NS00060719	NS00060934	[REDACTED]	
DTX-1101		SRPT-VYDS-0155447	SRPT-VYDS-0155544	Collins 3880 Account Book, [REDACTED]	
DTX-1102	9/15/2004	SRPT-VYDS-0155545	SRPT-VYDS-0155594	Laboratory Notebook, [REDACTED]	
DTX-1103	6/16/2004	SRPT-VYDS-0155833	SRPT-VYDS-0156009	Laboratory Notebook, [REDACTED] 1	
DTX-1104	6/6/2001	SRPT-VYDS-0156010	SRPT-VYDS-0156084	Laboratory Notebook for [REDACTED]	
DTX-1105		SRPT-VYDS-0156293	SRPT-VYDS-0156401	Laboratory Notebook, [REDACTED] Collins 3880 Account Book	
DTX-1106		SRPT-VYDS-0156402	SRPT-VYDS-0156510	Jiminy Laboratory Notebook, [REDACTED]	
DTX-1107		SRPT-VYDS-0156511	SRPT-VYDS-0156678	Laboratory Notebook, Antisense Oligos [REDACTED] [REDACTED]	
DTX-1108	5/18/2017	SRPT-VYDS-0213381	SRPT-VYDS-0213382	Second Amendment to Commercial Supply Agreement between [REDACTED] and [REDACTED]	
DTX-1109	9/2/2020	SRPT-VYDS-0213404	SRPT-VYDS-0213410	Fourth Amendment to Commercial Supply Agreement between [REDACTED] and [REDACTED]	
DTX-1110	6/5/2019	SRPT-VYDS-0213411	SRPT-VYDS-0213444	Supply and Services Agreement between [REDACTED] [REDACTED] and [REDACTED] [REDACTED]	

Sarepta-UWA Tenth Revised Trial Exhibit List

November 25, 2024

Confidential

DTX-1111	5/1/2019	SRPT-VYDS-0213451	SRPT-VYDS-0213457	First Amendment to Distribution Services Agreement between [REDACTED] and [REDACTED]	
DTX-1112	12/4/2015	SRPT-VYDS-0213458	SRPT-VYDS-0213507	Distribution Services Agreement between [REDACTED] and [REDACTED]	
DTX-1113	12/7/2022	SRPT-VYDS-0219875	SRPT-VYDS-0219882	Sixth Amendment to Commercial Outsourcing Services Agreement between [REDACTED] and [REDACTED]	
DTX-1114	10/22/2021	SRPT-VYDS-0219892	SRPT-VYDS-0219932	Master Development and Supply Agreement between Curia Global, Inc. and Sarepta Therapeutics, Inc.	
DTX-1115	4/28/2020	SRPT-VYDS-0219933	SRPT-VYDS-0219938	Third Amendment to Commercial Outsourcing Services Agreement between [REDACTED] and [REDACTED]	
DTX-1116	10/22/2021	SRPT-VYDS-0219939	SRPT-VYDS-0219944	Product Addendum between C [REDACTED] and [REDACTED]	
DTX-1117	11/2/2022	SRPT-VYDS-0219945	SRPT-VYDS-0219962	Master Services Agreement between [REDACTED] and [REDACTED]	
DTX-1118	11/13/2015	SRPT-VYDS-0219991	SRPT-VYDS-0220030	Commercial Outsourcing Services Agreement between [REDACTED] and [REDACTED]	
DTX-1119	6/12/2022	SRPT-VYDS-0220031	SRPT-VYDS-0220039	Fifth Amendment to Commercial Outsourcing Services Agreement between [REDACTED] and [REDACTED]	
DTX-1120	11/1/2019	SRPT-VYDS-0220070	SRPT-VYDS-0220073	Second Amendment to Commercial Outsourcing Services Agreement between [REDACTED] and [REDACTED]	

Sarepta-UWA Tenth Revised Trial Exhibit List

November 25, 2024

Confidential

DTX-1121	10/11/2018	SRPT-VYDS-0220074	SRPT-VYDS-0220079	First Amendment to Commercial Outsourcing Services Agreement between [REDACTED] and [REDACTED]	
DTX-1122	4/14/2023	SRPT-VYDS-0213812	SRPT-VYDS-0213820	Certified Copy of Patent Assignment for Application Number 11570691	
DTX-1123	4/14/2023	SRPT-VYDS-0213821	SRPT-VYDS-0213826	Certified Copy of Patent Assignment for Application Number 11570691	
DTX-1124	11/19/2008	UWA0000003	UWA0000006	Patent Assignment Agreement between Smithkline Beecham Corporation and The University of Western Australia	
DTX-1125		NS00065377	NS00065377	Excel relating to sample size and molarity	
DTX-1126		NS00065379	NS00065379	Excel relating to sample size and molarity	
DTX-1127		NS00065381	NS00065381	Excel relating to sample size and molarity	
DTX-1128		NS00065387	NS00065387	Excel relating to sample size and molarity	
DTX-1129		NS00065389	NS00065389	Excel relating to sample size and molarity	
DTX-1130		NS00065391	NS00065391	Excel relating to sample size and molarity	
DTX-1131		NS00065392	NS00065392	Excel relating to sample size and molarity	
DTX-1132		NS00065395	NS00065395	Excel relating to sample size and molarity	
DTX-1133		NS00065396	NS00065396	Excel relating to sample size and molarity	
DTX-1134		NS00065397	NS00065397	Excel relating to sample size and molarity	
DTX-1135		NS00065409	NS00065409	Excel relating to sample size and molarity	
DTX-1136		NS00065411	NS00065411	Excel relating to sample size and molarity	
DTX-1137		NS00065425	NS00065425	[REDACTED]	
DTX-1138		NS00065425	NS00065425	Certified English translation of [REDACTED]	
DTX-1139	8/4/2010	NS00074013	NS00074018	Form 15 (pertaining to Article 18) Drafting Form	

November 25, 2024

Confidential

DTX-1140	3/31/2009	NS00090900	NS00090902	Foreign Document entitled 'Joint study; Shinichi Takeda, Director, Genetic Diseases Treatment Study Division, National Center of Neurology and Psychiatry - Study of Duchenne Muscular Dystrophy Treatment with Nucleic Acid Derivatives' and its certified english translation	
DTX-1141	1/24/2013	NS00091140	NS00091192	Foreign Document entitled 'NS-0655 - Muscular Dystrophy Therapeutic Agent - Development Council Materials' and it's certified English translation	
DTX-1142	6/16/2018	NS00091207	NS00091223	Foreign Document entitled 'Joint Research Agreement' between National Center of Neurology and Psychiatry and Nippon Shinyaku' and its certified english translation	
DTX-1143	5/30/2019	NS00039502	NS00039680	Clinical Study Report: A Phase II, Dose Finding Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NS-065/NCNP-01 in Boys with Duchenne Muscular Dystrophy (DMD)	
DTX-1144	2022-10-00	NS00041265	NS00041265	P. Clemens et al., Efficacy and safety of viltolarsen in boys with duchenne muscular dystrophy: results from the phase 2, open-label, 4-year extension study, NS Pharma (2022)	
DTX-1145	4/18/2018	NS000050775	NS00050786	H. Komaki et al., Systemic administration of the antisense oligonucleotide NS-065/NCNP-01 for skipping of exon 53 in patients with Duchenne muscular dystrophy, Science Translational Medicine (2018)	

November 25, 2024

Confidential

DTX-1146	6/24/2021	NS00053735	NS00053750	S. Takeda et al., Exon-skipping in Duchenne muscular dystrophy, Journal of Neuromuscular Diseases (2021)	
DTX-1147	2018-12-00	NS00054234	NS000054241	N. Watanabe et al., NS-065/NCNP-01: an antisense oligonucleotide for potential treatment of exon 53 skipping in Duchenne muscular dystrophy, Molecular Therapy: Nucleic Acids 13: 442-449 (2018)	
DTX-1148		NS00066226	NS00066227	2.7.6 Synopses of Individual Studies	
DTX-1149	7/30/2018	NS00128908	NS00129028	Clinical Study Report: NS-065/NCNP-01 Clinical Study Report - A phase I/II study of NS-065/NCNP-01 in patients with Duchenne muscular dystrophy - A dose-finding study -	
DTX-1150	5/19/2020	NS00036882	NS00036887	Service Agreement for Pharmacovigilance Activities of Viltolarsen between Nippon Shinyaku Co. and NS Pharma, Inc.	
DTX-1151		NS00036909	NS00036927	Foreign Document entitled 'Joint Research Agreement' between National Center of Neurology and Psychiatry and Nippon Shinyaku and its certified english translation	
DTX-1152	4/1/2010	NS00036948	NS00036956	Foreign Document Entitled 'Contracting and Joint Research Agreement' between T. Higuchi and J. Yano and it's certified english translation	
DTX-1153	2019-09-00	NS00065822	NS00065826	Memorandum [REDACTED] [REDACTED] [REDACTED] from Nippon Shinyaku Co., Ltd. to NS Pharma, Inc.	

Sarepta-UWA Tenth Revised Trial Exhibit List

November 25, 2024

Confidential

DTX-1154	3/2/2016	NS00091120	NS00091122	Foreign Document entitled 'Memorandum [REDACTED] [REDACTED] and Nippon Shinyaku and its certified english translation	
DTX-1155	3/24/2017	NS00091123	NS00091127	Foreign Document entitled 'Memorandum [REDACTED] [REDACTED] and Nippon Shinyaku and its certified english translation	
DTX-1156	2/18/2013	NS00091128	NS00091139	Foreign Document entitled [REDACTED] 'Agreement' between [REDACTED] [REDACTED] and Nippon Shinyaku and its certified english translation	
DTX-1157	2/18/2013	NS00091198	NS00091206	Foreign Document entitled 'Agreement [REDACTED] [REDACTED] [REDACTED] and Nippon Shinyaku and its certified english translation	
DTX-1158	2021-00-00	NS00036988	NS00036988	[REDACTED]	
DTX-1159	2022-00-00	NS00036989	NS00036989	[REDACTED]	
DTX-1160	2022-00-00	NS00036990	NS00036990	[REDACTED]	
DTX-1161	2022-00-00	NS00036991	NS00036991	[REDACTED]	
DTX-1162	2020-00-00	NS00036992	NS00036992	[REDACTED] [REDACTED]	
DTX-1163 DTX-0083	2021-00-00	NS00036993	NS00036993	[REDACTED]	
DTX-1164	2020-00-00	NS00036994	NS00036994	[REDACTED] [REDACTED]	

November 25, 2024

Confidential

DTX-1165	5/14/2021	NS00073824	NS00073830		
DTX-1166	2021-12-00	NS00140987	NS00140987		
DTX-1167		NS00140988	NS00140994		
DTX-1168		NS00140995	NS00140995		
DTX-1169		NS00140996	NS00140996		
DTX-1170		NS00140997	NS00140997		
DTX-1171	1/21/2020	NS00140998	NS00140998		
DTX-1172	1/21/2020	NS00140999	NS00140999		
DTX-1173	1/21/2020	NS00141000	NS00141000		
DTX-1174	8/1/2023	NS00141001	NS00141001		
DTX-1175	2/10/2023	NS00090821	NS00090875	Agreement between [REDACTED] and Nippon Shinyaku Co., LTD	
DTX-1176	2020-00-00	NS00036986	NS00036986	Excel related to NS pharma [REDACTED]	
DTX-1177	7/17/2019	NS00065881	NS00065910	Agreement between Nippon Shinyaku and [REDACTED]	
DTX-1178	1/17/2019	NS00065917	NS00065927	Agreement between [REDACTED] and Nippon Shinyaku	

Sarepta-UWA Tenth Revised Trial Exhibit List

November 25, 2024

Confidential

DTX-1179	10/6/2014	NS00073419	NS00073425	Foreign Document entitled [REDACTED] [REDACTED] Agreement' between Nippon Shinyaku and [REDACTED].	
DTX-1180		NS00073442	NS00073450	Foreign Document entitled [REDACTED] [REDACTED] Agreement' between Nippon Shinyaku and [REDACTED]	
DTX-1181		NS00073831	NS00073839	Foreign Document entitled [REDACTED] [REDACTED] contract' between Nippon Shinyaku and [REDACTED]	
DTX-1182		NS00073840	NS00073848	Foreign Document entitled [REDACTED] [REDACTED] Agreement' [REDACTED] [REDACTED] Fujimoto Chemicals Co	
DTX-1183	9/7/2022	NS00073863	NS00073865	Foreign Document entitled [REDACTED] Memorandum on the [REDACTED] [REDACTED] between Nippon Shinyaku, [REDACTED] [REDACTED]	
DTX-1184	4/16/2021	NS00074932	NS00074932	Letter to Fallone from S. Projansky RE: [REDACTED]	
DTX-1185	11/6/2020	NS00074986	NS00074986	Letter from T. Tanaka to J. Wayment RE: Notice of [REDACTED] [REDACTED] Agreement between NS Pharma, Inc., including its parent company, Nippon Shinyaku Co., Ltd., and [REDACTED]	
DTX-1186	8/1/2020	NS00074987	NS00075032	[REDACTED] Agreement between NS Pharma, Inc. and [REDACTED] [REDACTED]	Gendron 22

November 25, 2024

Confidential

DTX-1187	4/19/2021	NS00075033	NS00075033	Letter from S. Projansky to Scott RE: [REDACTED] [REDACTED]	
DTX-1188	1/26/2023	NS00075076	NS00075078	[REDACTED] [REDACTED] Agreement between McKesson Plasma and [REDACTED] [REDACTED]	
DTX-1189	4/21/2020	NS00075121	NS00075121	[REDACTED] Agreement between NS Pharma, Inc. and [REDACTED] [REDACTED]	
DTX-1190	4/21/2021	NS00075162	NS00075162	[REDACTED] [REDACTED] Agreement between Nippon Shinyaku Co. and [REDACTED]	
DTX-1191	12/8/2021	NS00075163	NS00075164	[REDACTED] [REDACTED] Agreement between Nippon Shinyaku Co. and [REDACTED]	
DTX-1192	8/26/2022	NS00090567	NS00090572	[REDACTED] Agreement between Nippon Shinyaku and [REDACTED] [REDACTED]	
DTX-1193	1/25/2021	NS00090914	NS00090926	Foreign Document entitled [REDACTED] Agreement' between Nippon Shinyaku and [REDACTED] and its english certified translation	
DTX-1194	7/6/2012	NS00090927	NS00090941	Foreign Document entitled [REDACTED] Agreement for [REDACTED] [REDACTED] between Nippon Shinyaku and [REDACTED] [REDACTED] and its certified english translation	
DTX-1195	9/9/2019	NS00090942	NS00090962	Foreign Document entitled [REDACTED] Agreement' between Nippon Shinyaku and [REDACTED] [REDACTED] and its english certified translation	

November 25, 2024

Confidential

DTX-1196	10/6/2014	NS00090963	NS00090977	Foreign Document entitled [REDACTED] Agreement for the Manufacture [REDACTED] [REDACTED] between Nippon Shinyaku and [REDACTED] [REDACTED] and its certified english translation	
DTX-1197		NS00090978	NS00090980	Foreign Chart entitled [REDACTED] [REDACTED] and it's certified english translation	
DTX-1198		NS00090981	NS00090983	Foreign Chart entitled [REDACTED] and its certified english translation	
DTX-1199	8/30/2019	NS00090984	NS00091012	Foreign Document entitled [REDACTED] Agreement [REDACTED] [REDACTED]' between Nippon Shinyaku and [REDACTED] and its certified english translation	
DTX-1200	10/19/2018	NS00091013	NS00091031	Foreign Document entitled [REDACTED] [REDACTED] Agreement' between Nippon Shinyaku and [REDACTED]. and its certified english translation	
DTX-1201	7/12/2018	NS00091032	NS00091050	Foreign Document entitled [REDACTED] [REDACTED] Agreement' between Nippon Shinyaku and [REDACTED] and its certified english translation	
DTX-1202	2/13/2017	NS00091051	NS00091065	Foreign Document entitled [REDACTED] [REDACTED] Agreement' between Nippon Shinyaku and [REDACTED] and its certified english translation	
DTX-1203	8/20/2014	NS00091066	NS00091090	Foreign Document entitled [REDACTED] Agreement' between Nippon Shinyaku and [REDACTED]. and its certified english translation	

November 25, 2024

Confidential

DTX-1204	9/7/2022	NS00091106	NS00091112	Foreign Document entitled 'Memorandum of [REDACTED] [REDACTED] between Nippon Shinyaku and [REDACTED] . and its certified english translation	
DTX-1205	8/26/2022	NS00090697	NS00090722	[REDACTED] Agreement between Nippon Shinyaku and [REDACTED]	
DTX-1206		NS00061464	NS00061467	Neuromuscular Disorders (2010)	
DTX-1207	7/29/2010	NS00085516	NS00085521	Foreign document entitled 'Joint patent application'	
DTX-1208	2010-00-00	SRPT-VYDS-0007688	SRPT-VYDS-0007701	L. Popplewell et al., Comparative analysis of antisense oligonucleotide sequences targeting exon 53 of the human DMD gene: implications for future clinical trials, Neuromuscular Disorders 20:102-110 (2010)	Hastings 29 Wood 112 Wood 34
DTX-1209	7/1/2010	SRPT-VYDS-0008510	SRPT-VYDS-0008544	U.S. Patent Application Publication No. 2010/0168212 A1 to Popplewell et al.	Hastings 28 Dowdy 08
DTX-1210	2007-10-00			A. Aartsma-Rus & G. Van Ommen, Antisense- mediated exon skipping: a versatile tool with therapeutic and research applications, Cold Spring Harbor Laboratory Press 13: 1609-1624 (2007)	
DTX-1211 DTX-0239	2010-00-00	SRPT-VYDS-0008328	SRPT-VYDS-0008343	P. Szani et al., Safety pharmacology and genotoxicity evaluation of AVI-4658, International Journal of Toxicology 29(2):143-156 (2010)	Takeda 09 Ueda 07
DTX-1212	11/17/2021	NS00090490	NS00090509	Statement of Work [REDACTED] [REDACTED] [REDACTED] Agreement between Nippon Shinyaku and [REDACTED] [REDACTED]	

November 25, 2024

Confidential

DTX-1213	7/31/2003	SRPT-VYDS-0156679	SRPT-VYDS-0156739		
DTX-1214 DTX-0485	8/25/2016	SRPT-VYDS-0229337	SRPT-VYDS-0229351	Correspondence on behalf of Nippon Shinyaku to the European Patent Office RE: European Patent No. 2,206,781 B1	
DTX-1215		SRPT-VYDS-0156740	SRPT-VYDS-0156912	Laboratory Notebook to	
DTX-1216		SRPT-VYDS-0156913	SRPT-VYDS-0157030	Laboratory Notebook,	
DTX-1217		SRPT-VYDS-0157031	SRPT-VYDS-0157197	Laboratory Notebook,	
DTX-1218	5/2/2002	SRPT-VYDS-0157198	SRPT-VYDS-0157329	Laboratory Notebook,	
DTX-1219		SRPT-VYDS-0157330	SRPT-VYDS-0157364	Laboratory Notebook, S	
DTX-1220	7/2/2003	SRPT-VYDS-0157365	SRPT-VYDS-0157533	Laboratory Notebook,	
DTX-1221	7/3/2022	SRPT-VYDS-0157534	SRPT-VYDS-0157652	Laboratory Notebook,	
DTX-1222	6/12/2004	SRPT-VYDS-0157653	SRPT-VYDS-0157821	Laboratory Notebook,	
DTX-1223		SRPT-VYDS-0157822	SRPT-VYDS-0157937	Laboratory Notebook,	
DTX-1224	12/13/2019			FDA approves sarepta therapeutics' vyondys 53 for treatment of DMD amenable to exon 53 skipping; mdaquest.org/fda-approves-sarepta-therapeutics-vyondys-53-fdor-treatment-of-dmd-amenable-to-exon-53-skipping/	
DTX-1225		SRPT-VYDS-0157938	SRPT-VYDS-0158108	Laboratory Notebook,	
DTX-1226		SRPT-VYDS-0158436	SRPT-VYDS-0158607	Laboratory Notebook,	
DTX-1227	2/6/2023			Declaration of Michelle L. Hastings, PH.D in C.A. No. 21-1015 (GBW)	Hastings 06

November 25, 2024

Confidential

DTX-1228		SRPT-VYDS-0158608	SRPT-VYDS-0158778	Laboratory Notebook, [REDACTED]	
DTX-1229		SRPT-VYDS-0158779	SRPT-VYDS-0158884	Laboratory Notebook, [REDACTED]	
DTX-1230		SRPT-VYDS-0159421	SRPT-VYDS-0159585	Laboratory Notebook, Jiminy [REDACTED]	
DTX-1231		SRPT-VYDS-0159586	SRPT-VYDS-0159753	Laboratory Notebook, Jiminy [REDACTED]	
DTX-1232		SRPT-VYDS-0160171	SRPT-VYDS-0160340	Laboratory Notebook, [REDACTED]	
DTX-1233		SRPT-VYDS-0160341	SRPT-VYDS-0160520	Laboratory Notebook, [REDACTED]	
DTX-1234	5/10/2005	SRPT-VYDS-0160820	SRPT-VYDS-0160946	Laboratory Notebook, [REDACTED]	
DTX-1235		SRPT-VYDS-0161481	SRPT-VYDS-0161649	Laboratory Notebook, [REDACTED]	
DTX-1236		SRPT-VYDS-0161957	SRPT-VYDS-0162088	Laboratory Notebook, [REDACTED]	
DTX-1237		SRPT-VYDS-0162462	SRPT-VYDS-0162632	Laboratory Notebook, [REDACTED]	
DTX-1238	8/25/2010	SRPT-VYDS-0162633	SRPT-VYDS-0162802	Laboratory Notebook, [REDACTED]	
DTX-1239		SRPT-VYDS-0162803	SRPT-VYDS-0162959	Laboratory Notebook, Jiminy [REDACTED]	
DTX-1240		SRPT-VYDS-0163302	SRPT-VYDS-0163462	Laboratory Notebook, [REDACTED]	
DTX-1241		SRPT-VYDS-0164137	SRPT-VYDS-0164360	Laboratory Notebook, [REDACTED]	
DTX-1242		SRPT-VYDS-0200992	SRPT-VYDS-0201120	Laboratory Notebook, [REDACTED]	
DTX-1243		SRPT-VYDS-0201121	SRPT-VYDS-0201250	Laboratory Notebook, [REDACTED]	
DTX-1244		SRPT-VYDS-0201393	SRPT-VYDS-0201523	Laboratory Notebook, [REDACTED]	
DTX-1245		SRPT-VYDS-0213544	SRPT-VYDS-0213678	Laboratory Notebook, [REDACTED]	
DTX-1246		SRPT-VYDS-0213679	SRPT-VYDS-0213811	Laboratory Notebook, [REDACTED]	

November 25, 2024

Confidential

DTX-1247		SRPT-VYDS-0221203	SRPT-VYDS-0221215	Highlights of Prescribing Information of VYONDYS 53 (golodirsen)	
DTX-1248	8/31/2011			Foreign document relating to PCT/JP2011/070318	Schnell 25
DTX-1249	7/14/2015			Watanabe Patent (U.S. Patent 9,079,934)	
DTX-1250	2/12/2021			Correspondence from Z. Feng to USPTO RE: Information Disclosure Statement (IDS)	
DTX-1251	3/9/2019			Foreign document entitled 'Written Opinion' to Reference Number P12-0190-B and its certified english translation	
DTX-1252	2/16/2011			European Patent Specification 1,766,010	
DTX-1253	6/26/2023			Transcript Excerpt of Naoki Watanabe, Ph.D. in Case: Nippon Shinyaku Co -v- Sarepta Therapeutics	
DTX-1254	2018-12-00	NS00131235	NS00131242	N. Watanabe et al., NS-065/NCNP-01: am antisense oligonucleotide for potential treatment of exon 53 skipping in duchenne muscular dystrophy, Molecular Therapy: Nucleic Acids 13: 442-449	
DTX-1255	2020-08-00	NS00035795	NS00035806	Highlights of prescribing information of VILTEPSO (Revised: 8/2020)	
DTX-1256	2021-03-00	NS00035807	NS00035817	Highlights of prescribing information of VILTEPSO	
DTX-1257		NS00035832	NS00035832	3.2.P.1 Description and Composition of Drug Product [Viltolarsen Injection]	
DTX-1258		NS00035833	NS00035833	3.2.P.2.1 Components of the Drug Product [Viltolarsen Injection]	
DTX-1259		NS00035834	NS00035834	3.2.S.1.1 Nomenclature [Viltolarsen, Ajinomoto Co., Inc.]	
DTX-1260		NS00035835	NS00035835	3.2.S.1.2 Structure [Viltolarsen, Ajinomoto Co., Inc.]	
DTX-1261	2021-00-00	NS00039861	NS00039862	Patient Assistance Program Application from NS Support	

November 25, 2024

Confidential

DTX-1262	2022-00-00	NS00041309	NS00041315	Foreign document bearing beginning bates stamp NS00041309; Foreign pamphlet for Viltepso entitled 'Cada momento con Viltepso es un relato'	
DTX-1263	2021-00-00	NS00041348	NS00041354	Pamphlet entitled 'Patient Assistance Program - No insurance coverage? We may be able to help.'	
DTX-1264	2021-00-00	NS00041521	NS00041523	Material entitled 'Viltepso provided significant improvements in dystrophin expression'	
DTX-1265		NS00041787	NS00041787	NS video entitled 'Mechanism of Exon Skipping'	
DTX-1266		NS00065554	NS00065566	2.3.P.2 Pharmaceutical Development	
DTX-1267		NS00065928	NS00065938	2.3.P.2 Pharmaceutical Development [Viltolarsen Injection]	
DTX-1268		NS00066346	NS00066364	3.2.S.3.1 Elucidation of Structure and Other Characteristics	
DTX-1269	3/11/2021	NS00066365	NS00066378	Letter to Dr. Philips from T. Buracchio RE: Supplemental Approval	
DTX-1270	2019-09-00	NS00066379	NS00066389	Highlights of prescribing information of Viltepso (Revised: 9/2019)	
DTX-1271	2020-08-00	NS00066390	NS00066400	Highlights of prescribing information of Viltepso (Revised: 8/2020)	
DTX-1272	9/5/2019	NS00066424	NS00066427	Patient information submitted with the filing of an NDA, amendment, or supplement signed by Dr. M. Meyer	
DTX-1273	1/28/2019	NS00066433	NS00066437	Application to market a new or abbreviated new drug or biologic for human use for Viltepso signed by T. Stover	
DTX-1274	10/4/2022	NS00066438	NS00066443	Application to market a new or abbreviated new drug or biologic for human use for Viltepso signed by K. Philips	

November 25, 2024

Confidential

DTX-1275	11/18/2020	NS00066450	NS00066451	Letter to Dr. Bastings from K. Philips RE: Labeling Supplement - CBE-30	
DTX-1276	11/28/2018	NS00066452	NS00066455	Letter to Dr. Dunn from T. Stover RE: Request for Submission of Portions of an Application (IND 127474, SN0040)	
DTX-1277	6/30/2018	NS00066971	NS00067091	NS-065/NCNP-01 Clinical Study Report	
DTX-1278 DTX-1322	3/2020	NS00067092	NS00067102	Highlights of prescribing information of Viltepso (Revised: 03/2021)	
DTX-1279		NS00073876	NS00073888	2.3.S.2 Manufacture [Viltolarsen Ajinomoto Co., Inc.]	
DTX-1280		NS00073889	NS00073890	3.2.P.3.1 Manufacture [Viltolarsen Injection]	
DTX-1281	6/24/2021	SRPT-VYDS-0007271	SRPT-VYDS-0007286	S. Takeda et al., Exon-skipping in Duchenne muscular dystrophy, Journal of Neuromuscular Diseases 8: S343-S358 (2021)	
DTX-1282	6/15/2020	SRPT-VYDS-0007287	SRPT-VYDS-0007296	P. Clemens et al., Safety, tolerability, and efficacy of Viltolarsen in boys with Duchenne muscular dystrophy amenable to Exon 53 skipping - A phase 2 randomized Clinical Trial, JAMA Neurology 77(8): 982-991 (2020)	
DTX-1283 DTX-0455	4/18/2018	SRPT-VYDS-0183317	SRPT-VYDS-0183328	H. Komaki et al., Systemic administration of the antisense oligonucleotide NS-065/NCNP-01 for skipping of exon 53 in patients with Duchenne muscular dystrophy, Science Translational Medicine 10 (2018)	
DTX-1284	2005-00-00	SRPT-VYDS-0009221	SRPT-VYDS-0009238	A. Aartsma-Rus et al., Functional analysis of 114 exon-internal AONs for targeted dmd exon skipping: indication for steric hinderance of sr protein binding sites, Oligonucleotides 15(4): 284-297 (2005)	

November 25, 2024

Confidential

DTX-1285	2000-00-00	SRPT-VYDS-0008104	SRPT-VYDS-0008112	I. Ginjaar, Dystrophin nonsense mutation induces different levels of exon 29 skipping and leads to variable phenotypes within one BMD family, European Journal of Human Genetics 8: 793-796 (2000)	
DTX-1286	12/27/2007	SRPT-VYDS-0008724	SRPT-VYDS-0008728	E. Hoffman, Skipping toward personalized molecular medicine, New England Journal of Medicine 357(26):2719-2722 (2007)	
DTX-1287	3/26/2006	SRPT-VYDS-0007636	SRPT-VYDS-0007645	G. McClorey et al., Induced dystrophin exon skipping in human muscle explants, Neuromuscular Disorders 16: 583-590 (2006)	
DTX-1288	2010-05-00	SRPT-VYDS-0009086	SRPT-VYDS-0009095	F. Muntoni et al., The development of antisense oligonucleotide therapies for Duchenne muscular dystrophy: Report on a treat-nmd workshop hosted by the European Medicines Agency (EMA), on September 25th 2009, Neuromuscular Disorders 20(5): 355-362 (2010)	
DTX-1289	2017-00-00	SRPT-VYDS-0227082	SRPT-VYDS-0227106	J. Summerton, Invention and early history of morpholinos: From pipe dream to practical products, Methods in Molecular Biology - Morpholino Oligomers - Methods and Protocols, pp. 1-16 (2017)	
DTX-1290	2009-07-00	SRPT-VYDS-0009251	SRPT-VYDS-0009271	C. Trollet et al., Gene therapy for muscular dystrophy: current progress and future prospects, Expert Opinion on Biological Therapy 9(7): 849-866	
DTX-1291	2009-01-00	SRPT-VYDS-0007375	SRPT-VYDS-0007385	T. Yokota et al., A renaissance for antisense oligonucleotide drugs in neurology, Neurological Review 66(1): 9-38 (2009)	
DTX-1292	9/1/2010	SRPT-VYDS-0015713	SRPT-VYDS-0015764	English Translated Copy of JP 2010-196032	

November 25, 2024

Confidential

DTX-1293	8/28/2003			United States Patent Application Publication 2003/0166588	
DTX-1294	1/27/2012	SRPT-VYDS-0008545	SRPT-VYDS-0008638	Certified copy of United States Patent Application Number 61/591,654	
DTX-1295	12/29/2020			United States Patent 10,875,880	
DTX-1296	5/27/2010	SRPT-VYDS-0007397	SRPT-VYDS-0007595	United States Patent Application Publication 2010/0130591	
DTX-1297	6/27/1991	NS00064142	NS00064236	International Publication Number for Patent: WO 91/09033	
DTX-1298	3/28/2002	NS00063103	NS00063145	International Publication Number WO 02/024906	
DTX-1299	1/5/2006	SRPT-VYDS-00007982	SRPT-VYDS-0008103	International Publication Number WO 2006/000057	
DTX-1300	5/22/2009	NS00063207	NS00063255	International Publication Number WO 2009/064471	
DTX-1301	5/19/2011	SRPT-VYDS-0008753	SRPT-VYDS-0008854	International Publication Number WO 2011/057350	
DTX-1302	1/12/2011	SRPT-VYDS-0008855	SRPT-VYDS-0009040	International Publication Number WO 2011/150408	
DTX-1303	6/21/2021			Petition for Inter Partes Review in IPR2021-01134	
DTX-1304	10/8/2021			Patent Owner Preliminary Response in IPR2021-01134	
DTX-1305	1/20/2022			Decision Granting Institution of Inter Partes Review in IPR2021-01134	
DTX-1306		NS00075489	NS00075515	Foreign Document relating to NDK-65	
DTX-1307		NS00081271	NS00081291	Foreign Presentation entitled 'Selection of candidate products'	
DTX-1308	6/21/2021	SRPT-VYDS-0009383	SRPT-VYDS-0009470	Petition for Inter Partes Review in IPR2021-01140	
DTX-1309	1/7/2022	SRPT-VYDS-0017323	SRPT-VYDS-0017367	Decision Granting Institution of Inter Partes Review in IPR2021-01134	
DTX-1310	1/7/2022	SRPT-VYDS-0079455	SRPT-VYDS-0079502	Decision Granting Institution of Inter Partes Review in IPR2021-01135	

November 25, 2024

Confidential

DTX-1311	1/11/2022	SRPT-VYDS-0090887	SRPT-VYDS-0090939	Decision Granting Institution of Inter Partes Review in IPR2021-01140	
DTX-1312 DTX-0779	6/7/2020	SRPT-VYDS-0225125	SRPT-VYDS-0225184	Communication of Further Notices of Opposition Pursuant to Rule 79(2) EPC for Application 15199455.5-1111/3018211 from Nippon Shinyaku	
DTX-1313	2003-01-00			S. Errington et al., Target selection for antisense oligonucleotide induced exon skipping in the dystrophin gene, The Journal of Gene Medicine 5: 518-527 (2003)	
DTX-1314	11/25/2003	NS00036355	NS00036366	Matsuo et al. United States Patent 6,653,467	
DTX-1315	1997-00-00	SRPT-VYDS-0008314	SRPT-VYDS-0008327	J. Summerton & D. Weller, Morpholino antisense oligomer; design, preparation, and properties, Antisense & Nucleic Acid Drug Development 7(3): 187-195 (1997)	
DTX-1316	9/30/2004	NS00036399	NS00036469	International Publication Number WO 2004/083432	
DTX-1317	1/5/2006	SRPT-VYDS-0007982	SRPT-VYDS-0008103	International Publication Number WO 2006/000057	
DTX-1318	4/29/2010	NS00064755	NS00064916	International Publication Number WO 2010/048586	Schnell 09
DTX-1319	5/19/2011	SRPT-VYDS-0008753	SRPT-VYDS-0008854	International Publication Number WO 2011/057350	Meloni 10
DTX-1320 DTX-0852	4/27/2020	NS00048946	NS00048949	FDA grants accelerated approval to first targeted treatment for rare duchenne muscular dystrophy mutation; https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-first-targeted-treatment-rare-duchenne-muscular-dystrophy-...	
DTX-1321 DTX-0038 DTX-0622		SRPT-VYDS-0201524	SRPT-VYDS-0201588	Selection of PMO Sequences for Exon Skip-NMD Grant#305370	

November 25, 2024

Confidential

DTX-1322 DTX-1278	2021-03-00	NS00067092	NS00067102	Highlights of prescribing information of Viltepso (Revised: 3/2021)	
DTX-1323	2018-12-00	SRPT-VYDS-0007263	SRPT-VYDS-0007270	N. Watanabe et al., NS-065/NCNP-01: an antisense oligonucleotide for potential treatment of exon 53 skipping in Duchenne muscular dystrophy, Molecular Therapy: Nucleic Acids 13: 442-449 (2018)	
DTX-1324	11/15/2007	SRPT-VYDS-0007346	SRPT-VYDS-0007356	F. Muntoni et al., 149th ENMC international workshop and 1st TREAT-NMD workshop on: "planning phase I/II clinical trials using systemically delivered antisense oligonucleotides in Duchenne muscular dystrophy"	
DTX-1325	6/15/2015	SRPT-VYDS-0123193	SRPT-VYDS-0129053	Excerpt from Prosecution History of Patent Application No. 14/740,097	
DTX-1326		FLETCHER0000226	FLETCHER0000309	NHMRC Research Grant Application, Application Summary	Fletcher 02
DTX-1327		SRPT-VYDS-0007014	SRPT-VYDS-0007015	2.2 Introduction to Summary	
DTX-1328		SRPT-VYDS-0007043	SRPT-VYDS-0007047	2.6.1 Introduction	
DTX-1329				Nippon Shinyaku's First Supplemental Responses and Objections to Sarepta's Sixth Set of Interrogatories (Nos. 30-35)	
DTX-1330		SRPT-VYDS-0004509	SRPT-VYDS-0004997	Information Disclosure Statement (IDS) Filed , Application No. 15705172	
DTX-1331	2/6/2015	NS00000772	NS00000784	Excerpt of Prosecution History of U.S. Patent Application No. 14/615,504 to N. Watanabe	Hirshfeld 08
DTX-1332	2/19/2008	WILTON0001293	WILTON0001297	E-mail from S. Fletcher to S. Wilton, RE: Grant Your Copy	Fletcher 01
DTX-1333				Curriculum Vitae of B. Pentelute	
DTX-1334				Curriculum Vitae of S. Dowdy	
DTX-1335				Curriculum Vitae of A. Hirshfeld	
DTX-1336				Curriculum Vitae of Y. Lu	
DTX-1337				Curriculum Vitae of S. Nelson	

November 25, 2024

Confidential

DTX-1338	2022-01-00	NS00041583	NS00041587	Viltepso advertisement entitled 'Every moment with VILTEPSO tells a story'	
DTX-1339	3/27/2022	NS00074040	NS00074040	Excel spreadsheet entitled [REDACTED] [REDACTED]	Gendren 38
DTX-1340	2/8/2022	NS00074041	NS00074041	Excel spreadsheet entitled [REDACTED]	
DTX-1341 DTX-0082	2/8/2022	NS00074042	NS00074042	Excel spreadsheet entitled [REDACTED]	
DTX-1342	9/21/2022	NS00074043	NS00074043	Excel spreadsheet regarding [REDACTED] [REDACTED]	
DTX-1343	2022-12-00	NS00074044	NS00074044	Excel spreadsheet entitled [REDACTED] [REDACTED]	
DTX-1344 DTX-0096	8/28/2020	NS00074895	NS00074931	[REDACTED] agreement between NS Pharma and [REDACTED]	
DTX-1345	6/1/2023	NS00090754	NS00090756	Amendment number 2 to Statement of Work [REDACTED] Agreement [REDACTED] between NS and [REDACTED]	
DTX-1346	9/30/2022	NS00090757	NS00090764	Amendment number 1 to Statement of Work [REDACTED] agreement [REDACTED] between NS and [REDACTED]	
DTX-1347	3/10/2006	SRPT-VYDS-0154895	SRPT-VYDS-0154901	Appendix A - Patent Assignment Agreement between UWA and GSK	
DTX-1348		SRPT-VYDS-0212480	SRPT-VYDS-0212484	Advertisement for Exondys 51 and Vyondys 53	
DTX-1349		SRPT-VYDS-0212578	SRPT-VYDS-0212579	Advertisement for Exondys 51 and Vyondys 53 entitled 'Sarepta is committed to the advancement of therapy'	
DTX-1350		SRPT-VYDS-0212667	SRPT-VYDS-0212667	Snip of Sarepta Therapeutics website 'Our Products' section	

November 25, 2024

Confidential

DTX-1351	2020-05-00	SRPT-VYDS-0213046	SRPT-VYDS-0213052	Vyondys 53 Dosing and Administration Guide	
DTX-1352	9/9/2022	NS00091224	NS00091258	██████ agreement between NS and ██████ ████████████████████	
DTX-1353	2/3/2023	NS00091259	NS00091283	██████ agreement between NS and ██████ ██████	
DTX-1354	1/31/2022	NS00091310	NS00091310	████████████████████ ████████████████████	
DTX-1355	9/7/2023	NS00141991	NS00141992	Orange book: approved drug products with therapeutic equivalence evaluations ; https://www.accessdata.fda.gov/scripts/cder/ob/patent_info.cfm?Product_No=001&Appl_No=211970&Appl_type=N (2023)	
DTX-1356	1983-00-00	NS00141993	NS00141998	S. Salop and D. Scheffman, Raising rival's costs, The American Economic Review 73(2):267-271 (1983)	
DTX-1357	8/3/2017	SRPT-VYDS-0205761	SRPT-VYDS-0206131	Sarepta Therapeutics form 10-Q for the quarterly period ended June 30, 2017	
DTX-1358	2020-05-00	SRPT-VYDS-0221067	SRPT-VYDS-0221067	Excel spreadsheet regarding ██████ ██████	
DTX-1359	7/15/2010	SRPT-VYDS-0150694	SRPT-VYDS-0150830	Prosecution History Excerpts from U.S. Patent Application No. 12837359 (US Patent 8,232,384)	Kamholz 05
DTX-1360				N. Luedtke dissertation, RNA Affinity and Specificity of Modified Aminoglycosides, Metal Complexes, and Intercalating Agents That Target the HIV-1 Rev Response Element	Luedtke 03
DTX-1361				User Guide, Applied Biosystems 3400 DNA Synthesizer	Luedtke 08
DTX-1362	3/18/2010			International Publication Number WO 2010/028780 A2 to Luedtke et al.	Luedtke 09

November 25, 2024

Confidential

DTX-1363				Caregiver Support Across the Multidisciplinary Care Continuum, https://event.on24.com/wcc/r/3018979/EF80501A4D7C4FA75A2413C24C410	Strober 04
DTX-1364				Patient information	Strober 05
DTX-1365	12/8/2020	NS00143179	NS00143184	Department of Health Care Services, Antisense Oligonucleotide Treatment of Duchenne Muscular Dystrophy	Strober 06
DTX-1366	5/25/2021			Department of Health Care Services, Antisense Oligonucleotide Treatment of Duchenne Muscular Dystrophy	Strober 07
DTX-1367	4/15/2020			A. Fay et al, Targeted Treatments for Inherited Neuromuscular Diseases of Childhood, (2020)	Strober 08
DTX-1368	11/13/2023			Provider Stories: Jonathan Strober, https://www.ucsfbenioffchildrens.org/provider-stories/jonathan-strober	Strober 10
DTX-1369				F. Muntoni, Six-Year Long-Term Safety and Efficacy of Golodirsen in Patients With DMD vs Mutation-Matched External Controls, (2023)	Strober 14
DTX-1370 DTX-1746				J. Iff, Delayed Pulmonary Progression in Golodirsen-Treated Patients With Duchenne Muscular Dystrophy vs Mutation-Matched External Controls, (2023)	Strober 15
DTX-1371	11/7/2023			M. Flanagan, KOL Views Q&A: Leading expert puts Elevydis' missed confirmatory endpoint in perspective in DMD, (2023)	Strober 18
DTX-1372	10/30/2023			Dough Ingram, Patients can't wait for the next breakthrough in medical research, (2023)	Strober 19

November 25, 2024

Confidential

DTX-1373				A. Hinrich et al, Therapeutic correction of ApoER2 splicing in Alzheimer's disease mice using antisense oligonucleotides, (2016)	Hastings 09
DTX-1374	9/28/2016			F. Depreux, Antisense oligonucleotides delivered to the amniotic cavity in utero modulate gene expression in the postnatal mouse, (2016)	Hastings 10
DTX-1375				J. Chang et al., Targeting Amyloid-13 Precursor Protein, APP, Splicing with Antisense Oligonucleotides Reduces Toxic Amyloid-f3 Production, (2018)	Hastings 11
DTX-1376	6/5/2020			W. Michaels, Antisense oligonucleotide-mediated correction of CFTR splicing improves chloride secretion in cystic fibrosis patient-derived bronchial epithelial cells, (2020)	Hastings 12
DTX-1377				J. Centa, Therapeutic efficacy of antisense oligonucleotides in mouse models of CLN3 Batten disease, (September 2020)	Hastings 13
DTX-1378	2022-00-00			W. Michaels, Open reading frame correction using splice-switching antisense oligonucleotides for the treatment of cystic fibrosis, (2022)	Hastings 14
DTX-1379	6/5/2020			W. Michaels, Antisense oligonucleotide-mediated correction of CFTR splicing improves chloride secretion in cystic fibrosis patient-derived bronchial epithelial cells, (2020)	Hastings 15
DTX-1380		NS00153927	NS00153962	[REDACTED]	Hastings 16
DTX-1381		NS00153963	NS00153997	[REDACTED]	Hastings 17

Sarepta-UWA Tenth Revised Trial Exhibit List

November 25, 2024

Confidential

DTX-1382	12/12/2017			U.S. Patent No. 9,840,706 B2 to Watanabe et al.	Hastings 21
DTX-1383	3/30/2023			U.S. Patent Application Publication No. 2023/0097387 A1 to HONDA et al.	Hastings 22
DTX-1384	12/4/2018			U.S. Patent No. 10,144,931 B2 to Enya et al.	Hastings 23
DTX-1385	5/7/2020			International Publication No. WO 2020/089325 A1	Hastings 24
DTX-1386	9/11/2015	SRPT-VYDS-0057510	SRPT-VYDS-0058529	First Preliminary Amendment, Patent Application of P. Sazani	Hastings 37
DTX-1387	9/17/2015	SRPT-VYDS-0072805	SRPT-VYDS-0073834	Amendment in Response to Non-Final Office Action Under 37 C.F.R. 1.111, Patent Application of P. Sazani	Hastings 38
DTX-1388		SRPT-VYDS-0074084	SRPT-VYDS-0075125	First Preliminary Amendment Under 37 C.F.R. 1.115, Patent Application of P. Sazani	Hastings 39
DTX-1389	1/31/2017			Amendment and Reply Under 37 C.F.R. § 1.111, EXON SKIPPING COMPOSITIONS FOR TREATING MUSCULAR DYSTROPHY	Hastings 40
DTX-1390	7/11/2023			Nippon Shinyaku's Final Invalidity Contentions	Hastings 43
DTX-1391		SRPT-VYDS-0246093	SRPT-VYDS-0246106	OpenPayments Reports for S. Nelson and J. Strober	
DTX-1392	2020-00-00	NS00055861	NS00055865	P. Clemens et al., Safety tolerability, and efficacy of viltolarsen in boys with Duchenne muscular dystrophy amenable to exon 53 skipping, JAMA Neurology 77(8):Supp2 (2020)	
DTX-1393	9/8/2012	SRPT-VYDS-0213902		E-mail from D. Frank to S. Wilton. RE: [REDACTED]	
DTX-1394	9/13/2012	SRPT-VYDS-0213921	SRPT-VYDS-0213922	E-mail from D. Frank to S. Fletcher. RE: [REDACTED]	
DTX-1395	9/24/2012	SRPT-VYDS-0213932	SRPT-VYDS-0213933	E-mail from D. Frant to A. Adams. RE: [REDACTED]	

November 25, 2024

Confidential

DTX-1396	10/19/2012	SRPT-VYDS-0213991		E-mail from D. Frank to A. Adams. RE: [REDACTED] [REDACTED] Attachments: [REDACTED] [REDACTED]	
DTX-1397	11/1/2012	SRPT-VYDS-0214082		E-mail from D. Frank to S. Fletcher. RE: [REDACTED]	
DTX-1398	4/2/2013	SRPT-VYDS-0215558	SRPT-VYDS-0215562	E-mail from D. Frank to S. Fletcher. RE: Myoblasts	
DTX-1399	4/4/2013	SRPT-VYDS-0215616	SRPT-VYDS-0215620	E-mail from D. Frank to S. Fletcher. RE: Myoblasts	
DTX-1400	1/15/2013	SRPT-VYDS-0214804		E-mail to D. Frank to D. Mourich. RE: [REDACTED] [REDACTED]	
DTX-1401		SRPT-VYDS-0214805	SRPT-VYDS-0214818	K. Anthony, Exon Skipping Quantification by Quantitative Reverse-Transcription, (2012)	
DTX-1402	1/17/2013	SRPT-VYDS-0214815	SRPT-VYDS-0214817	E-mail from D. Frank to D. Mourich. RE: Teleconference: February Meeting	
DTX-1403	10/27/2011	SRPT-VYDS-0214818	SRPT-VYDS-0214823	The Dubowitz Neuromuscular Centre, Authorised by Karen Anthony	
DTX-1404	2/4/2023	SRPT-VYDS-0215126	SRPT-VYDS-0215127	D. Frank to D. Mourich. RE: Transition Meeting?	
DTX-1405		SRPT-VYDS-0215408	SRPT-VYDS-0215425	[REDACTED] [REDACTED]	Bestwick 11 Frank 21
DTX-1406	1/15/2013	SRPT-VYDS-0216695		E-mail from D. Frank to D. Mourich. RE: [REDACTED] [REDACTED]	
DTX-1407	10/11/2023			Dowdy Rebuttal Expert Report, Exhibit C	
DTX-1408	7/31/2012	SRPT-VYDS-0150694	SRPT-VYDS-0153403	Prosecution History of Application No. 12837359	
DTX-1409	8/27/2009	NS00036941	NS00036947	[REDACTED] agreement between Nippon Shinyaku and [REDACTED]	Takagaki 15

November 25, 2024

Confidential

DTX-1410 DTX-0075	11/13/2020	NS00036995	NS00036998	Certified English translation of document entitled [REDACTED] [REDACTED]"	Gendron 05A
DTX-1411 DTX-0076	12/25/2020	NS00037036	NS00037041	Certified English translation of document titled [REDACTED] [REDACTED]	Gendron 06A
DTX-1412 DTX-0089	8/22/2022	NS00090751	NS00090753	Certified English translation to foreign document titled "Presentation, On the [REDACTED] [REDACTED] and the [REDACTED] [REDACTED] (updated version)"	Gendron 13 A
DTX-1413 DTX-0252	2/17/2010	NS00061181	NS00061182	Certified Translation of foreign document entitled [REDACTED]	
DTX-1414		NS00081271	NS00081291	Certified English translation of foreign document entitled [REDACTED]	
DTX-1415		NS00075489	NS00075515	Certified English translation of Foreign Document relating to [REDACTED]	
DTX-1416		NS00085516	NS00085521	Certified English translation of Foreign document entitled 'Joint patent application'	
DTX-1417	9/7/2022	NS00073863	NS00073865	Certified English translation of Foreign Document entitled [REDACTED] [REDACTED] [REDACTED] [REDACTED]	
DTX-1418		NS00073840	NS00073848	Certified English translation of Foreign Document entitled [REDACTED] [REDACTED] [REDACTED]	

November 25, 2024

Confidential

DTX-1419		NS00073831	NS00073839	Certified English translation of Foreign Document entitled [REDACTED] contract' between Nippon Shinyaku and [REDACTED].	
DTX-1420		NS00073442	NS00073450	Certified English translation of Foreign Document entitled [REDACTED] Agreement' between Nippon Shinyaku and [REDACTED]	
DTX-1421	10/6/2014	NS00073419	NS00073425	Certified English translation of Foreign Document entitled [REDACTED] Agreement' between Nippon Shinyaku and [REDACTED]	
DTX-1422	6/21/2013	NS00090249	NS00090251	Certified English translation of Foreign document entitled [REDACTED]	
DTX-1423		NS00088569	NS00088575	Certified English translation of Foreign Document entitled [REDACTED]	
DTX-1424	9/22/2010	NS00061256	NS00061261	Certified English translation of Foreign Presentation entitled [REDACTED]	
DTX-1425	2/24/2011	NS00081507	NS00081560	Certified English translation of Foreign presentation entitled [REDACTED] for Duchenne Muscular Dystrophy	
DTX-1426	5/21/2010	NS00083858	NS00083911	Certified English translation of Foreign document entitled 'Duchenne Muscular Dystrophy (DMD) [REDACTED]	
DTX-1427	9/9/2019	NS00073866	NS00073875	Certified English translation of Foreign document entitled [REDACTED] contract' between Nippon Shinyaku and Fujii [REDACTED]	

November 25, 2024

Confidential

DTX-1428	8/30/2019	NS00073849	NS00073862	Certified English translation of Foreign document entitled [REDACTED] Agreement on [REDACTED] [REDACTED] between Nippon Shinyaku, [REDACTED]	
DTX-1429	20014-08-20	NS00073467	NS00073478	Certified English translation of Foreign document entitled [REDACTED] Agreement between Nippon Shinyaku, [REDACTED] [REDACTED]	
DTX-1430	20107-02-13	NS00073460	NS00073466	Certified English translation of Foreign document entitled [REDACTED] Agreement	
DTX-1431	7/12/2018	NS00073451	NS00073459	Certified English translation of Foreign document entitled [REDACTED] contract' between Nippon Shinyaku and [REDACTED] [REDACTED]	
DTX-1432	8/30/2019	NS00073428	NS00073441	Certified English translation of Foreign document entitled [REDACTED] Agreement [REDACTED] [REDACTED] between Nippon Shinyaku, [REDACTED]	
DTX-1433	2/13/2017	NS00073409	NS00073418	Certified English translation of Foreign document entitled [REDACTED] contract' between Nippon Shinyaku [REDACTED]	
DTX-1434	7/6/2012	NS00073402	NS00073408	Certified English translation of Foreign Document entitled [REDACTED] Agreement' between Nippon Shinyaku [REDACTED] [REDACTED]	

November 25, 2024

Confidential

DTX-1435	7/6/2021	SRPT-VYDS-0223211	SRPT-VYDS-0223214	Certified English translation of Foreign translation of Email from J. Zenkus to M. Toda RE: Draft note to NS	Toda 36 Luedtke 06 Zenkus 19
DTX-1436	6/25/2021	NS00090452	NS00090452	Certified English translation of Foreign Document entitled 'Business Trip Report' by Kazuhisa Takagaki	
DTX-1437	5/5/2022			Nippon Shinyaku Co. Ltd. and NS Pharma, Inc.'s Responses and Objections to Sarepta Therapeutics, Inc.'s First Request for the Production of Documents and Things (Nos. 1-70)	
DTX-1438	5/16/2022			Nippon Shinyaku Co. Ltd. and NS Pharma, Inc.'s Responses and Objections to Sarepta Therapeutics, Inc.'s First Set of Interrogatories (Nos. 1-11)	
DTX-1439	11/10/2022			Nippon Shinyaku Co. LTD. and NS Pharma, Inc.'s Responses and Objections to Sarepta Therapeutics, Inc.'s Second Request for the Production of Documents and Things (Nos. 71-77)	
DTX-1440	11/10/2022			Nippon Shinyaku Co. Ltd. and NS Pharma, Inc.'s Responses and Objections to Sarepta Therapeutics, Inc.'s Second Set of Interrogatories (No. 12)	
DTX-1441	11/21/2022			Nippon Shinyaku Co. Ltd. and NS Pharma, Inc.'s Responses and Objections to Sarepta Therapeutics, Inc.'s Third Request for Production of Documents and Things (Nos. 78-90)	
DTX-1442	12/30/2022			Nippon Shinyaku Co. Ltd. and NS Pharma, Inc.'s Responses and Objections to Sarepta Therapeutics, Inc.'s Fourth Request for the Production of Documents and Things (Nos. 91-94)	

November 25, 2024

Confidential

DTX-1443	3/16/2023			Nippon Shinyaku Co. Ltd. and NS Pharma, Inc.'s Responses and Objections to Sarepta Therapeutics, Inc.'s Third Set of Interrogatories (Nos. 13-17)	
DTX-1444	4/17/2023			Nippon Shinyaku Co. Ltd. and NS Pharma, Inc.'s Responses and Objections to Sarepta Therapeutics, Inc.'s Fourth Set of Interrogatories (Nos. 18-22)	
DTX-1445	6/5/2023			Nippon Shinyaku Co. Ltd. and NS Pharma, Inc.'s Responses and Objections to Sarepta Therapeutics, Inc.'s Fifth Set of Interrogatories (Nos. 23-29)	
DTX-1446	6/21/2023			Nippon Shinyaku Co. Ltd. and NS Pharma, Inc.'s First Supplemental Responses and Objections to Sarepta Therapeutics, Inc.'s Second Set of Interrogatories (No. 12)	
DTX-1447	6/21/2023			Nippon Shinyaku Co. Ltd. and NS Pharma, Inc.'s First Supplemental Responses and Objections to Sarepta Therapeutics, Inc.'s First Set of Interrogatories (Nos. 1-5, 5 and 6)	
DTX-1448	7/27/2023			Nippon Shinyaku Co. Ltd. and NS Pharma, Inc.'s First Supplemental Responses and Objections to Sarepta Therapeutics, Inc.'s Fourth Set of Interrogatories (No. 21)	
DTX-1449	7/27/2023			Appendix to Nippon Shinyaku Co. Ltd. and NS Pharma, Inc.'s First Supplemental Responses and Objections to Sarepta Therapeutics, Inc.'s Fourth Set of Interrogatories (No. 21)	

November 25, 2024

Confidential

DTX-1450	7/27/2023			Nippon Shinyaku Co. Ltd. and NS Pharma, Inc.'s Responses and Objections to Sarepta Therapeutics, Inc.'s Fifth Request for the Production of Documents and Things (Nos. 95-100)	
DTX-1451	7/27/2023			Nippon Shinyaku Co. Ltd. and NS Pharma, Inc.'s Responses and Objections to Sarepta Therapeutics, Inc.'s Sixth Set of Interrogatories (Nos. 30-35)	
DTX-1452	8/15/2023			Nippon Shinyaku Co. Ltd. and NS Pharma, Inc.'s Second Supplemental Responses and Objections to Sarepta Therapeutics, Inc.'s First Set of Interrogatories (Nos. 1-11)	
DTX-1453	8/15/2023			Nippon Shinyaku Co. Ltd. and NS Pharma, Inc.'s Second Supplemental Responses and Objections to Sarepta Therapeutics, Inc.'s Second Set of Interrogatories (Nos. 12)	
DTX-1454	8/15/2023			Nippon Shinyaku Co. Ltd. and NS Pharma, Inc.'s First Supplemental Responses and Objections to Sarepta Therapeutics, Inc.'s Third Set of Interrogatories (Nos. 13-17)	
DTX-1455	8/15/2023			Nippon Shinyaku Co. Ltd. and NS Pharma, Inc.'s Second Supplemental Responses and Objections to Sarepta Therapeutics, Inc.'s Fourth Set of Interrogatories (Nos. 18-22)	
DTX-1456	8/15/2023			Nippon Shinyaku Co. Ltd. and NS Pharma, Inc.'s First Responses and Objections to Sarepta Therapeutics, Inc.'s Fifth Set of Interrogatories (Nos. 23-29)	

November 25, 2024

Confidential

DTX-1457	8/15/2023			Nippon Shinyaku Co. Ltd. and NS Pharma, Inc.'s First Supplemental Responses and Objections to Sarepta Therapeutics, Inc.'s Sixth Set of Interrogatories (Nos. 30-35)	
DTX-1458	4/11/2022			Sarepta's Responses and Objections to NS's First Set of Requests for Production to Sarepta (Nos. 1-149)	
DTX-1459	4/11/2022			Sarepta's Responses and Objections to NS's First Set of Interrogatories (Nos. 1-13)	
DTX-1460	4/3/2023			Sarepta's Responses and Objections to NS's Second Set of Interrogatories (Nos. 14-21)	
DTX-1461	6/6/2023			UWA's Responses to Nippon Shinyaku's Previously Served Discovery Requests	
DTX-1462	6/9/2023			Sarepta's and UWA's Supplemental Responses and Objections to NS's Interrogatories (nos. 6-9 and 15)	
DTX-1463	7/27/2023			Sarepta's Objections and Responses to NS's Third Set of Interrogatories (Nos. 22-34)	
DTX-1464	8/15/2023			Sarepta's Supplemental Response and Objections to NS's Interrogatories (Nos. 1-6, 8-23, 25-30, 32-34)	
DTX-1466	7/5/2021			Email from M. Toda to A. Williamson RE: Draft note to NS	
DTX-1467	6/5/2023			Nippon Shinyaku Co. Ltd. and NS Pharma, Inc.'s Responses and Objections to Sarepta Therapeutics, Inc.'s First Set of Requests for Admission (Nos. 1-37)	
DTX-1468	7/27/2023			Nippon Shinyaku Co. Ltd. and NS Pharma, Inc.'s Responses and Objections to Sarepta Therapeutics, Inc.'s First Set of Requests for Admission (Nos. 38-48)	

November 25, 2024

Confidential

DTX-1469	4/3/2023			Sarepta Therapeutics, Inc.'s Responses to Nippon Shinyaku Co., Ltd.'s and NS Pharma, Inc.'s First Set of Requests for Admission (Nos. 1-10)	
DTX-1470	7/27/2023			Sarepta Therapeutics, Inc.'s Responses to Nippon Shinyaku Co., Ltd.'s and NS Pharma, Inc.'s First Set of Requests for Admission (Nos. 11-56)	
DTX-1471	8/3/2023			Sarepta Therapeutics, Inc.'s Supplemental Objections and Responses to Nippon Shinyaku Co., Ltd.'s and NS Pharma, Inc.'s Second Set of Requests for Admission (Nos. 36-38)	
DTX-1472	9/9/2023			Tab 3 of Opening Expert Report of John C. Jarosz, Damages Summary	
DTX-1473	9/8/2023			Tab 4 of Opening Expert Report of John C. Jarosz, Sarepta Lost Profits and Damages Aug 19, 2020-Apr 30, 2023	
DTX-1474	9/8/2023			Tab 5 of Opening Expert Report of John C. Jarosz, Sarepta Reasonable Royalty Damages - U.S. and O.U.S. Viltepso Sales Aug 19, 2020 - May 31, 2023	
DTX-1475	9/8/2023			Tab 6 of Opening Expert Report of John C. Jarosz, Viltepso to Vyondys 53 Estimated Vial Conversion Ratio	
DTX-1476	9/8/2023			Tab 7 of Opening Expert Report of John C. Jarosz, Sarepta Incremental Expenses Calculation	
DTX-1477	9/8/2023			Tab 8 of Opening Expert Report of John C. Jarosz, Sarepta - Vyondys 53 Monthly U.S. Sales July 2019 - March 2023	
DTX-1478	9/8/2023			Tab 9 of Opening Expert Report of John C. Jarosz, Sarepta Quarterly Consolidated Statement of Operations 2018-2022	

Sarepta-UWA Tenth Revised Trial Exhibit List

November 25, 2024

Confidential

DTX-1479	9/8/2023			Tab 10 of Opening Expert Report of John C. Jarosz, NS - Viltepso U.S. Monthly Sales August 2020 - April 2023	
DTX-1480	9/8/2023			Tab 11 of Opening Expert Report of John C. Jarosz, NS - Viltepso O.U.S. Monthly Sales and Royalties January 2022 - June 2023	
DTX-1481	9/8/2023			Tab 12 of Opening Expert Report of John C. Jarosz, Nippon Shinyaku Co., Ltd. Income Statement FY 2018 - FY 2022	
DTX-1482	9/8/2023			Tab 13 of Opening Expert Report of John C. Jarosz, Vyondys 53 and Viltepso U.S. Average Selling Price Per Vial December 2019 - April 2023	
DTX-1483	9/8/2023			Tab 14 of Opening Expert Report of John C. Jarosz, Sarepta Counterclaim Patents-In-Suit	
DTX-1484	9/8/2023			Tab 15 of Opening Expert Report of John C. Jarosz, Sarepta and NS Development Timeline of Selected DMD Therapies	
DTX-1485	9/8/2023			Tab 16 of Opening Expert Report of John C. Jarosz, Sarepta and UWA License Agreement Summary	
DTX-1486	9/8/2023			Tab 17 of Opening Expert Report of John C. Jarosz, Sarepta Therapeutics, Inc. Commercial Agreement Summary	
DTX-1487	9/8/2023			Tab 18 of Opening Expert Report of John C. Jarosz, Nippon Shinyaku Co., Ltd. and NS Pharma License Agreement Summary	
DTX-1488	9/8/2023			Tab 19 of Opening Expert Report of John C. Jarosz, Nippon Shinyaku Co., Ltd. and NS Pharma Commercial Summary Agreement Summary	

November 25, 2024

Confidential

DTX-1489	9/8/2023			Tab 20 of Opening Expert Report of John C. Jarosz, Pharmaceutical Industry Average Royalty Rates - Royalty Rate Comparison By Development Stage Less Life Sciences Royalty Rates & Deal Terms Surveys 2014 - 2021	
DTX-1490	9/8/2023			Tab 21 of Opening Expert Report of John C. Jarosz, Prejudgment Interest Factors	
DTX-1491	10/11/2023			Tab 3 of Rebuttal Expert Report of John C. Jarosz, Rebuttal Damages Scenario	
DTX-1492	10/11/2023			Tab 4 of Rebuttal Expert Report of John C. Jarosz, Rebuttal Damages Summary	
DTX-1493	10/11/2023			Tab 5 of Rebuttal Expert Report of John C. Jarosz, Jarosz Reasonable Royalty Damages Dec 12, 2019 - Mar 31, 2023	
DTX-1494	10/11/2023			Tab 6 of Rebuttal Expert Report of John C. Jarosz, Summary of Quantitative Adjustments to Hosfield Lost Profits Analysis Aug 19, 2020 - Mar 31, 2023	
DTX-1495	10/11/2023			Tab 7 of Rebuttal Expert Report of John C. Jarosz, NS Japan and NS Pharma Adjusted Hosfield Lost Profits Combined Adjustments Aug 19, 2020 - Mar 31, 2023	
DTX-1496	10/11/2023			Tab 8 of Rebuttal Expert Report of John C. Jarosz, NS Japan and NS Pharma Adjusted Hosfield Lost Profits Adjusted for Ramp Up Aug 19, 2020 - Mar 31, 2023	
DTX-1497	10/11/2023			Tab 9 of Rebuttal Expert Report of John C. Jarosz, NS Japan and NS Pharma Adjusted Hosfield Lost Profits Combined Profitability Adjustments Aug 19, 2020 - Mar 31, 2023	

November 25, 2024

Confidential

DTX-1498	10/11/2023			Tab 10 of Rebuttal Expert Report of John C. Jarosz, NS Japan and NS Pharma Adjusted Hosfield Lost Profits Adjusted for Corrected ASP and NJ Japan Per Vial Profit Aug 19, 2020 - Mar 31, 2023	
DTX-1499	10/11/2023			Tab 11 of Rebuttal Expert Report of John C. Jarosz, NS Japan and NS Pharma Adjusted Hosfield Lost Profits Adjusted for NS Japan Incremental Expenses Aug 19, 2020 - Mar 31, 2023	
DTX-1500	10/11/2023			Tab 12 of Rebuttal Expert Report of John C. Jarosz, NS Japan and NS Pharma Adjusted Hosfield Lost Profits Adjusted Computation of Incremental Profit Margin for Fully Variable Operating Expenses Aug 19, 2020 - Mar 31, 2023	
DTX-1501	10/11/2023			Tab 13 of Rebuttal Expert Report of John C. Jarosz, NS Japan and NS Pharma Adjusted Hosfield Lost Profits Adjusted Calculation of Incremental Consulting and Marketing Expenses Aug 1, 2020 - Mar 31, 2023	
DTX-1502	10/11/2023			Tab 14 of Rebuttal Expert Report of John C. Jarosz, NS Japan and NS Pharma Adjusted Hosfield Lost Profits Adjusted Calculation of Incremental Administration Support Expenses Aug 19, 2020 - Mar 31, 2023	
DTX-1503	10/11/2023			Tab 15 of Rebuttal Expert Report of John C. Jarosz, NS Japan and NS Pharma Adjusted Hosfield Lost Profits Adjusted for Incremental Marketplace Creation Expenses Aug 19, 2020 - Mar 31, 2023	
DTX-1504	10/11/2023			Tab 16 of Rebuttal Expert Report of John C. Jarosz, NS Pharma - Viltepso Average Cost of Therapy	

November 25, 2024

Confidential

DTX-1505	10/11/2023			Tab 17 of Rebuttal Expert Report of John C. Jarosz, NS Japan Estimated Cost of Supply Free Vials of Vyondys in But-For World	
DTX-1506	10/11/2023			Tab 18 of Rebuttal Expert Report of John C. Jarosz, NS Pharma Lost Vial Sales Adjusted for Ramp Up Aug 19, 2020 - Mar 31, 2023	
DTX-1507	10/11/2023			Tab 19 of Rebuttal Expert Report of John C. Jarosz, NS Japan Adjusted Profit Per Vial Calculation Combined Adjustments Aug 19, 2020 - Apr 30, 2023	
DTX-1508	10/11/2023			Tab 20 of Rebuttal Expert Report of John C. Jarosz, NS Pharma Vilepso Net Average Selling Price Based on Sales Data Aug 19, 2020 - Mar 31, 2023	
DTX-1509	10/11/2023			Tab 21 of Rebuttal Expert Report of John C. Jarosz, NS Pharma Comparison of Vials and Gross Sales in Stretch Forecast, Financials, and Hosfield Report Aug 19, 2020 - Apr 30, 2023	
DTX-1510	10/11/2023			Tab 22 of Rebuttal Expert Report of John C. Jarosz, Adjusted NS Japan Profit Per Vial Calculation Using Actual Vial Sales and Excluding Sales to NS HQ Aug 19, 2020 - Apr 30, 2023	
DTX-1511	10/11/2023			Tab 23 of Rebuttal Expert Report of John C. Jarosz, Adjusted JS Japan Profit Per Vial Calculation Adjusted for NS Japan Incremental Expenses Aug 19, 2020 - Apr 30, 2023	
DTX-1512	10/11/2023			Tab 24 of Rebuttal Expert Report of John C. Jarosz, NS Japan Incremental Expenses Calculation	

November 25, 2024

Confidential

DTX-1513	10/11/2023			Tab 25 of Rebuttal Expert Report of John C. Jarosz, NS Pharma Viltepso Operating Profit Margin Calculation Using Adjusted Hosfield Approach Combined Profit Margin Adjustments Aug 19, 2020 - Mar 31, 2023	
DTX-1514	10/11/2023			Tab 26 of Rebuttal Expert Report of John C. Jarosz, NS Pharma Viltepso Operating Profit Margin Calculation Using Adjusted Hosfield Approach Adjusted Computation of Incremental Profit Margin for Fully Variable Operating Expenses Aug 19, 2002 - Mar 31, 2023	
DTX-1515	10/11/2023			Tab 27 of Rebuttal Expert Report of John C. Jarosz, NS Pharma Viltepso Operating Profit Margin Calculation Using Adjusted Hosfield Approach Adjusted Calculation of Incremental Consulting and Marketing Expenses Aug 19, 2020 - Mar 31, 2023	
DTX-1516	10/11/2023			Tab 28 of Rebuttal Expert Report of John C. Jarosz, NS Pharma Viltepso Operating Profit Margin Calculation Using Adjusted Hosfield Approach Adjusted Calculation of Incremental Administration Support Expenses Aug 19, 2020 - Mar 31, 2023	
DTX-1517	10/11/2023			Tab 29 of Rebuttal Expert Report of John C. Jarosz, Adjusted Hosfield Exhibit 5, Schedule 1.1 NS Pharma Estimated Profit on Lost Sales Aug 19, 2020 - Dec 31, 2020	
DTX-1518	10/11/2023			Tab 30 of Rebuttal Expert Report of John C. Jarosz, Adjusted Hosfield Exhibit 5, Schedule 1.2 NS Pharma Estimated Profit on Lost Sales Jan 1, 2021 - Dec 31, 2021	

Sarepta-UWA Tenth Revised Trial Exhibit List

November 25, 2024

Confidential

DTX-1519	10/11/2023			Tab 31 of Rebuttal Expert Report of John C. Jarosz, Adjusted Hosfield Exhibit 5, Schedule 1.3 NS Pharma Estimated Profit on Lost Sales Jan 1, 2022 - Dec 31, 2022	
DTX-1520	10/11/2023			Tab 32 of Rebuttal Expert Report of John C. Jarosz, Adjusted Hosfield Exhibit 5, Schedule 1.4 NS Pharma Estimated Profit on Lost Sales Jan 1, 2023 - Mar 31, 2023	
DTX-1521	10/11/2023			Tab 33 of Rebuttal Expert Report of John C. Jarosz, NS Pharma - Viltepso But-For Incremental Ongoing Marketing and Marketplace Creation Expenses Aug 19, 2020 - Mar 31, 2023	
DTX-1522	10/11/2023			Tab 34 of Rebuttal Expert Report of John C. Jarosz, Sarepta - Vyondys 53 U.S. Upfront Marketplace Creation Expense Jul 2019 - Dec 11, 2019	
DTX-1523	10/11/2023			Tab 35 of Rebuttal Expert Report of John C. Jarosz, NS Pharma - Viltepso U.S. Marketing Expenses Aug 19, 2020 - Apr 30, 2023	
DTX-1524	10/11/2023			Tab 36 of Rebuttal Expert Report of John C. Jarosz, Hosfield Reasonable Royalty Damages Comparison of Per-Vial and Percentage of Net Sales Royalty Structures Dec 12, 2019 - Mar 31, 2023	
DTX-1525	10/11/2023			Tab 37 of Rebuttal Expert Report of John C. Jarosz, NS Pharma - Viltepso U.S. Monthly Sales Aug 2020 - Apr 2023	
DTX-1526	10/11/2023			Tab 38 of Rebuttal Expert Report of John C. Jarosz, Sarepta - Vyondys 53 Monthly U.S. Sales Jul 2019 - Mar 2023	

November 25, 2024

Confidential

DTX-1527	10/11/2023			Tab 39 of Rebuttal Expert Report of John C. Jarosz, Sarepta - Vyondys 53 Monthly O.U.S Sales Apr 2020 - Mar 2023	
DTX-1528	10/11/2023			Tab 40 of Rebuttal Expert Report of John C. Jarosz, Sarepta - Vyondys 53 Monthly Worldwide Sales Jul 2019 - Mar 2023	
DTX-1529	10/11/2023			Tab 41 of Rebuttal Expert Report of John C. Jarosz, Nippon Shinyaku Co., Ltd. Quarterly Consolidated Statement of Operations FY 2018 - FY 2021	
DTX-1530	10/11/2023			Tab 42 of Rebuttal Expert Report of John C. Jarosz, Sarepta Therapeutics, Inc. Quarterly Consolidated Statement of Operations 2018 - 2022	
DTX-1531	10/11/2023			Tab 43 of Rebuttal Expert Report of John C. Jarosz, NS Patents-In-Suit	
DTX-1532	10/11/2023			Tab 44 of Rebuttal Expert Report of John C. Jarosz, Sarepta and NS Development Timeline of Selected DMD Therapies	
DTX-1533	10/11/2023			Tab 45 of Rebuttal Expert Report of John C. Jarosz, NS Japan and NS Pharma License Agreement Summary	
DTX-1534	10/11/2023			Tab 46 of Rebuttal Expert Report of John C. Jarosz, NS Japan and NS Pharma Commercial Agreement Summary	
DTX-1535	10/11/2023			Tab 47 of Rebuttal Expert Report of John C. Jarosz, Sarepta Therapeutics, Inc. License Agreement Summary	
DTX-1536	10/11/2023			Tab 48 of Rebuttal Expert Report of John C. Jarosz, Sarepta Therapeutics, Inc. Commercial Agreement Summary	

November 25, 2024

Confidential

DTX-1537	10/11/2023			Tab 49 of Rebuttal Expert Report of John C. Jarosz, Hosfield Adjusted Breach of Contract Damages Adjusted IP Litigation Damages May 3, 2021 - Apr 30, 2022	
DTX-1538	10/11/2023			Tab 50 of Rebuttal Expert Report of John C. Jarosz, Hosfield Adjusted Breach of Contract Damages Adjusted PTAB Damages Jun 24, 2021 - Apr 29, 2022	
DTX-1539	10/27/2023			Tab 1 of Reply Expert Report of John C. Jarosz, Curriculum Vitae	
DTX-1540	10/27/2023			Tab 3 of Reply Expert Report of John C. Jarosz, Financials of Incremental Vyondys 53 Sales Based on Hosfield Rebuttal Report Lost Profits Analysis	
DTX-1541	10/27/2023			Tab 4 of Reply Expert Report of John C. Jarosz, Financials of Incremental Viltepso Sales Based on Hosfield Opening Report Lost Profits Analysis	
DTX-1542	10/27/2023			Tab 5 of Reply Expert Report of John C. Jarosz, Lagged Incremental Expenses Calculation	
DTX-1543				Appendix C of Rebuttal Expert Report of Steven Dowdy, materials considered list.	
DTX-1544				Appendix D of Reply Expert Report of Steven Dowdy, materials considered list	
DTX-1545				Appendix B of Opening Expert Report of Steven Dowdy, materials considered list	
DTX-1546				Appendix B of Opening Expert Report of Andrew Hirshfeld, materials considered list	
DTX-1547				Appendix A of Rebuttal Expert Report of Andrew Hirshfeld, materials considered list	

November 25, 2024

Confidential

DTX-1548				Appendix B to Rebuttal Expert Report of Yao Lu, materials considered list	
DTX-1549				Exhibit B of Opening Expert Report of Stanley Nelson, materials considered list	
DTX-1550				Appendix C of Rebuttal Expert Report of Stanley Nelson, materials considered list	
DTX-1551				Appendix B of Opening Expert Report of Bradley Pentelute, materials considered list	
DTX-1552				Appendix C of Rebuttal Expert Report of Bradley Pentelute, materials considered list	
DTX-1553				Exhibit 2 of Opening Expert Report of Christine Esau, materials considered list	
DTX-1554				Exhibit A of Rebuttal Expert Report of Christine Esau, materials considered list	
DTX-1555				Exhibit 1 of Opening Expert Report of Michelle Hastings, materials considered list	
DTX-1556				Appendix to the Reply Expert Report of Dr. Michelle L. Hastings Regarding the Invalidity of the UWA Patents, materials considered list	
DTX-1557				Exhibit 1 of Responsive Expert Report of Michelle Hastings, materials considered list	
DTX-1558				Exhibit 2 of Opening Expert Report of Mark Hosfield, materials considered list	
DTX-1559				Exhibit 2 of Rebuttal Expert Report of Mark Hosfield, materials considered list	
DTX-1560				Exhibit 2 of Reply Expert Report of Mark Hosfield, materials considered list	
DTX-1561				Exhibit A of Opening Expert Report of Scott Kamholz, materials considered list	

November 25, 2024

Confidential

DTX-1562				Exhibit 1 of Responsive Expert Report of Scott Kamholz, materials considered list	
DTX-1563				Appendix of Reply Expert Report of Scott Kamholz, materials considered list	
DTX-1564				Exhibit 2 of Opening Expert Report of Nathan Luedtke, materials considered list	
DTX-1565				Appendix B of Opening Expert Report of Robert Maness, materials considered list	
DTX-1566				Appendix A of Reply Expert Report of Robert Maness, materials considered list	
DTX-1567				Exhibit 1 of Opening Expert Report of Jonathan Strober, materials considered list	
DTX-1568				Exhibit 2 of Rebuttal Expert Report of Jonathan Strober, materials considered list	
DTX-1569				Exhibit 1 of Opening Expert Report of Matthew Wood, materials considered list	
DTX-1570				Exhibit 1 of Rebuttal Expert Report of Matthew Wood, materials considered list	
DTX-1571				Exhibit 1 of Reply Expert Report of Matthew Wood, materials considered list	
DTX-1572	11/7/2023			P. Clemens & E. Hoffman, Reply to F. Muntoni et al.: "In response to P.R. Clemens et al., Efficacy and Safety of Viltolarsen in boys with Duchenne muscular dystrophy: results from the phase 2, open-label, 4-year extension study, and long-term functional efficacy and safety of viltolarsen in patients with Duchenne muscular dystrophy, Journal of Neuromuscular Diseases 10: 1155-1157 (2023)	
DTX-1573	11/7/2023			NS00053735	

November 25, 2024

Confidential

DTX-1574	3/22/2024			Kansteiner, F, Italfarmico nabs FDA approval for new Duchenne med (2024) https://www.fiercepharma.com/pharma/italfarmaco-nabs-fda-approval-new-nonsteroidal-duchenne-muscular-dystrophy-med-teeing?utm_medium=email&utm_source=nl&utm_campaign=LS-NL-FiercePharma&oly_enc_id=9129J5689890E4D	
DTX-1575	10/28/2009	WILTON0010161	WILTON0010161	Email from S. Wilton to L. Popplewell; A. Aartsma-Rus; G. Dickson; C. Adkin; V. Arechavala; J. Morgan; F. Muntoni; and ig2@sanger.co.uk RE: Exon 53 paper	
DTX-1576	12/18/2023			Merger Guidelines, U.S. Department of Justice and Federal Trade Commission	
DTX-1577				Tab 2 of Opening Expert Report of John Jarosz, materials considered list	
DTX-1578				Tab 2 of Rebuttal Expert Report of John Jarosz, materials considered list	
DTX-1579				Tab 2 of Reply Expert Report of John Jarosz, materials considered list	
DTX-1580	11/20/2022	NS00143952	NS00143956	Certified English translation of Email from K. Kobayashi to I. Kazuya RE: Actual-E1	
DTX-1581	2023-12-00	SRPT-VYDS-0246333	SRPT-VYDS-0246333	Excel Entitled [REDACTED]	
DTX-1582		NS00156733	NS00156733	Page indicating that it was left Intentionally Blank	
DTX-1583	8/24/2023	NS00156734	NS000156766	Morgan Lewis invoice for summary of services for the period ended July 31, 2023	
DTX-1584	9/15/2023	NS000156767	NS000156807	Morgan Lewis invoice for summary of services for the period ended August 31, 2023	

November 25, 2024

Confidential

DTX-1585	10/30/2023	NS000156808	NS000156829	Morgan Lewis invoice for summary of services for the period ended September 30, 2023	
DTX-1586	11/29/2023	NS000156830	NS000156853	Morgan Lewis invoice for summary of services for the period ended October 31, 2023	
DTX-1587	12/26/2023	NS000156854	NS000156873	Morgan Lewis invoice for summary of services for the period ended November 30, 2023	
DTX-1588	1/17/2024	NS000156874	NS000156888	Morgan Lewis invoice for summary of services for the period ended December 31, 2023	
DTX-1589	2/22/2024	NS000156889	NS000156909	Morgan Lewis invoice for summary of services for the period ended January 31, 2024	
DTX-1590	3/8/2024	NS000156910	NS000156925	Morgan Lewis invoice for summary of services for the period ended February 29, 2024	
DTX-1591		NS000156926	NS000156926	Abe, Ikubo & Katayama: Attorney Fee for Nippon Shinyaku - US IP Litigation	
DTX-1592	10/6/2023	NS00156927	NS000156928	Foreign document entitled 'Statement of Delivery' and its certified english translation	
DTX-1593	11/8/2023	NS000156929	NS000156930	Foreign document entitled 'Statement of Delivery' and its certified english translation	
DTX-1594	12/7/2023	NS000156931	NS000156932	Foreign document entitled 'Statement of Delivery' and its certified english translation	
DTX-1595	1/12/2024	NS000156933	NS000156934	Foreign document entitled 'Statement of Delivery' and its certified english translation	

Sarepta-UWA Tenth Revised Trial Exhibit List

November 25, 2024

Confidential

DTX-1596	2/7/2024	NS000156935	NS000156939	Foreign document entitled 'Statement of Delivery' and its certified english translation	
DTX-1597	3/7/2024	NS000156937	NS000156938	Foreign document entitled 'Statement of Delivery' and its certified english translation	
DTX-1598	2020-00-00	NS000156939	NS000156940	Foreign document	
DTX-1599	2/14/2024	NS000156941	NS000156941	Letter to Mr. Yoshihiko Makita regarding Final Royalty Rate of Viltespo for Calendar Year 2023	
DTX-1600	2022-00-00	NS000156942	NS000156942	Chart showing 'Ship to R Pharm' and 'Ship to Clinigen' information	
DTX-1601	2/26/2024	NS000156943	NS000156943	Invoice from Nippon Shinyaku to NS Phanna, Inc. for Viltolarsen Licence Royalty 2023	
DTX-1602	2020-08-00	NS000156944	NS000156944	Excel relating to expenses and fees from August 2020 - February 2024	
DTX-1603	4/1/2024	NS000156945	NS000156945	MUFG report showing wire transfer to Nippon Shinyaku Co.	
DTX-1604	3/11/2024			Letter from A. Salimi to E. Steffe In Re: Patent Term Extension Certificate for U.S. Patent No. RE47,691	
DTX-1605	2006-08-00	WILTON0007795	WILTON0007827	Making Sense in Spite of Nonsense: An Antisense therapy for Duchenne Muscular Dystrophy, August 2006	
DTX-1606	4/3/2024	SRPT-VYDS-0246334	SRPT-VYDS-0246334	H.15 Selected Interest Rates for Apr 03, 2024	
DTX-1607	5/2/2023	SRPT-VYDS-0246335	SRPT-VYDS-0246408	Sarepta Form 10-Q for the quarterly period ended March 31, 2023	
DTX-1608	8/2/2023	SRPT-VYDS-0246409	SRPT-VYDS-0246626	Sarepta form 10-Q for the quarterly period ended June 30, 2023	
DTX-1609	11/1/2023	SRPT-VYDS-0246627	SRPT-VYDS-0246709	Sarepta form 10-Q for the quarterly period ended September 30, 2023SR	

November 25, 2024

Confidential

DTX-1610	2/28/2024	SRPT-VYDS-0246710	SRPT-VYDS-0246877	Sarepta form 10-K for the fiscal year ended December 31, 2023	
DTX-1611	4/12/2024			Tab 1 of Supplemental Expert Report of John C. Jarosz, Curriculum Vitae	
DTX-1612	4/12/2024			Tab 2 of Supplemental Expert Report of John C. Jarosz, Materials Considered List	
DTX-1613	4/12/2024			Tab 3 of Supplemental Expert Report of John C. Jarosz, Damages Summary	
DTX-1614	4/12/2024			Tab 4 of Supplemental Expert Report of John C. Jarosz, Sarepta Lost Profits Damages from August 19, 2020 - May 13, 2024	
DTX-1615	4/12/2024			Tab 5 of Supplemental Expert Report of John C. Jarosz, Sarepta Reasonable Royalty Damages U.S. and O.U.S. Viltepso Sales from August 19, 2020 - May 31, 2024	
DTX-1616	4/12/2024			Tab 6 of Supplemental Expert Report of John C. Jarosz, Viltepso to Vyondys 53 Estimated Vial Conversion Ratio	
DTX-1617	4/12/2024			Tab 7 of Supplemental Expert Report of John C. Jarosz, Sarepta Incremental Expenses Calculation	
DTX-1618	4/12/2024			Tab 8 of Supplemental Expert Report of John C. Jarosz, Sarepta Vyondys 53 Monthly U.S. Sales from July 2019 - February 2024	
DTX-1619	4/12/2024			Tab 9 of Supplemental Expert Report of John C. Jarosz, Sarepta Therapeutic, Inc. Quarterly Consolidated Statement of Operations from 2018 - 2023	
DTX-1620	4/12/2024			Tab 10 of Supplemental Expert Report of John C. Jarosz, NS Viltepso U.S. Monthly Sales from August 2020 - February 2024	

November 25, 2024

Confidential

DTX-1621	4/12/2024			Tab 11 of Supplemental Expert Report of John C. Jarosz, NS Viltepso O.U.S. Monthly Sales and Royalties from January 2022 - February 2024	
DTX-1622	4/12/2024			Tab 12 of Supplemental Expert Report of John C. Jarosz, Nippon Shinyaku, Ltd. Income Statement from FY 2018 - FY 2022	
DTX-1623	4/12/2024			Tab 13 of Supplemental Expert Report of John C. Jarosz, Vyondys 53 and Viltepso U.S. Average Selling Price Per Vial from December 2019 - February 2024	
DTX-1624	4/12/2024			Tab 14 of Supplemental Expert Report of John C. Jarosz, Sarepta Counterclaim Patents-In-Suit	
DTX-1625	4/12/2024			Tab 15 of Supplemental Expert Report of John C. Jarosz, Sarepta and NS Development Timeline of Selected DMD Therapies	
DTX-1626	4/12/2024			Tab 16 of Supplemental Expert Report of John C. Jarosz, Sarepta and UWA License Agreement Summary	
DTX-1627	4/12/2024			Tab 17 of Supplemental Expert Report of John C. Jarosz, Sarepta Therapeutics, Inc. Commercial Agreement Summary	
DTX-1628	4/12/2024			Tab 18 of Supplemental Expert Report of John C. Jarosz, Nippon Shinyaku Co., Ltd. and NS Pharma License Agreement Summary	
DTX-1629	4/12/2024			Tab 19 of Supplemental Expert Report of John C. Jarosz, Nippon Shinyaku Co., Ltd. and NS Pharma Commercial Agreement Summary	

November 25, 2024

Confidential

DTX-1630	4/12/2024			Tab 20 of Supplemental Expert Report of John C. Jarosz, Pharmaceutical Industry Average Royalty Rates - Royalty Rates Comparison by Development Stage Les Life Sciences Royalty Rates & Deal Terms Surveys from 2014 - 2021	
DTX-1631	4/12/2024			Tab 21 of Supplemental Expert Report of John C. Jarosz, Prejudgment Interest Factors	
DTX-1632	1/7/2015	SRPT-VYDS-0222196	SRPT-VYDS-0222205	Email from C. Roegner to B. Cumbo and M. Toda RE: [REDACTED]	
DTX-1633	1/18/2011	SRPT-VYDS-0222025	SRPT-VYDS-0222025	Email from C. Pohlod to K. Itabashi; K. Kameyama; M. Nakata; and H. Osaki RE: [REDACTED] and attachment [REDACTED]	
DTX-1634	2011-01-00	SRPT-VYDS-0222026	SRPT-VYDS-0222100	AVI BioPharma Presentation entitled 'AVI BioPharma Program in Duchenne Muscular Dystrophy'	
DTX-1635	1/24/2011	SRPT-VYDS-D0222101	SRPT-VYDS-0222102	Email from K. Kameyama to C. Pohlod RE: [REDACTED]	Toda 26
DTX-1636	1/26/2021	SRPT-VYDS-0221986	SRPT-VYDS-0221989	Email from J. Zenkus to M. Toda RE: [EXTERNAL] RE: [REDACTED]	
DTX-1637	1/26/2021	SRPT-VYDS-0221986	SRPT-VYDS-0221989	Certified Japanese translation of Email from J. Zenkus to M. Toda RE: [EXTERNAL] RE: [REDACTED]	
DTX-1638	3/25/2020	SRPT-VYDS-0222193	SRPT-VYDS-0222195	Email from M. Gall to M. Toda RE: [EXTERNAL] RE: [REDACTED]	
DTX-1639	3/25/2020	SRPT-VYDS-0222193	SRPT-VYDS-0222195	Certified Japanese Translation of Email from M. Gall to M. Toda RE: [EXTERNAL] RE: [REDACTED]	

November 25, 2024

Confidential

DTX-1640	9/16/2010	SRPT-VYDS-0222966	SRPT-VYDS-0222967	Email from M. Takagi to partnering@avibio.com RE: [REDACTED] [REDACTED]	
DTX-1641	9/25/2013	SRPT-VYDS-0222165	SRPT-VYDS-0222165	Email from N. Shirakawa to ecox@sareptatherapeutics.com RE: [REDACTED] [REDACTED] [REDACTED] [REDACTED]	
DTX-1642	10/2/2017	SRPT-VYDS-0222811	SRPT-VYDS-0222813	Email from M. Gall to M. Toda RE: [REDACTED] [REDACTED]	Luedtke 05 Schnell 20
DTX-1643	10/2/2017	SRPT-VYDS-0222811	SRPT-VYDS-0222813	Certified Japanese Translation of Email from M. Gall to M. Toda RE: [REDACTED]	
DTX-1644	10/25/2013	SRPT-VYDS-0222311	SRPT-VYDS-0222318	Email from N. Shirakawa to C. Roegner RE: [REDACTED] [REDACTED] [REDACTED] [REDACTED] -resend-	
DTX-1645	10/26/2018	SRPT-VYDS-0222975	SRPT-VYDS-0222976	Email from M. Today to M. Gall RE: Sarepta [REDACTED]	
DTX-1646	10/26/2018	SRPT-VYDS-0222975	SRPT-VYDS-0222976	Certified Japanese Translation of Email from M. Today to M. Gall RE: [REDACTED]	
DTX-1647	11/18/2017	SRPT-VYDS-0222896	SRPT-VYDS-0222897	Email from M. Toda to smahatme@sarepta.com RE: [REDACTED]	
DTX-1648		SRPT-VYDS-0222896	SRPT-VYDS-0222897	Certified Japanese translation of Email from M. Toda to smahatme@sarepta.com RE: [REDACTED] [REDACTED]	

November 25, 2024

Confidential

DTX-1649	11/24/2010	SRPT-VYDS-0223297	SRPT-VYDS-0223297	Email from C. Pohlod to S. Igori and K. Tougou RE: [REDACTED] [REDACTED] [REDACTED]	
DTX-1650	11/15/2010	SRPT-VYDS-0223298	SRPT-VYDS-0223372	AVI BioPharma Presentation entitled [REDACTED] [REDACTED] [REDACTED]	
DTX-1651	11/26/2010	SRPT-VYDS-0223295	SRPT-VYDS-0223296	Email from S. Igori to C. Pohlod RE: [REDACTED] [REDACTED]	
DTX-1652	11/30/2015	SRPT-VYDS-0222958	SRPT-VYDS-0222959	Email from M. Toda M. Gall RE: [REDACTED] [REDACTED]	Toda 28
DTX-1653	11/30/2015	SRPT-VYDS-0222958	SRPT-VYDS-0222959	Certified Japanese Translation of Email from M. Toda M. Gall RE: [REDACTED]	Toda 28A
DTX-1654	12/6/2010	SRPT-VYDS-0222004	SRPT-VYDS-0222004	Email from C. Pohlod to S. Igori RE: [REDACTED] [REDACTED] and attachment [REDACTED] [REDACTED]	
DTX-1655	12/13/2010	SRPT-VYDS-0222019	SRPT-VYDS-0222020	Email from C. Pohlod to S. Igori RE: FW: [REDACTED] [REDACTED] and attachment [REDACTED] [REDACTED]	
DTX-1656	12/30/2019	SRPT-VYDS-0222626	SRPT-VYDS-0222628	Email from M. Gall to M. Toda RE: [EXTERNAL] RE: [REDACTED] [REDACTED]	
DTX-1657	12/30/2019	SRPT-VYDS-0222626	SRPT-VYDS-0222628	Certified Japanese Translation of Email from M. Gall to M. Toda RE: [EXTERNAL] RE: [REDACTED] [REDACTED]	
DTX-1658	12/5/2023	SRPT-VYDS-0246107	SRPT-VYDS-0246112	Jonathan Brett Strober, general payment information in 2020	
DTX-1659	12/5/2023	SRPT-VYDS-0246113	SRPT-VYDS-0246136	Jonathan Bret Strober, general payment information in 2022	

November 25, 2024

Confidential

DTX-1660	12/5/2023	SRPT-VYDS-0246137	SRPT-VYDS-0246140	Jonathan Bret Strober, associated research funding payment information in 2020	
DTX-1661	12/5/2023	SRPT-VYDS-0246141	SRPT-VYDS-0246156	Jonathan Bret Strober, general payment information in 2019	
DTX-1662	12/5/2023	SRPT-VYDS-0246157	SRPT-VYDS-0246168	Stanley F Nelson, general payment information in 2021	
DTX-1663	12/5/2023	SRPT-VYDS-0246169	SRPT-VYDS-0246216	Jonathan Bret Strober, general payment information in 2018	
DTX-1664	12/5/2023	SRPT-VYDS-0246217	SRPT-VYDS-0246220	Stanley F Nelson, associated research funding payment information in 2021	
DTX-1665	12/5/2023	SRPT-VYDS-0246221	SRPT-VYDS-0246224	Stanley F Nelson, general payment information in 2017	
DTX-1666	12/5/2023	SRPT-VYDS-0246225	SRPT-VYDS-0246235	Jonathan Bret Strober, general payment information in 2016	
DTX-1667	12/5/2023	SRPT-VYDS-0246236	SRPT-VYDS-0246240	Stanley F Nelson, general payment information in 2018	
DTX-1668	12/5/2023	SRPT-VYDS-0246241	SRPT-VYDS-0246244	Stanley F Nelson, associated research funding payment information in 2019	
DTX-1669	12/5/2023	SRPT-VYDS-0246245	SRPT-VYDS-0246262	Stanley F Nelson, general payment information in 2022	
DTX-1670	12/5/2023	SRPT-VYDS-0246263	SRPT-VYDS-0246266	Jonathan Bret Strober, associated research funding payment information in 2019	
DTX-1671	12/5/2023	SRPT-VYDS-0246267	SRPT-VYDS-0246292	Jonathan Bret Strober, general payment information in 2017	
DTX-1672	12/5/2023	SRPT-VYDS-0246293	SRPT-VYDS-0246296	Stanley F Nelson, associated research funding payment information in 2020	
DTX-1673	12/5/2023	SRPT-VYDS-0246297	SRPT-VYDS-0246301	Stanley F Nelson, general payment information in 2019	
DTX-1674	12/5/2023	SRPT-VYDS-0246302	SRPT-VYDS-0246306	Stanley F Nelson, general payment information in 2016	
DTX-1675	12/5/2023	SRPT-VYDS-0246307	SRPT-VYDS-0246317	Stanley F Nelson, general payment information in 2020	

November 25, 2024

Confidential

DTX-1676	12/5/2023	SRPT-VYDS-0246318	SRPT-VYDS-0246321	Jonathan Bret Strober, associated research funding payment information in 2021	
DTX-1677	12/5/2023	SRPT-VYDS-0246322	SRPT-VYDS-0246332	Jonathan Bret Strober, general payment information in 2021	
DTX-1678	1/2/2020	SRPT-VYDS-0223074	SRPT-VYDS-0223077	Foreign translation of Email from M. Toda to M. Gall RE: [REDACTED] and attachment 'ATT00001.jpg'	Toda 33A
DTX-1679	8/15/2016			Certified Japanese Translation of Experimental Report of Dr. Watanabe in Opposition of EP 2,206,781	
DTX-1680	2009-00-00	NS00059696	NS00059696	English translation of foreign document bearing Bates number NS00059696	
DTX-1681	8/15/2016			Certified Japanese translation of Experimental Report of Dr. Watanabe in Opposition of EP 2,206,781	
DTX-1682	9/26/2017			Certified Japanese translation of Experimental Report of Dr. Watanabe DATED 9/26/17	
DTX-1683	9/26/2017			Certified Japanese translation of Experimental Report of Mr. Tone dated 9/26/17	
DTX-1684				Certified Japanese translation of Experimental report and declaration of Mr. Ueda for EP 3,018,211 dated 3/16/18 and 10/27/21	
DTX-1685	4/19/2024			Tab 1 of Supplemental Rebuttal Expert Report of John C. Jarosz, Curriculum Vitae	
DTX-1686	4/19/2024			Tab 2 of Supplemental Rebuttal Expert Report of John C. Jarosz, Documents Reviewed and/or Relied Upon	
DTX-1687	4/19/2024			Tab 3 of Supplemental Rebuttal Expert Report of John C. Jarosz, Rebuttal Damages Scenarios	

November 25, 2024

Confidential

DTX-1688	4/19/2024			Tab 4 of Supplemental Rebuttal Expert Report of John C. Jarosz, Rebuttal Damages Summary	
DTX-1689	4/19/2024			Tab 5 of Supplemental Rebuttal Expert Report of John C. Jarosz, Jarosz Reasonable Royalty Damages for December 12, 2019 - February 29, 2024	
DTX-1690	4/19/2024			Tab 6 of Supplemental Rebuttal Expert Report of John C. Jarosz, Summary of Quantitative Adjustments to Hosfield Lost Profits Analysis from August 19, 2020 - February 29, 2024	
DTX-1691	4/19/2024			Tab 7 of Supplemental Rebuttal Expert Report of John C. Jarosz, NS Japan and NS Pharma Adjusted Hosfield Lost Profits Combined Adjustments August 19, 2020 - February 29, 2024	
DTX-1692	4/19/2024			Tab 8 of Supplemental Rebuttal Expert Report of John C. Jarosz, NS Japan and NS Pharma Adjusted Hosfield Lost Profits Adjusted for Ram Up from August 19, 2020 - February 29, 2024	
DTX-1693	4/19/2024			Tab 9 of Supplemental Rebuttal Expert Report of John C. Jarosz, NS Japan and NS Pharma Adjusted Hosfield Lost Profits Combined Profitability Adjustments from August 19, 2020 - February 29, 2024	
DTX-1694	4/19/2024			Tab 10 of Supplemental Rebuttal Expert Report of John C. Jarosz, NS Japan and NS Pharma Adjusted Hosfield Lost Profits Adjusted for NS Japan Per Vial Profit from August 19, 2020 - February 29, 2024	

November 25, 2024

Confidential

DTX-1695	4/19/2024			Tab 11 of Supplemental Rebuttal Expert Report of John C. Jarosz, NS Japan and NS Pharma Adjusted Hosfield Lost Profits Adjusted for NS Japan Incremental Expenses from August 19, 2020 - February 29, 2024	
DTX-1696	4/19/2024			Tab 12 of Supplemental Rebuttal Expert Report of John C. Jarosz, NS Japan and NS Pharma Adjusted Hosfield Lost Profits Adjusted Calculation of Incremental Consulting and Marketing Expenses from August 19, 2020 - February 29, 2024	
DTX-1697	4/19/2024			Tab 13 of Supplemental Rebuttal Expert Report of John C. Jarosz, NS Japan and NS Pharma Adjusted Calculation of Incremental Administration Support Expenses from August 19, 2020 - February 29, 2024	
DTX-1698	4/19/2024			Tab 14 of Supplemental Rebuttal Expert Report of John C. Jarosz, NS Japan and NS Pharma Adjusted Hosfield Lost Profits Adjusted for Incremental Marketplace Creation Expenses from August 19, 2020 - February 29, 2024	
DTX-1699	4/19/2024			Tab 15 of Supplemental Rebuttal Expert Report of John C. Jarosz, NS Pharma - Viltepso Average Cost of Therapy	
DTX-1700	4/19/2024			Tab 16 of Supplemental Rebuttal Expert Report of John C. Jarosz, NS Japan Estimated Cost to Supply Free Vials of Vyondys 53 in But-For World	

November 25, 2024

Confidential

DTX-1701	4/19/2024			Tab 17 of Supplemental Rebuttal Expert Report of John C. Jarosz, NS Pharma Lost Vial Sales Adjusted for Ramp Up and Vial Conversion Rate from August 19, 2020 - February 29, 2024	
DTX-1702	4/19/2024			Tab 18 of Supplemental Rebuttal Expert Report of John C. Jarosz, NS Japan Adjusted NS Japan Profit Per Vial Calculation Combined Adjustments from August 19, 2020 - February 29, 2024	
DTX-1703	4/19/2024			Tab 19 of Supplemental Rebuttal Expert Report of John C. Jarosz, NS Japan Adjusted NS Japan Profit Per Vial Calculation Excluding Sales to NS HQ from August 19, 2024 - February 29, 2024	
DTX-1704	4/19/2024			Tab 20 of Supplemental Rebuttal Expert Report of John C. Jarosz, NS Japan Adjusted NS Japan Profit Per Vial Calculation Adjusted for NS Japan Incremental Expenses from August 19, 2020 - January 31, 2024	
DTX-1705	4/19/2024			Tab 21 of Supplemental Rebuttal Expert Report of John C. Jarosz, NS Japan Incremental Expenses Calculation	
DTX-1706	4/19/2024			Tab 22 of Supplemental Rebuttal Expert Report of John C. Jarosz, NS Pharma Vilepso Operating Profit Margin Calculation Using Adjusted Hosfield Approach Combined Profit Margin Adjustments from August 19, 2020 - February 29, 2024	

November 25, 2024

Confidential

DTX-1707	4/19/2024			Tab 23 of Supplemental Rebuttal Expert Report of John C. Jarosz, NS Pharma Viltepso Operating Profit Margin Calculation Using Adjusted Hosfield Approach Adjusted Calculation of Incremental Consulting and Marketing Expenses from August 19, 2020 - February 29, 2024	
DTX-1708	4/19/2024			Tab 24 of Supplemental Rebuttal Expert Report of John C. Jarosz, NS Pharma Viltepso Operating Profit Margin Calculation Using Adjusted Hosfield Approach Adjusted Calculation of Incremental Administration Support Expenses from August 19, 2020 - February 29, 2024	
DTX-1709	4/19/2024			Tab 25 of Supplemental Rebuttal Expert Report of John C. Jarosz, NS Pharma Estimated Profit on Lost Sales from August 19, 2020 - December 31, 2020	
DTX-1710	4/19/2024			Tab 26 of Supplemental Rebuttal Expert Report of John C. Jarosz, NS Pharma Estimated Profit on Lost Sales from January 1, 2021 - December 31, 2021	
DTX-1711	4/19/2024			Tab 27 of Supplemental Rebuttal Expert Report of John C. Jarosz, NS Pharma Estimated Profit on Lost Sales from January 1, 2022 - December 31, 2022	
DTX-1712	4/19/2024			Tab 28 of Supplemental Rebuttal Expert Report of John C. Jarosz, NS Pharma Estimated Profit on Lost Sales from January 1, 2023 - December 31, 2023	

Sarepta-UWA Tenth Revised Trial Exhibit List

November 25, 2024

Confidential

DTX-1713	4/19/2024			Tab 29 of Supplemental Rebuttal Expert Report of John C. Jarosz, NS Pharma Estimated Profit on Lost Sales from January 1, 2024 - February 29, 2024	
DTX-1714	4/19/2024			Tab 30 of Supplemental Rebuttal Expert Report of John C. Jarosz, But-For Incremental Ongoing Marketing and Marketplace Creation Expenses from August 19, 2020 - February 29, 2024	
DTX-1715	4/19/2024			Tab 31 of Supplemental Rebuttal Expert Report of John C. Jarosz, Sarepta and VYONDYS 53, U.S. UpFront Marketplace Creation Expense from July 2019 - December 11, 2019	
DTX-1716	4/19/2024			Tab 32 of Supplemental Rebuttal Expert Report of John C. Jarosz, NS Pharma and Viltepso, U.S. Marketing Expenses from August 19, 2020 - February 29, 2024	
DTX-1717	4/19/2024			Tab 33 of Supplemental Rebuttal Expert Report of John C. Jarosz, Comparison of Per-Vial and Percentage of Net Sales Royalty Structures from December 12, 2019 - February 29, 2024	
DTX-1718	4/19/2024			Tab 34 of Supplemental Rebuttal Expert Report of John C. Jarosz, NS and Viltepso U.S. Monthly Sales from August 2020 - February 2024	
DTX-1719	4/19/2024			Tab 35 of Supplemental Rebuttal Expert Report of John C. Jarosz, Sarepta and VYONDYS 53 Monthly U.S. Sales from July 2019 - February 2024	

November 25, 2024

Confidential

DTX-1720	4/19/2024			Tab 35 of Supplemental Rebuttal Expert Report of John C. Jarosz, Sarepta and VYONDYS 53 Monthly O.U.S. Sales from April 2020 February 2024	
DTX-1721	4/19/2024			Tab 37 of Supplemental Rebuttal Expert Report of John C. Jarosz, Sarepta and VYONDYS 53 Monty Worldwide Sales from July 2019 - February 2024	
DTX-1722	4/19/2024			Tab 38 of Supplemental Rebuttal Expert Report of John C. Jarosz, Nippon Shinyaku Quarterly Consolidated Statement of Operations for FY 2018 - FY 2022	
DTX-1723	4/19/2024			Tab 39 of Supplemental Rebuttal Expert Report of John C. Jarosz, Sarepta Quarterly Consolidated Statement of Operations 2018-2023	
DTX-1724	4/19/2024			Tab 40 of Supplemental Rebuttal Expert Report of John C. Jarosz, NS Patents-In-Suit	
DTX-1725	4/19/2024			Tab 41 of Supplemental Rebuttal Expert Report of John C. Jarosz, Sarepta and NS Development Timeline of Selected DMD Therapies	
DTX-1726	4/19/2024			Tab 42 of Supplemental Rebuttal Expert Report of John C. Jarosz, NS Japan and NS Pharma License Agreement Summary	
DTX-1727	4/19/2024			Tab 43 of Supplemental Rebuttal Expert Report of John C. Jarosz, NS Japan and NS Pharma Commercial Agreement Summary	
DTX-1728	4/19/2024			Tab 44 of Supplemental Rebuttal Expert Report of John C. Jarosz, Sarepta License Agreement Summary	
DTX-1729	4/19/2024			Tab 45 of Supplemental Rebuttal Expert Report of John C. Jarosz, Sarepta Commercial Agreement Summary	

November 25, 2024

Confidential

DTX-1730	4/19/2024			Tab 46 of Supplemental Rebuttal Expert Report of John C. Jarosz, Adjusted IP Litigation Damages from May 3, 2021 - April 30, 2022	
DTX-1731	4/19/2024			Tab 47 of Supplemental Rebuttal Expert Report of John C. Jarosz, Adjusted PTAB Damages from June 24, 2021 - April 29, 2022	
DTX-1732		NS00138040	NS00138040	Certified English translation of Excel Spreadsheet entitled '2 OMES'	
DTX-1733		NS00138040	NS00138040	Certified English translation of Excel spreadsheet entitled 'NDK Sequence Names'	
DTX-1734 DTX-0397	8/13/2011			S. Cirak et al., Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study, The Lancet 378(9791):595-605 (2011)	
DTX-1735 DTX-0453	2009-10-00			M. Kinali et al., Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study, Lancet Neurology 8(10):918-928 (2009)	
DTX-1736	4/21/2011			N. Goemans et al., Systemic administration of PRO051 in Duchenne's muscular dystrophy, The New England Journal of Medicine 364(16):1513-1522 (2011)	

Sarepta-UWA Tenth Revised Trial Exhibit List

November 25, 2024

Confidential

DTX-1737	12/27/2007			J. van Deutekom et al., Local dystrophin restoration with antisense oligonucleotide PRO051, The New England Journal of Medicine 357(26):2677-2686 (2007)	
DTX-1738	2/27/2024			J. Iff et al., Survival among patients receiving eteplirsen for up to 8 years for the treatment of Duchenne muscular dystrophy and contextualization with natural history controls, Muscle & Nerve (2024)	
DTX-1739		SRPT-VYDS-0236259	SRPT-VYDS-0236265	Centene Corporation's Clinical Policy on Viltolarsen (Viltepso)	
DTX-1740	11/2/2023			The National Center of Neurology and Psychiatry Department of Molecular Therapy National Institute of Neuroscience - Our Team	Wood 06
DTX-1741	5/5/2022			PepGen Common Stock Form	Wood 09
DTX-1742	8/18/2022			Foreign Patent Document WO 2022/171,972	Wood 12
DTX-1743				CV of Dr. Matthew Wood	Wood 05
DTX-1744	8/9/2023			PepGen - Pipeline - Expanding therapeutic possibilities, https://www.pepgen.com/pipeline/ (2023)	Wood 10
DTX-1745	2023-10-00			F. Muntoni, Six-Year Long-Term Safety and Efficacy of Golodirsen in Patients With DMD vs Mutation-Matched External Controls, (2023)	
DTX-1746 DTX-1369	2023-10-00			J. Iff et al., Delayed Pulmonary Progression in Golodirsen-Treated Patients With Duchenne Muscular Dystrophy vs Mutation-Matched External Controls, (2023)	
DTX-1747	12/11/2023			Plaintiff's Concise Statement of Facts in Support of its Motion for Partial Summary Judgment No. 1 Regarding Invalidity of the UWA Patents	

November 25, 2024

Confidential

DTX-1748	12/11/2023			Plaintiff's Concise Statement of Facts in Support of its Motion for Partial Summary Judgment No. 2 Regarding Infringement of Certain NS Patents	
DTX-1749	12/11/2023			Plaintiff's Concise Statement of Facts in Support of its Motion for Partial Summary Judgment No. 3 Regarding Its Breach of Contract Claim	
DTX-1750	12/11/2023			Plaintiff's Concise Statement of Facts in Support of its Motion for Partial Summary Judgment No. 4 No Anticipation	
DTX-1751	12/11/2023			Plaintiff's Concise Statement of Facts in Support of its Motion for Partial Summary Judgment No. 5 Regarding No Inequitable Conduct	
DTX-1752	1/12/2024			NS's Concise Statement of Facts in Support of its Response to Sarepta and UWA's Motion for Partial Summary Judgment No. 1 Regarding Infringement of U.S. Patent Nos. 9,994,851 and 10,227,590	
DTX-1753	1/12/2024			NS's Concise Statement of Facts in Support of its Opposition to Defendants' Motion for Partial Summary Judgment No. 2 Regarding Lost Profits	
DTX-1754	1/12/2024			NS's Concise Statement of Facts in Support of its Response to Sarepta and UWA's Motion for Partial Summary Judgment No. 3 of No Inequitable Conduct and No Walker Process Fraud	
DTX-1755	1/12/2024			NS Responses to Concise Statement of Facts in Support of Sarepta Therapeutics, Inc. and the University of Western Australia's Motion for Summary Judgement	

November 25, 2024

Confidential

DTX-1756	1/26/2024			NS's Response to Sarepta Therapeutics, Inc. and The University of Western Australia's Responsive Concise Statement of Facts	
DTX-1757	2024-03-00			J. Iff et al., Delayed pulmonary progression in Golodirsén-treated patients with Duchenne muscular dystrophy vx mutation-matched external controls, 2024 MDA Clinical and Scientific Conference (2024)	
DTX-1758	5/24/2010			Y. Miyagoe-Suzuki & S. Takeda, Gene therapy for muscle disease, Experimental Cell Research 316, 3087-3092 (2010)	
DTX-1759 DTX-0839	5/22/2009			A. Nakamura & S. Takeda, Exon-skipping therapy for Duchenne muscular dystrophy, Neuropathology 29: 494-501 (2009)	Takeda 11
DTX-1760	2024-03-00			F. Muntoni et al., Six-year long-term safety and efficacy of Golodirsén in patients with DMD vs mutation-matched external controls (2024)	
DTX-1761	5/1/2024	SRPT-VYDS-0247045	SRPT-VYDS-0247045	Sarepta Therapeutics Inc. 2020 Intracompany Royalties Report (Acct 419500 Entity 105 Sarepta GL Details)	
DTX-1762	5/1/2024	SRPT-VYDS-0247046	SRPT-VYDS-0247046	ST International Holdings Two, Inc. 2020 Intracompany Royalties Report (Acct 519500 Entity 150 Sarepta GL Details)	
DTX-1763	5/1/2024	SRPT-VYDS-0247047	SRPT-VYDS-0247047	Sarepta Therapeutics Inc. 2021 Intracompany Royalties Report (Acct 419500 Entity 105 Sarepta GL Details)	
DTX-1764	5/1/2024	SRPT-VYDS-0247048	SRPT-VYDS-0247048	ST International Holdings Two, Inc. 2021 Intracompany Royalties Report (Acct 419500 Entity 150 Sarepta GL Details)	

November 25, 2024

Confidential

DTX-1765	5/1/2024	SRPT-VYDS-0247049	SRPT-VYDS-0247049	Sarepta Therapeutics Inc. 2021 Intracompany Royalties Report (Acct 519500 Entity 105 Sarepta GL Details)	
DTX-1766	5/1/2024	SRPT-VYDS-0247050	SRPT-VYDS-0247050	ST International Holdings Two, Inc. 2021 Intracompany Royalties Report (Acct 519500 Entity 150 Sarepta GL Details)	
DTX-1767	5/1/2024	SRPT-VYDS-0247051	SRPT-VYDS-0247051	ST International Holdings Two, Inc. 2022 Intracompany Royalties Report (Acct 419500 Entity 150 Sarepta GL Details)	
DTX-1768	5/1/2024	SRPT-VYDS-0247052	SRPT-VYDS-0247052	Sarepta Therapeutics Inc. 2022 Intracompany Royalties Report (Acct 519500 Entity 105 Sarepta GL Details)	
DTX-1769	5/1/2024	SRPT-VYDS-0247053	SRPT-VYDS-0247054	ST International Holdings Two, Inc. 2023 Intracompany Royalties Report (Acct 419500 Entity 150 Sarepta GL Details)	
DTX-1770	5/1/2024	SRPT-VYDS-0247055	SRPT-VYDS-0247056	Sarepta Therapeutics Inc. 2023 Intracompany Royalties Report (Acct 519500 Entity 105 Sarepta GL Details)	
DTX-1771	5/1/2024	SRPT-VYDS-0247057	SRPT-VYDS-0247057	ST International Holdings Two, Inc.. Q1 2024 Intracompany Royalties Report (Acct 419500 Entity 150 Sarepta GL Details)	
DTX-1772	5/1/2024	SRPT-VYDS-0247058	SRPT-VYDS-0247058	Sarepta Therapeutics Inc. Q1 2024 Intracompany Royalties Report (Acct 519500 Entity 105 Sarepta GL Details)	
DTX-1773	6/10/2012	SRPT-VYDS-0247089	SRPT-VYDS-0247092	Articles of Amendment of the Fourth Restated and Amended Articles of Incorporation for AVI BioPharma, Inc.	
DTX-1774	12/27/2012	SRPT-VYDS-0246878	SRPT-VYDS-0246884	Assignment and Assumption agreement between Sarepta International C.V., ST International Holdings Two, Inc., and Sarepta Therapeutics, Inc.	
DTX-1775	12/31/2012	SRPT-VYDS-0246885	SRPT-VYDS-0246896	Contract Research Agreement between Sarepta Therapeutics, Inc. and Sarepta International C.V.	

November 25, 2024

Confidential

DTX-1776	5/18/2022	SRPT-VYDS-0246897	SRPT-VYDS-0246921	Ex-U.S. Sublicense Agreement between Sarepta Therapeutics, Inc. and ST International Holdings Two, Inc.	
DTX-1777	1/28/2016	SRPT-VYDS-0246922	SRSRPT-VYDS-0246947	Manufacturing and Distribution Agreement by and between Sarepta International C.V. and Sarepta Therapeutics, Inc.	
DTX-1778	9/28/2017	SRPT-VYDS-0246948	SRPT-VYDS-0246949	Letter from Sarepta International C.V. to Sarepta Therapeutics, Inc. RE: Manufacture of Products for Sale to Sarepta International C.V.	
DTX-1779	12/31/2012	SRPT-VYDS-0246950	SRPT-VYDS-0246981	Ex-U.S. License Agreement between Sarepta Therapeutics, Inc. and Sarepta International C.V.	
DTX-1780	4/1/2021	SRPT-VYDS-0246982	SRPT-VYDS-0246983	Termination Agreement between ST International Holdings Two, Inc. and Sarepta Therapeutics, Inc.	
DTX-1781	12/31/2012	SRPT-VYDS-0246984	SRPT-VYDS-0247019	U.S. License Agreement between Sarepta Therapeutics, Inc. and Sarepta C.V.	
DTX-1782	5/11/2022	SRPT-VYDS-0247020	SRPT-VYDS-0247044	U.S. Sublicense Agreement between Sarepta Therapeutics, Inc. and ST International Holdings Two, Inc.	
DTX-1783	12/27/2012	SRPT-VYDS-0247059	SRPT-VYDS-0247079	Limited Partnership Agreement in Respect of Sarepta International C.V.	
DTX-1784	5/4/2024	SRPT-VYDS-0247080	SRPT-VYDS-0247080	Termination Notice of Manufacturing and Distribution Agreement-Sarepta Therapeutics Inc. - April 1, 2021 - Sarepta - Ironclad; https://ironcladapp.com/5e8238c0dc84a950c1ab47d7/workflow/IC-4601 (2024)	

November 25, 2024

Confidential

DTX-1785	1/4/2022	SRPT-VYDS-0247081	SRPT-VYDS-0247082	Email from DocuSign System to Sarepta Legal RE: [EXTERNAL] Completed: Termination Notice (Sarepta Therapeutics Inc. and Sarepta) and attachment 'Termination Notice (Sarepta Therapeutics Inc. and Sarepta).pdf	
DTX-1786	6/5/2013	SRPT-VYDS-0247083	SRPT-VYDS-0247088	Certificate of Incorporation of Sarepta Therapeutics, Inc.	
DTX-1787		NS00000753	NS00000794	Certified Japanese translation of the '361 patent file history.	
DTX-1788	5/8/2024			Declaration of John Cremer	
DTX-1789	5/5/2015	SRPT-VYDS-0247093	SRPT-VYDS-0247199	University of Western Australia Patent (United States Patent 9,024,007 B2)	
DTX-1790		SRPT-VYDS-0247382	SRPT-VYDS-0247429	File History for Wilton Patent Application (App. No. 14/316,609 - U.S. Patent 9,024,007)	
DTX-1791	00/00/2004	NS00157155	NS00157162	Aartsma-Rus et al., "Comparative Analysis of Antisense Oligonucleotide Analogs for Targeted DMD Exon 46 Skipping in Muscle Cells," Gene Ther (2004) 11:1391-98	
DTX-1792	2005-12-00	SRPT-VYDS-0247610	SRPT-VYDS-0247627	A. Aartsma-Rus et al., Functional Analysis of 114 exon-internal AONs for targeted DMD exon skipping: indication for steric hindrance of SR protein binding sites, Oligonucleotides, 15:284-297 (2005)	
DTX-1793	00/00/1984	NS00157072	NS00157077	Asseline et al., "Oligodeoxynucleotides Covalently Linked to Intercalating Dyes as Base Sequence-Specific Ligands. Influence of Dye Attachment Site," EMBO J (1984) 3:795-800	
DTX-1794	00/00/2019	NS00157181	NS00157191	Aung-Htut et al., "In Vitro Validation of Phosphorodiamidate Morpholino Oligomers," Molecules (2019) 24:2922	

November 25, 2024

Confidential

DTX-1795	2005-01-00	SRPT-VYDS-0247603	SRPT-VYDS-0247609	J. Deere et al., Antisense phosphorodiamidate morpholino oligomer length and target position effects on gene-specific inhibition in escherichia coli, Antimicrobial Agents and Chemotherapy, 49(1):249-255 (2005)	Wood 110
DTX-1796	00/00/2007	NS00157258	NS00157263	Fletcher et al., "Morpholino Oligomer-Mediated Exon Skipping Averts the Onset of Dystrophic Pathology in the mdx Mouse," Mol Ther (2007) 15:1587-1592	
DTX-1797	2003-07-00	SRPT-VYDS-0247352	SRPT-VYDS-0247365	M. Fulco et al., Sir2 regulates skeletal muscle differentiation as a potential sensor of the redox state, Molecular Cell. 12:51-62 (2003)	
DTX-1798	3/1/2002	SRPT-VYDS-0247344	SRPT-VYDS-0247351	F. Galvagni et al., The utrophin gene is transcriptionally up-regulated in regenerating muscle, The Journal of Biological Chemistry, 277(21):19106-19113 (2002)	
DTX-1799	12/20/2005	NS00157726	NS00157727	Gene Tool Website: https://web.archive.org/web/20051220171348/http://www.genetools.com/node/9	
DTX-1800	12/20/2005	NS00157722	NS00157725	Gene Tool Website: https://web.archive.org/web/20051220181301/http://www.genetools.com/node/5	Wood 106
DTX-1801	12/22/2005	NS00157712	NS00157714	Gene Tool Website: https://web.archive.org/web/20051222184949/http://www.genetools.com:80/node/23	
DTX-1802	3/26/2006	NS00157718	NS00157721	Gene Tool Website: https://web.archive.org/web/20060326092604/http://www.genetools.com/node/23	
DTX-1803	6/30/2007	NS00157715	NS00157716	Gene Tool Website: https://web.archive.org/web/20070630114759/http://www.genetools.com:80/node/36	

November 25, 2024

Confidential

DTX-1804	5/26/2011	NS00157717	NS00157717	Gene Tool Website: https://web.archive.org/web/20110526180010/http://www.genetools.com/node/15	
DTX-1805	2002-00-00	SRPT-VYDS-0247376	SRPT-VYDS-0247381	J. Heasman, Morpholino oligos: making sense of antisense?, Developmental Biology, 243:209-214 (2002)	Hastings 109
DTX-1806	00/00/2009	NS00049729	NS00049738	Heemskerk et al., "In Vivo Comparison of 2'-O-Methyl Phosphorothioate and Morpholino Antisense Oligonucleotides for Duchenne Muscular Dystrophy Exon Skipping," J Gene Med (2009) 11:257-266	
DTX-1807	2004-05-00	SRPT-VYDS-0247200	SRPT-VYDS-0247211	S. Iezzi et al., Deacetylase inhibitors increase muscle cell size by promoting myoblast recruitment and fusion through induction of follistatin, Developmental Cell, 6:673-684 (2004)	
DTX-1808	00/00/2021	NS00157302	NS00157309	Li et al., "Fully Automated Fast-Flow Synthesis of Antisense Phosphorodiamidate Morpholino Oligomers," Nat Comm (2021) 12:4396	
DTX-1809				European Patent Application No. 1568769 A1 to Matsuo	Takeda 12A
DTX-1810	00/00/2002	NS00157317	NS00157342	Manoharan, "Oligonucleotide Conjugates as Potential Antisense Drugs with Improved Uptake, Biodistribution, Targeted Delivery, and Mechanism of Action," Antisense & Nucleic Acid Drug Dev. (2002) 12:103-128	
DTX-1811	2006-00-00	SRPT-VYDS-0247633	SRPT-VYDS-0247641	G. McClorey et al., Antisense oligonucleotide-induced exon skipping restores dystrophin expression in vitro in a canine model of DMD, Gene Therapy, 13:1373-1381 (2006)	

November 25, 2024

Confidential

DTX-1812	00/00/2005	NS00143623	NS00143630	Muntoni et al., "128th ENMC International Workshop on 'Preclinical Optimization and Phase I/II Clinical Trials Using Oligonucleotides in Duchenne Muscular Dystrophy' 22-24 October 2004, Naarden, the Netherlands," Neuromuscul. Disord. (2005) 15:450-57	Wilton 04
DTX-1813	2000-10-00	SRPT-VYDS-0247628	SRPT-VYDS-0247632	A. Nasevicius & S. Ekker, Effective targeted gene 'knockdown' in zebrafish, Nature Genetics, 26:216-220 (2000)	
DTX-1814	00/00/1996	NS00157664	NS00157670	Partridge et al., "A Simple Method for Delivering Morpholino Antisense Oligos into the Cytoplasm of Cells," Antisense & Nucleic Acid Drug Dev. (1996) 6:169-175	
DTX-1815	5/6/2010	SRPT-VYDS-0247430	SRPT-VYDS-0247481	WO 2010/050802 A2	
DTX-1816	2001-00-00	SRPT-VYDS-0247366	SRPT-VYDS-0247375	P. Sazani et al., Nuclear antisense effects of neutral, anionic and cationic oligonucleotide analogs, Oxford University Press, 29(19):3965-3974 (2001)	
DTX-1817	00/00/2002	NS00157679	NS00157684	Sazani et al., "Systemically Delivered Antisense Oligomers Upregulate Gene Expression in Mouse Tissues," Nat Biotech (2002) 20:1228-33	
DTX-1818	1999-00-00	SRPT-VYDS-0247653	SRPT-VYDS-0247659	G. Schmajuk et al., Antisense oligonucleotides with different backbones: modification of splicing pathways and efficacy of uptake, The Journal of Biological Chemistry, 274(31):21783-21789 (1999)	
DTX-1819	3/16/2010	SRPT-VYDS-0247642	SRPT-VYDS-0247652	Q. Wang et al., In vitro evaluation of novel antisense oligonucleotides is predictive of in vivo exon skipping activity for Duchenne muscular dystrophy, The Journal of Gene Medicine, 12:354-364 (2010)	

November 25, 2024

Confidential

DTX-1820	8/18/2022	SRPT-VYDS-0247212	SRPT-VYDS-0247343	WO 2022/172019 A1	
DTX-1821	8/18/2022	SRPT-VYDS-0247482	SRPT-VYDS-0247602	WO 2022/171972 A1	
DTX-1822	11/5/2024			Jarosz Second Supplemental Tab 1: Curriculum Vitae of John C. Jarosz	
DTX-1823	11/5/2024			Jarosz Second Supplemental Tab 2: Documents Reviewed and/or Relied Upon	
DTX-1824	11/5/2024			Jarosz Second Supplemental Tab 3: Damages Summary	
DTX-1825	11/5/2024			Jarosz Second Supplemental Tab 4: Sarepta Lost Profits Damages August 19, 2020 - December 15, 2024	
DTX-1826	11/5/2024			Jarosz Second Supplemental Tab 5: Sarepta Reasonable Royalty Damages U.S. and O.U.S. Viltepso Sales August 19, 2020 - December 15, 2024	
DTX-1827	11/5/2024			Jarosz Second Supplemental Tab 6: Viltepso to Vyondys 53 Estimated Vial Conversion Ratio	
DTX-1828	11/5/2024			Jarosz Second Supplemental Tab 7: Sarepta Incremental Expenses Calculation	
DTX-1829	11/5/2024			Jarosz Second Supplemental Tab 8: Sarepta - Vyondys 53 Monthly U.S. Sales, July 2019 - August 2024	
DTX-1830	11/5/2024			Jarosz Second Supplemental Tab 9: Sarepta Therapeutics, Inc. Quarterly Consolidated Statement of Operations 2018 - Q2 2024	
DTX-1831	11/5/2024			Jarosz Second Supplemental Tab 10: NS - Viltepso U.S. Monthly Sales August 2020 - August 2024	
DTX-1832	11/5/2024			Jarosz Second Supplemental Tab 11: NS - Viltepso O.U.S. Monthly Sales and Royalties January 2022 - August 2024	

November 25, 2024

Confidential

DTX-1833	11/5/2024			Jarosz Second Supplemental Tab 12: Nippon Shinyaku Co., Ltd. Income Statement FY 2018 - FY 2023	
DTX-1834	11/5/2024			Jarosz Second Supplemental Tab 13: Vyondys 53 and Viltepso U.S. Average Selling Price per Vial December 2019 - August 2024	
DTX-1835	11/5/2024			Jarosz Second Supplemental Tab 14: Sarepta Wilton Patent	
DTX-1836	11/5/2024			Jarosz Second Supplemental Tab 15: Sarepta and NY Development Timeline of Selected DMD Therapies	
DTX-1837	11/5/2024			Jarosz Second Supplemental Tab 16: Sarepta and UWA License Agreement Summary	
DTX-1838	11/5/2024			Jarosz Second Supplemental Tab 17: Sarepta Therapeutics, Inc. Commercial Agreement Summary	
DTX-1839	11/5/2024			Jarosz Second Supplemental Tab 18: Nippon Shinyaku Co., Ltd. and NS Pharma License Agreement Summary	
DTX-1840	11/5/2024			Jarosz Second Supplemental Tab 19: Nippon Shinyaku Co., Ltd. and NS Pharma Commercial Agreement Summary	
DTX-1841	11/5/2024			Jarosz Second Supplemental Tab 20: Pharmaceutical Industry Average Royalty Rates Royalty Rate Comparison by Development Stage LES Life Sciences Royalty Rates & Deal Terms Surveys 2014-2021	
DTX-1842	11/5/2024			Jarosz Second Supplemental Tab 21: Prejudgment Interest Factors	

November 25, 2024

Confidential

DTX-1843	11/5/2024			Jarosz Second Supplemental Tab 22: Sarepta Therapeutics, Inc., Sarepta International C.V., and St International Holdings Two, Inc. Agreement Summary	
DTX-1844	undated	NS00157826	NS00157826	NS Pharma Worldwide Access Program Sales	
DTX-1845	10/25/2025	NS00157824	NS00157824	NS Pharma VILTEPSO Income Statement	
DTX-1846	undated	SRPT-VYDS-0247660	SRPT-VYDS-0247660	VYONDYS 53 Financial Summary	
DTX-1847	3/32/2024	SRPT-VYDS-0247661	SRPT-VYDS-0247732	Sarepta Therapeutics, Inc. SEC Form 10-Q for the quarterly period ended March 31, 2024	
DTX-1848	6/30/2024	SRPT-VYDS-0247733	SRPT-VYDS-0247808	Sarepta Therapeutics, Inc. SEC Form 10-Q for the quarterly period ended June 30, 2024	
DTX-1849	00/00/2024	SRPT-VYDS-0247809	SRPT-VYDS-0247826	https://www.exchange-rates.org/exchange-rate-history/jpy-usd-2024	
DTX-1850	3/31/2024	SRPT-VYDS-0247827	SRPT-VYDS-0247837	"Outline of Consolidated Financial Results for the Year Ended March 31, 2024 (IFRS)," Nippon Shinyaku Co., Ltd., available at https://www.nippon-shinyaku.co.jp/file/download.php?file_id=7538	
DTX-1851	11/1/2024	SRPT-VYDS-0247838	SRPT-VYDS-0247838	H.15 Selected Interest Rates for Nov 01, 2024	
DTX-1852	4/5/2011	WILTON0018492	WILTON0018500	Email chain between S. Wilton, M. Wood, F. Muntoni, and G. Dickson	Wood 108
DTX-1853	8/20/2009			International Publication No. WO 2009/101399	Wood 115
DTX-1854	1/18/2014	NS00143268	NS00143451	Declaration of Matthew J.A. Wood University of Western Australia v Academisch Ziekenhuis Leiden	Wood 116
DTX-1855	2/11/2014			U.S. Patent 8,648,053	Hastings 111
DTX-1856	11/12/2019			U.S. Patent 10,472,634	Hastings 112

November 25, 2024

Confidential

DTX-1857	10/25/2025	NS00157825	NS00157825	NS Actual Shipping Costs to the United States	
DTX-1858	7/3/2024			Appendix to the Supplemental Opening Expert Report of Dr. Michelle L. Hastings, materials considered list	
DTX-1859	7/3/2024			Exhibit 1 to the Supplemental Expert Report of Matthew J.A. Wood, materials considered list	
DTX-1860	9/4/2024			Exhibit 1 to the Supplemental Reply Expert Report of Matthew J.A. Wood, materials considered list	
DTX-1861	11/5/2024			Second Supplemental Exhibit 2 to the Second Supplemental Expert Report of Mark J. Hosfield, materials considered list	
DTX-1862	11/12/2024			Second Supplemental Exhibit 2 to the Second Supplemental Rebuttal Expert Report of Mark J. Hosfield, materials considered list	
DTX-1863	8/14/2024			Appendix E to the Supplemental Rebuttal Expert Report of Steven F. Dowdy, Ph.D, materials considered list	
DTX-1864	11/12/2024			Jarosz Second Supplemental Rebuttal Tab 1: Curriculum Vitae of John C. Jarosz	
DTX-1865	11/12/2024			Jarosz Second Supplemental Rebuttal Tab 2: Documents Reviewed and/or Relied Upon	
DTX-1866	11/12/2024			Jarosz Second Supplemental Rebuttal Tab 3: Rebuttal Damages Scenarios	
DTX-1867	11/12/2024			Jarosz Second Supplemental Rebuttal Tab 4: Rebuttal Damages Summary	
DTX-1868	11/12/2024			Jarosz Second Supplemental Rebuttal Tab 5: Jarosz Reasonable Royalty Damages December 12, 2019 - December 16, 2024	

November 25, 2024

Confidential

DTX-1869	11/12/2024			Jarosz Second Supplemental Rebuttal Tab 6: Summary of Quantitative Adjustments to Hosfield Lost Profits Analysis August 19, 2020 - December 16, 2024	
DTX-1870	11/12/2024			Jarosz Second Supplemental Rebuttal Tab 7: NS Japan and NS Pharma Adjusted Hosfield Lost Profits Combined Adjustments August 19, 2020 - December 16, 2024	
DTX-1871	11/12/2024			Jarosz Second Supplemental Rebuttal Tab 8: NS Japan and NS Pharma Adjusted Hosfield Lost Profits Adjusted for Ramp Up August 19, 2020 - december 16, 2024	
DTX-1872	11/12/2024			Jarosz Second Supplemental Rebuttal Tab 9: NS Japan and NS Pharma Adjusted Hosfield Lost Profits Combined Profitability Adjustments August 19, 2020 - December 16, 2024	
DTX-1873	11/12/2024			Jarosz Second Supplemental Rebuttal Tab 10: NS Japan and NS Pharma Adjusted Hosfield Lost Profits Adjusted for NS Japan Incremental Expenses August 19 2020 - December 16, 2024	
DTX-1874	11/12/2024			Jarosz Second Supplemental Rebuttal Tab 11: NS Japan and NS Pharma Adjusted Hosfield Lost Profits Adjusted Calculations of Incremental Consulting and Marketing Expenses August 19, 2020 - Decmeber 16, 2024	

November 25, 2024

Confidential

DTX-1875	11/12/2024			Jarosz Second Supplemental Rebuttal Tab 12: NS Japan and NS Pharma Adjusted Hosfield Lost Profits Adjusted Calculation of Incremental Administration Support Expenses August 19, 2020 - December 16, 2024	
DTX-1876	11/12/2024			Jarosz Second Supplemental Rebuttal Tab 13: NS Japan and NS Pharma Adjusted Hosfield Lost Profits Adjusted For Incremental Marketplace Creation Expenses August 19, 2020 December 16, 2024	
DTX-1877	11/12/2024			Jarosz Second Supplemental Rebuttal Tab 14: NS Pharma - Viltapso Average Cost of Therapy	
DTX-1878	11/12/2024			Jarosz Second Supplemental Rebuttal Tab 15: NS Japan Estimated Cost to Supply Free Vials of Vyondys 53 in But-For World	
DTX-1879	11/12/2024			Jarosz Second Supplemental Rebuttal Tab 16: NS Pharma Lost vial Sales Adjusted for Ramp Up and Vial Conversion Rate August 19, 2020 - August 31, 2024	
DTX-1880	11/12/2024			Jarosz Second Supplemental Rebuttal Tab 17: NS Japan Adjusted NS Japan Profit Per Vial Calculation Adjusted for NS Japan Incremental Expenses August 19, 2020 - August 31, 2024	
DTX-1881	11/12/2024			Jarosz Second Supplemental Rebuttal Tab 18: NS Japan Incremental Expenses Calculation	

November 25, 2024

Confidential

DTX-1882	11/12/2024			Jarosz Second Supplemental Rebuttal Tab 19: NS Pharma Viltepso Operating Profit Margin Calculation Using Adjusted Hosfield Approach Combined Profit Margin Adjstments August 19, 2020 - August 31, 2024	
DTX-1883	11/12/2024			Jarosz Second Supplemental Rebuttal Tab 20: NS Pharma Viltepso Operating Profit Margin Calculation Using Adjusted Hosfield Approach Calculation of Incremental Consulting and Marketing Expenses August 19, 2020 - August 31, 2024	
DTX-1884	11/12/2024			Jarosz Second Supplemental Rebuttal Tab 21: NS Pharma Viltepso Operating Profit Margin Calculation Using Adjusted Hosfield Approach Calculation of Incremental Administration Support Expenses August 19, 2020 - August 31, 2024	
DTX-1885	11/12/2024			Jarosz Second Supplemental Rebuttal Tab 22: Adjusted Hosfield Second Supplemental Exhibit 5, Schedule 1.1, NS Pharma Estimated Profit on Lost Sales August 19, 2020 - December 31, 2020	
DTX-1886	11/12/2024			Jarosz Second Supplemental Rebuttal Tab 23: Adjusted Hosfield Second Supplemental Exhibit 5, Schedule 1.2, NS Pharma Estimated Profit on Lost Sales January 1, 2021 - December 31, 2021	
DTX-1887	11/12/2024			Jarosz Second Supplemental Rebuttal Tab 24: Adjusted Hosfield Second Supplemental Exhibit 5, Schedule 1.3, NS Pharma Estimated Profit on Lost Sales January 1, 2022 - December 31, 2022	

Sarepta-UWA Tenth Revised Trial Exhibit List

November 25, 2024

Confidential

DTX-1888	11/12/2024			Jarosz Second Supplemental Rebuttal Tab 25: Adjusted Hosfield Second Supplemental Exhibit 5, Schedule 1.4, NS Pharma Estimated Profit on Lost Sales January 1, 2023 - December 31, 2023	
DTX-1889	11/12/2024			Jarosz Second Supplemental Rebuttal Tab 26: Adjusted Hosfield Second Supplemental Exhibit 5, Schedule 1.5, NS Pharma Estimated Profit on Lost Sales January 1, 2024 - December 31, 2024	
DTX-1890	11/12/2024			Jarosz Second Supplemental Rebuttal Tab 27: NS Pharma - Viltepso But-For Incremental Ongoing Marketing and Marketplace Creation Expenses August 19, 2020 - August 31, 2024	
DTX-1891	11/12/2024			Jarosz Second Supplemental Rebuttal Tab 28: Sarepta - Vyondys 53 U.S. Upfront Marketplace Creation Expense July 2019 - December 11, 2019	
DTX-1892	11/12/2024			Jarosz Second Supplemental Rebuttal Tab 29: NS Pharma - Viltepso U.S. Marketing Expenses August 19, 2020 - August 31, 2024	
DTX-1893	11/12/2024			Jarosz Second Supplemental Rebuttal Tab 30: Hosfield Reasonable Royalty Damages Comparison of Per-Vial and Percentage of Net Sales Royalty Structures December 12, 2019 - December 16, 2024	
DTX-1894	11/12/2024			Jarosz Second Supplemental Rebuttal Tab 31: NS Viltepso U.S. Monthly Sales August 2020 - August 2024	
DTX-1895	11/12/2024			Jarosz Second Supplemental Rebuttal Tab 32: Sarepta - Vyondys 53 Monthly U.S. Sales July 2019 - August 2024	

Sarepta-UWA Tenth Revised Trial Exhibit List

November 25, 2024

Confidential

DTX-1896	11/12/2024			Jarosz Second Supplemental Rebuttal Tab 33: Sarepta - Vyondys 53 Monthly O.U.S. Sales April 2020 - August 2024	
DTX-1897	11/12/2024			Jarosz Second Supplemental Rebuttal Tab 34: Sarepta - Vyondys 53 Monthly Worldwide Sales July 2019 - August 2024	
DTX-1898	11/12/2024			Jarosz Second Supplemental Rebuttal Tab 35: Nippon Shinyaku Co., Ltd. Quarterly Consolidated Statement of Operations FY 2018 - FY 2021	
DTX-1899	11/12/2024			Jarosz Second Supplemental Rebuttal Tab 36: Sarepta Therapeutics, Inc. Quarterly Consolidated Statement of Operations 2018 - Q2 2024	
DTX-1900	11/12/2024			Jarosz Second Supplemental Rebuttal Tab 37: NS Patents-In-Suit	
DTX-1901	11/12/2024			Jarosz Second Supplemental Rebuttal Tab 38: Sarepta and NS Development Timeline of Selected DMD Therapies	
DTX-1902	11/12/2024			Jarosz Second Supplemental Rebuttal Tab 39: NS Japan and NS Pharma License Agreement Summary	
DTX-1903	11/12/2024			Jarosz Second Supplemental Rebuttal Tab 40: NS Japan and NS Pharma Commercial Agreement Summary	
DTX-1904	11/12/2024			Jarosz Second Supplemental Rebuttal Tab 41: Sarepta Therapeutics, Inc. License Agreement Summary	
DTX-1905	11/12/2024			Jarosz Second Supplemental Rebuttal Tab 42: Sarepta Therapeutics, Inc. Commercial Agreement Summary	

November 25, 2024

Confidential

DTX-1906	11/12/2024			Jarosz Second Supplemental Rebuttal Tab 43: Sarepta Therapeutics, Inc., Sarepta International C.V., and St International Holdings Two, Inc. Agreement Summary	
DTX-1907	5/28/2024	SRPT-VYDS-0247839	SRPT-VYDS-0247841	NS Press Release, NS Pharma's DMD Candidate Viltespo Fails Confirmatory Phase III Trial, available at biospace.com/ns-pharma-s-dmd-drug-viltespo-fails-confirmatory-phase-iii-trial	
DTX-1908	10/26/2023	SRPT-VYDS-0247842	SRPT-VYDS-0247849	A 48-Week, Open Label, Study to Evaluate the Efficacy and Safety of AMONDYS 45, EXONDYS 51, VYONDYS 53 in Subjects With DuchenneMuscular Dystrophy Carrying Eligible DMD Duplications, available at clinicaltrials.gov/study/NCT04179409	
DTX-1909	10/22/2024	SRPT-VYDS-0247850	SRPT-VYDS-0247857	Study Details A Gene Delivery Study to Evaluate the Safety and Expression of Delandistrogene Moxeparovec in Participants Under the Age of Four With Duchenne Muscular Dystrophy (DMD), available at clinicaltrials.gov/study/NCT06128564	
DTX-1910	10/29/2024	SRPT-VYDS-0247858	SRPT-VYDS-0247869	A Randomized, Double-blind, Placebo-controlled Study of Delandistrogene Moxeparovec (SRP-9001) for Duchenne Muscular Dystrophy (DMD), available at clinicaltrials.gov/study/NCT03769116	
DTX-1911	8/18/2023	SRPT-VYDS-0247870	SRPT-VYDS-0247876	A Study to Evaluate Safety, Tolerability, and Efficacy of Eteplirsen in Participants With Duchenne Muscular Dystrophy (DMD) Who Have Completed Study 4658-102 (NCT03218995), available at	

November 25, 2024

Confidential

DTX-1912	8/13/2024	SRPT-VYDS-0247877	SRPT-VYDS-0247883	A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) Following Imlifidase Infusion in Participants With Duchenne Muscular Dystrophy (DMD) Determined to Have Pre-existing Antibodies to Recombinant Adeno-Associated Virus Serotype (rAAVrh74), available at clinicaltrials.gov/study/NCT06241950	
DTX-1913	10/16/2024	SRPT-VYDS-0247884	SRPT-VYDS-0247890	Study Details A Gene Transfer Therapy to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) Following Therapeutic Plasma Exchange (Plasmapheresis) in Participants With Duchenne Muscular Dystrophy (DMD) and Pre-existing Antibodies to AAVrh74, available at clinicaltrials.gov/study/NCT06597656	
DTX-1914	10/1/2024	SRPT-VYDS-0247891	SRPT-VYDS-0247907	Study Details Study of SRP-4045 (Casimersen) and SRP-4053 (Golodirsen) in Participants With Duchenne Muscular Dystrophy (DMD), available at clinicaltrials.gov/study/NCT02500381	
DTX-1915	10/27/2023	SRPT-VYDS-0247908	SRPT-VYDS-0247919	Study to Assess the Efficacy and Safety of Viltolarsen in Ambulant Boys With DMD (RACER53), available at clinicaltrials.gov/study/NCT04060199	
DTX-1916	2/14/2024	SRPT-VYDS-0247920	SRPT-VYDS-0247928	Study to Assess the Safety and Efficacy of Viltolarsen in Ambulant Boys With DMD (RACER53-X) available at clinicaltrials.gov/study/NCT04768062	

November 25, 2024

Confidential

DTX-1917	9/19/2024	SRPT-VYDS-0247929	SRPT-VYDS-0247940	An Extension Study to Evaluate Casimersen or Golodirsen in Patients With Duchenne Muscular Dystrophy, available at clinicaltrials.gov/study/NCT03532542	
DTX-1918	10/24/2024	SRPT-VYDS-0247941	SRPT-VYDS-0247957	Study Details A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparovec (SRP-9001) in Non-Ambulatory and Ambulatory Participants With Duchenne Muscular Dystrophy (DMD), available at clinicaltrials.gov/study/NCT05881408	
DTX-1919	9/3/2024	SRPT-VYDS-0247958	SRPT-VYDS-0247967	Study Details An Observational Study Comparing Delandistrogene Moxeparovec With Standard of Care in Participants With Duchenne Muscular Dystrophy, available at clinicaltrials.gov/study/NCT06270719	
DTX-1920	9/23/2024	SRPT-VYDS-0247968	SRPT-VYDS-0247976	Study Details A Long-term Observational Study Evaluating Eteplirsen, Golodirsen, or Casimersen in Routine Clinical Practice, available at clinicaltrials.gov/study/NCT06606340	
DTX-1921	8/18/2020	SRPT-VYDS-0247977	SRPT-VYDS-0247981	The Expanded Access Use of Viltolarsen in Duchenne Muscular Dystrophy With Confirmed Exon 53 Amenable Mutation, available in clinicaltrials.gov/study/NCT04337112	
DTX-1922	11/7/2024	SRPT-VYDS-0247982	SRPT-VYDS-0247984	N.P. Taylor, Sarepta axes late-phase DMD drug over safety signal, FDA talks, available at fiercebitech.com/biotech/sarepta-axes-late-phase-dmd-drug-over-safety-signal-fda-talks	

November 25, 2024

Confidential

DTX-1923	6/20/2024	SRPT-VYDS-0247985	SRPT-VYDS-0247991	Sarepta Press Release, Sarepta Therapeutics Announces Expanded US FDA Approval of ELEVIDYS to Duchenne Muscular Dystrophy Patients Ages 4 and Above, available at investorrelations.sarepta.com/news-releases/news-release-details/sarepta-therapeutics-announces-expanded-usfda-approval-elevidys	
DTX-1924	11/6/2024	SRPT-VYDS-0247992	SRPT-VYDS-0248021	Sarepta Press Release, Sarepta Therapeutics Announces Third Quarter 2024 Financial Results and Recent Corporate Developments, available at investorrelations.sarepta.com/news-releases/news-release-details/sarepta-therapeutics-announces-third-quarter-2024-financial	
DTX-1925	4/9/2024	SRPT-VYDS-0248022	SRPT-VYDS-0248024	Exondys 51 Extends Survival in DMD, Long-Term Study Shows, available at musculardystrophynews.com/news/exondys-51-extends-survival-dmd-long-term-study	
DTX-1926	5/27/2024	SRPT-VYDS-0248025	SRPT-VYDS-0248028	NS Press Release, NS Pharma Shares Preliminary Results of Viltolarsen (NS-065 / NCNP-01) Phase 3 Clinical Trial (RACER53 Study) available at prnewswire.com/news-releases/ns-pharma-shares-preliminary-results-of-viltolarsen-ns-065-ncnp-01-phase-3-clinical-trial-racer53-study-302155379.html	

Sarepta-UWA Tenth Revised Trial Exhibit List

November 25, 2024

Confidential

DTX-1927	5/28/2024			NS Presentation, The 7th Five-Year Medium-Term Management Plan (FY 2024 - FY 2028) - For Global Growth Beyond the cliff available at https://www.nspharma.com/pdfs/[NSP]_Press_Release_RACER53_Study_Results.pdf	
DTX-1928	9/17/2024			NS Press Release, Capricor Therapeutics Signs Binding Term Sheet with Nippon Shinyaku for European Expansion and Commercialization of Deramiciol for the Treatment of Duchenne Muscular Dystrophy	
DTX-1929	11/15/2024			NS Presentation, Outline of Consolidated Financial Results for the 2nd Quarter (Interim Period) Ended September 30, 2024	